



Adrenaline to improve survival in out-of-hospital
cardiac arrest
Perkins, Gavin D; Ji, Chen; Achana, Felix; Black, John Jm; Charlton, Karl; Crawford, James;
de Paeztron, Adam; Deakin, Charles; Docherty, Mark; Finn, Judith; Fothergill, Rachael T;
Gates, Simon; Gunson, Imogen; Han, Kyee; Hennings, Susie; Horton, Jessica; Khan,




Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Perkins, GD, Ji, C, Achana, F, Black, JJ, Charlton, K, Crawford, J, de Paeztron, A, Deakin, C, Docherty, M, Finn,
J, Fothergill, RT, Gates, S, Gunson, I, Han, K, Hennings, S, Horton, J, Khan, K, Lamb, S, Long, J, Miller, J,
Moore, F, Nolan, J, O'Shea, L, Petrou, S, Pocock, H, Quinn, T, Rees, N, Regan, S, Rosser, A, Scomparin, C,
Slowther, A & Lall, R 2021, 'Adrenaline to improve survival in out-of-hospital cardiac arrest: the PARAMEDIC2
RCT', Health Technology Assessment, vol. 25, no. 25, pp. 1-166. https://doi.org/10.3310/hta25250
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 11. May. 2021
Journals Library
DOI 10.3310/hta25250
Adrenaline to improve survival in 
out-of-hospital cardiac arrest:  
the PARAMEDIC2 RCT
Gavin D Perkins, Chen Ji, Felix Achana, John JM Black, Karl Charlton, James Crawford, 
Adam de Paeztron, Charles Deakin, Mark Docherty, Judith Finn, Rachael T Fothergill, 
Simon Gates, Imogen Gunson, Kyee Han, Susie Hennings, Jessica Horton, Kamran Khan, 
Sarah Lamb, John Long, Joshua Miller, Fionna Moore, Jerry Nolan, Lyndsey O’Shea,  
Stavros Petrou, Helen Pocock, Tom Quinn, Nigel Rees, Scott Regan, Andy Rosser,  
Charlotte Scomparin, Anne Slowther and Ranjit Lall
Health Technology Assessment
Volume 25 • Issue 25 • April 2021
ISSN 1366-5278

Adrenaline to improve survival in out-of-hospital
cardiac arrest: the PARAMEDIC2 RCT
Gavin D Perkins ,1,2* Chen Ji ,1 Felix Achana ,1
John JM Black ,3 Karl Charlton ,4 James Crawford ,1
Adam de Paeztron ,1 Charles Deakin ,5
Mark Docherty ,6 Judith Finn ,7 Rachael T Fothergill ,8
Simon Gates ,9 Imogen Gunson ,6 Kyee Han ,4
Susie Hennings ,1 Jessica Horton ,1 Kamran Khan ,1
Sarah Lamb ,1 John Long ,10 Joshua Miller ,6
Fionna Moore ,11 Jerry Nolan ,1,12 Lyndsey O’Shea ,13
Stavros Petrou ,1 Helen Pocock ,3 Tom Quinn ,14
Nigel Rees ,13 Scott Regan ,1 Andy Rosser ,6
Charlotte Scomparin ,1 Anne Slowther 1
and Ranjit Lall 1
1Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick,
Coventry, UK
2Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust,
Birmingham, UK
3South Central Ambulance Service NHS Foundation Trust, Bicester, UK
4North East Ambulance Service NHS Foundation Trust, Newcastle upon Tyne, UK
5Southampton University Hospital, Southampton, UK
6West Midlands Ambulance Service University NHS Foundation Trust, Brierley Hill, UK
7Prehospital, Resuscitation and Emergency Care Research Unit (PRECRU), Curtin
University, Perth, WA, Australia
8London Ambulance Service NHS Trust, London, UK
9Cancer Research Clinical Trials Unit (CRCTU), University of Birmingham,
Birmingham, UK
10Patient and Public Involvement Representative, Warwick, UK
11South East Coast Ambulance Service NHS Foundation Trust, Crawley, UK
12Royal United Hospitals Bath NHS Foundation Trust, Bath, UK
13Welsh Ambulance Service NHS Trust, St Asaph, UK
14Emergency, Cardiovascular and Critical Care Research Group, Faculty of Health,
Social Care and Education, Kingston University London and St George’s, University
of London, London, UK
*Corresponding author

Declared competing interests of authors: Gavin D Perkins is a board member of the Resuscitation
Council (UK) (2010–present), the European Resuscitation Council (2016–present) and the International
Liaison Committee on Resuscitation (co-chairperson; 2016–present), and is an editor for the scientific
journal Resuscitation (2010–present). He was also a member of the National Institute for Health
Research (NIHR) Programme Grants for Applied Research board (2016–20) and is a member of the
NIHR Health Technology Assessment (HTA) board (2020–present). Charles Deakin is a member of
the Advanced Life Support Working Group of the International Liaison Committee on Resuscitation
(January 2002–present). Simon Gates is a member of the HTA General Committee (2018–present).
Sarah Lamb was a member of the following boards: HTA Additional Capacity Funding Board
(2012–15), HTA Clinical Trials Board (2010–15), HTA End of Life Care and Add on Studies (2015–15),
HTA Funding Boards Policy Group (2010–15), HTA Maternal, Neonatal and Child Health Methods
Group (2013–15), HTA Post-board Funding Teleconference (2010–15), HTA Primary Care Themed Call
board (2013–14), HTA Prioritisation Group (2012–15) and the NIHR Clinical Trials Unit Standing
Advisory Committee (2012–16). Tom Quinn reports grants from NIHR [Health Services and Delivery
Research (HSDR) 11/2004/30 and HSDR 13/10/40)] and from the British Heart Foundation [Use and
impact of the pre-hospital 12-lead electrocardiogram in the primary PCI era. Mixed method study
(PHECG-2)], outside the submitted work. Anne Slowther reports grants from NIHR outside the
submitted work (for HSDR 13/10/14 and HSDR 15/15/09) and that she is a member of the Board of
Trustees of the UK Clinical Ethics Network (2013–present) and the Board of Trustees of the Institute
of Medical Ethics (2005–present).
Published April 2021
DOI: 10.3310/hta25250
This report should be referenced as follows:
Perkins GD, Ji C, Achana F, Black JJM, Charlton K, Crawford J, et al. Adrenaline to
improve survival in out-of-hospital cardiac arrest: the PARAMEDIC2 RCT. Health Technol Assess
2021;25(25).
Health Technology Assessment is indexed and abstracted in Index Medicus/MEDLINE, Excerpta







Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics
Science Citation Index.
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE)
(www.publicationethics.org/).
Editorial contact: journals.library@nihr.ac.uk
The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be
purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme,
and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.
Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis
methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.
HTA programme
Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can
be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate
any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that
have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote
health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include
any intervention used in the treatment, prevention or diagnosis of disease.
The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform
National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for
National Screening Committee (NSC) policy decisions.
This report
The research reported in this issue of the journal was funded by the HTA programme as project number 12/127/126. The
contractual start date was in March 2014. The draft report began editorial review in August 2019 and was accepted for
publication in July 2020. The authors have been wholly responsible for all data collection, analysis and interpretation, and for
writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to
thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages
or losses arising from material published in this report.
This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions
expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR,
NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this
publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect
those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.
Copyright © 2021 Perkins et al. This work was produced by Perkins et al. under the terms of a commissioning contract issued
by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the
Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in
any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication
must be cited.
Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland
(www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief
NIHR Journals Library Editors
Professor Ken Stein   Professor of Public Health, University of Exeter Medical School, UK
Professor John Powell Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals.
Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of 
Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK 
Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and 
Editor-in-Chief of HS&DR, PGfAR, PHR journals
Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management
and Marketing, University College Cork, Ireland
Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK
Dr Eugenia Cronin   Senior Scientific Advisor, Wessex Institute, UK
Dr Peter Davidson   Consultant Advisor, Wessex Institute, University of Southampton, UK
Ms Tara Lamont   Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK
Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK
Professor William McGuire   Professor of Child Health, Hull York Medical School, University of York, UK
Professor Geoffrey Meads   Emeritus Professor of Wellbeing Research, University of Winchester, UK
Professor James Raftery   Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, 
University of Southampton, UK
Dr Rob Riemsma   Reviews Manager, Kleijnen Systematic Reviews Ltd, UK
Professor Helen Roberts   Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK
Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK
Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, 
Swansea University, UK
Professor Ken Stein   Professor of Public Health, University of Exeter Medical School, UK
Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, 
University of Nottingham, UK 
Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors
Editorial contact:  journals.library@nihr.ac.uk
NIHR Journals Library www.journalslibrary.nihr.ac.uk
Abstract
Adrenaline to improve survival in out-of-hospital cardiac arrest:
the PARAMEDIC2 RCT
Gavin D Perkins ,1,2* Chen Ji ,1 Felix Achana ,1 John JM Black ,3
Karl Charlton ,4 James Crawford ,1 Adam de Paeztron ,1
Charles Deakin ,5 Mark Docherty ,6 Judith Finn ,7
Rachael T Fothergill ,8 Simon Gates ,9 Imogen Gunson ,6 Kyee Han ,4
Susie Hennings ,1 Jessica Horton ,1 Kamran Khan ,1 Sarah Lamb ,1
John Long ,10 Joshua Miller ,6 Fionna Moore ,11 Jerry Nolan ,1,12
Lyndsey O’Shea ,13 Stavros Petrou ,1 Helen Pocock ,3 Tom Quinn ,14
Nigel Rees ,13 Scott Regan ,1 Andy Rosser ,6 Charlotte Scomparin ,1
Anne Slowther 1 and Ranjit Lall 1
1Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK
2Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
3South Central Ambulance Service NHS Foundation Trust, Bicester, UK
4North East Ambulance Service NHS Foundation Trust, Newcastle upon Tyne, UK
5Southampton University Hospital, Southampton, UK
6West Midlands Ambulance Service University NHS Foundation Trust, Brierley Hill, UK
7Prehospital, Resuscitation and Emergency Care Research Unit (PRECRU), Curtin University, Perth,
WA, Australia
8London Ambulance Service NHS Trust, London, UK
9Cancer Research Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham, UK
10Patient and Public Involvement Representative, Warwick, UK
11South East Coast Ambulance Service NHS Foundation Trust, Crawley, UK
12Royal United Hospitals Bath NHS Foundation Trust, Bath, UK
13Welsh Ambulance Service NHS Trust, St Asaph, UK
14Emergency, Cardiovascular and Critical Care Research Group, Faculty of Health, Social Care and
Education, Kingston University London and St George’s, University of London, London, UK
*Corresponding author G.D.Perkins@warwick.ac.uk
Background: Adrenaline has been used as a treatment for cardiac arrest for many years, despite
uncertainty about its effects on long-term outcomes and concerns that it may cause worse neurological
outcomes.
Objectives: The objectives were to evaluate the effects of adrenaline on survival and neurological
outcomes, and to assess the cost-effectiveness of adrenaline use.
Design: This was a pragmatic, randomised, allocation-concealed, placebo-controlled, parallel-group
superiority trial and economic evaluation. Costs are expressed in Great British pounds and reported in
2016/17 prices.
Setting: This trial was set in five NHS ambulance services in England and Wales.
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Participants: Adults treated for an out-of-hospital cardiac arrest were included. Patients were
ineligible if they were pregnant, if they were aged < 16 years, if the cardiac arrest had been caused by
anaphylaxis or life-threatening asthma, or if adrenaline had already been given.
Interventions: Participants were randomised to either adrenaline (1 mg) or placebo in a 1 : 1 allocation
ratio by the opening of allocation-concealed treatment packs.
Main outcome measures: The primary outcome was survival to 30 days. The secondary outcomes
were survival to hospital admission, survival to hospital discharge, survival at 3, 6 and 12 months,
neurological outcomes and health-related quality of life through to 6 months. The economic evaluation
assessed the incremental cost per quality-adjusted life-year gained from the perspective of the NHS
and Personal Social Services. Participants, clinical teams and those assessing patient outcomes were
masked to the treatment allocation.
Results: From December 2014 to October 2017, 8014 participants were assigned to the adrenaline
(n = 4015) or to the placebo (n = 3999) arm. At 30 days, 130 out of 4012 participants (3.2%) in the
adrenaline arm and 94 out of 3995 (2.4%) in the placebo arm were alive (adjusted odds ratio for
survival 1.47, 95% confidence interval 1.09 to 1.97). For secondary outcomes, survival to hospital
admission was higher for those receiving adrenaline than for those receiving placebo (23.6% vs. 8.0%;
adjusted odds ratio 3.83, 95% confidence interval 3.30 to 4.43). The rate of favourable neurological
outcome at hospital discharge was not significantly different between the arms (2.2% vs. 1.9%;
adjusted odds ratio 1.19, 95% confidence interval 0.85 to 1.68). The pattern of improved survival but
no significant improvement in neurological outcomes continued through to 6 months. By 12 months,
survival in the adrenaline arm was 2.7%, compared with 2.0% in the placebo arm (adjusted odds ratio
1.38, 95% confidence interval 1.00 to 1.92). An adjusted subgroup analysis did not identify significant
interactions. The incremental cost-effectiveness ratio for adrenaline was estimated at £1,693,003 per
quality-adjusted life-year gained over the first 6 months after the cardiac arrest event and £81,070 per
quality-adjusted life-year gained over the lifetime of survivors. Additional economic analyses estimated
incremental cost-effectiveness ratios for adrenaline at £982,880 per percentage point increase in
overall survival and £377,232 per percentage point increase in neurological outcomes over the first
6 months after the cardiac arrest.
Limitations: The estimate for survival with a favourable neurological outcome is imprecise because of
the small numbers of patients surviving with a good outcome.
Conclusions: Adrenaline improved long-term survival, but there was no evidence that it significantly
improved neurological outcomes. The incremental cost-effectiveness ratio per quality-adjusted life-year
exceeds the threshold of £20,000–30,000 per quality-adjusted life-year usually supported by the NHS.
Future work: Further research is required to better understand patients’ preferences in relation to
survival and neurological outcomes after out-of-hospital cardiac arrest and to aid interpretation of the
trial findings from a patient and public perspective.
Trial registration: Current Controlled Trials ISRCTN73485024 and EudraCT 2014-000792-11.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 25. See the NIHR Journals Library website for further project information.
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Plain English summary
Cardiac arrest is a medical emergency that happens when the heart suddenly stops pumpingeffectively. When cardiac arrest happens, awareness is lost within seconds. If emergency
treatment is not started quickly, the person will die. The first treatments of cardiac arrest involve
pressing on the chest, giving rescue breaths and defibrillation (electric shocks applied to the heart).
If these treatments do not work, ambulance paramedics use a drug called adrenaline to try to restart
the heart. Although this treatment has been used for many years, some recent research suggests that
it may cause more harm than good.
In this research study, we compared the effects of giving adrenaline with the effects of not giving
adrenaline to people who had a cardiac arrest in the community. The research showed that adrenaline
was effective at restarting the heart, so more people survived long enough to be admitted to hospital.
Thirty days later, 130 out of 4012 patients (3.2%) who received adrenaline and 94 out of 3995 (2.4%)
who did not receive adrenaline were alive. However, adrenaline did not improve the number of patients
who went home from hospital having made a good recovery and were able to care for themselves. The
evidence suggests that adrenaline represents a poor use of NHS funds on cost-effectiveness grounds.
In a community survey, 95% of people who responded thought that long-term survival with good brain
function was more important than just being alive. Further research exploring the opinions of patients
and the public will help to understand the results of this research for the NHS.
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Each year, the NHS treats ≈ 30,000 people who are experiencing out-of-hospital cardiac arrest. Overall
survival rates are low (< 10%), falling further (to ≈ 3%) among patients who are unresponsive to initial
treatments; such patients require treatment escalation to the use of drugs. Adrenaline has been used
as a treatment for cardiac arrest for decades. The International Liaison Committee on Resuscitation
examined the evidence for the use of adrenaline in cardiac arrest and identified uncertainty about the
effects on long-term outcomes. Some recent, large, observational studies showed a pattern of worse
neurological outcomes in patients who received adrenaline. These findings prompted an international
call for a trial to examine the clinical effectiveness and safety of adrenaline as a treatment for out-of-
hospital cardiac arrest.
Objectives
The primary objective of this trial was to determine the clinical effectiveness of adrenaline in the
treatment of out-of-hospital cardiac arrest, measured as 30-day survival (i.e. the primary outcome). The
secondary objectives of the trial were to evaluate the effects of adrenaline on survival, neurological
outcomes and health-related quality of life among survivors, and to estimate the cost-effectiveness of
adrenaline use.
Methods
Ethics and regulatory approvals
The trial was approved by the South Central Oxford C Research Ethics Committee (reference number
14/SC/0157) and the Medicines and Healthcare Products Regulatory Agency (EudraCT number
2014-000792-11). The trial was sponsored by the University of Warwick and was conducted in accordance
with the Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 [European
Commission. Clinical Trials – Directive 2001/20/EC. URL: https://ec.europa.eu/health/human-use/clinical-
trials/directive_en (accessed 23 September 2020)], The Medicines for Human Use Act (Clinical Trial)
Regulations, Statutory Instrument 2004 No. 1031 and Amendment (No.2) Statutory Instrument 2006
No. 2984 [Great Britain. The Medicines for Human Use (Clinical Trials) Regulations 2004. London:
The Stationery Office; 2004 (and amendment in 2006)].
The Confidentiality Advisory Group provided approval under regulation 5 of the Health Service
(Control of Patient Information) Regulations 2002 [Great Britain. The Health Service (Control of Patient
Information) Regulations 2002. London: The Stationery Office; 2002] to process patient-identifiable
information without consent (reference number 14/CAG/1009).
Design
This was a pragmatic, randomised, allocation-concealed, placebo-controlled, parallel-group superiority
trial and economic evaluation.
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Inclusion and exclusion criteria
Patients were eligible if both of the following criteria were met:
1. cardiac arrest in out-of-hospital environment
2. advanced life support initiated and/or continued by ambulance service clinician.
Exclusion criteria at the time of arrest were as follows:
l known or apparent pregnancy
l known to be or apparently aged < 16 years
l cardiac arrest caused by anaphylaxis or life-threatening asthma
l adrenaline given prior to arrival of ambulance service clinician.
In London Ambulance Service, traumatic cardiac arrests were also excluded, in accordance with
local protocols.
Setting
Recruitment was undertaken in five NHS ambulance services in the UK (London Ambulance Service
NHS Trust, North East Ambulance Service NHS Foundation Trust, South Central Ambulance Service
NHS Foundation Trust, West Midlands Ambulance Service University NHS Foundation Trust and Welsh
Ambulance Service NHS Trust). These ambulance services serve a mix of urban and rural locations in
England and Wales, covering a population of 24 million people.
Consent
Cardiac arrest leads to an immediate loss of mental capacity, so it was not possible to obtain informed
consent from patients prior to enrolment. The time-critical nature of administering treatments for
cardiac arrest meant that it was not practical to obtain informed consent from a personal or professional
legal representative without the potential for causing harm through delaying patient treatment. In
accordance with the European Union Clinical Trials Directive and the Statutory Instrument 2004/1031,
we sought and obtained permission from a Research Ethics Committee to enrol patients prior to
obtaining informed consent. Research staff sought written, informed consent from the patient or
a legal representative for them to continue in the trial after the initial emergency had passed.
Resuscitation protocols and randomisation process
The NHS ambulance services followed the Joint Royal Colleges Ambulance Liaison Committee guidelines,
which are based on the Resuscitation Council (UK) National Institute for Health and Care Excellence-
accredited guidelines. The guidelines recommend that initial attempts at resuscitation should comprise
initiation of cardiopulmonary resuscitation (chest compressions and ventilations) and defibrillation
when indicated. For patients with non-shockable initial rhythms, adrenaline is recommended as soon
as vascular access is obtained. For those with shockable initial rhythms, adrenaline is delayed until after
the third shock is administered, if the patient remains in cardiac arrest.
The Pre-hospital Assessment of the Role of Adrenaline Measuring the Effectiveness of Drug
administration In Cardiac arrest 2 (PARAMEDIC2) trial followed these guidelines. If a patient
reached the point in the resuscitation protocol whereby adrenaline was indicated, they were
randomly assigned to receive either parenteral adrenaline or saline placebo by the opening of a
trial drug pack. Randomisation took place when a trial-trained paramedic opened an Investigational
Medicinal Product pack that contained either 10 syringes of adrenaline (1 mg each) or matching
placebo (0.9% saline). Patients were randomised to either adrenaline (intervention) or placebo (control)
in a 1 : 1 allocation ratio. The adrenaline and placebo packs and syringes were identical in appearance;
hence, clinicians, patients and trial personnel did not know whether any specific pack contained
adrenaline or placebo.
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Single doses of adrenaline or saline were administered every 3–5 minutes by an intravenous or
intraosseous route. Clinicians were instructed to use only one treatment pack per patient (10 × 3-ml
syringes). Treatments were continued until a sustained pulse was achieved, resuscitation was discontinued
or care was handed over to a clinician at the receiving hospital.
Outcomes
The primary outcome was survival to 30 days.
The secondary outcomes were as follows:
l survived event (sustained return of spontaneous circulation, with spontaneous circulation until
admission and transfer of care to medical staff at the receiving hospital)
l survival to hospital discharge (the point at which the patient is discharged from the hospital acute
care unit, regardless of neurological status, outcome or destination) and to 3, 6 and 12 months
l neurological outcome (measured using the modified Rankin Scale) at hospital discharge and at 3 and
6 months (assessed at discharge using the Rankin Focused Assessment), and completed at 3 and
6 months via the simplified modified Rankin Scale questionnaire
l neurological outcomes (measured using the Informant Questionnaire on Cognitive Decline in the
Elderly and ‘Two Simple Questions’) at 3 and 6 months
l health-related quality of life at 3 and 6 months (measured using the Short Form questionnaire-12
items and the EuroQol-5 Dimensions, five-level version)
l cognitive outcome at 3 months (measured using the Mini Mental State Examination)
l anxiety and depression at 3 months (measured using the Hospital Anxiety and Depression Scale)
l post-traumatic stress at 3 months (measured using the Post-traumatic stress disorder Checklist-
Civilian version)
l hospital length of stay
l intensive care unit length of stay.
Economic evaluation
The primary economic evaluation was the incremental cost per quality-adjusted life-year gained from
the perspective of the NHS and Personal Social Services.
The secondary economic evaluation considered the cost of critical care stay (level 2/3 days), the cost of
hospital stay, utilisation of NHS and Personal Social Services resources after discharge and broader
resource utilisation after discharge.
Data were collected on the health and social service resources used in the treatment of each trial
participant during the period between randomisation and 6 months post randomisation.
An incremental cost-effectiveness analysis was performed, and results were presented using incremental
cost-effectiveness ratios and cost-effectiveness acceptability curves, generated via seemingly unrelated
linear regressions and non-parametric bootstrapping. A decision-analytic model was used to extrapolate
economic outcomes beyond the trial-follow-up and to assess the cost-effectiveness of adrenaline over
the lifetimes of cardiac arrest survivors. Long-term costs and health consequences were reduced to
present values using discount rates recommended for health technology appraisal in the UK. A series of
probabilistic sensitivity analyses were undertaken to explore the implications of parameter uncertainty
on the incremental cost-effectiveness ratios.
Sample size and statistical analysis
The target sample size was 8000 participants, which was expected to give a width of the 95%
confidence interval for the risk ratio of approximately 0.4 or slightly less; for a risk ratio of 1.25, the
95% confidence interval was 1.07 to 1.46, and for a risk ratio of 1.0, it was 0.84 to 1.19. During the
conduct of the trial, the event rate for the primary outcomes was observed to be lower than that
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originally expected. Modelling various scenarios, and noting that an absolute risk reduction of 1% had
been used widely in resuscitation trials to define the minimal clinically important difference, it was
concluded that the trial would still yield valuable information about the safety and clinical effectiveness
of adrenaline if the observed survival rates continued to the end of the trial.
The primary analysis was performed with and without adjustment in the modified intention-to-treat
population, which included all the patients who had undergone randomisation and were confirmed to
have received the assigned intervention. Fixed-effect regression models were used to examine survival
outcomes with and without adjustment. Variables included in adjusted analyses were age, sex, the time
between the 999 call and the ambulance arriving at the scene, the time between the ambulance
arriving and trial drug administration, the suspected aetiology of the cardiac arrest, the initial heart
rhythm, whether or not the event was witnessed, and whether or not a bystander undertook
cardiopulmonary resuscitation.
The Hodges–Lehmann method was used to estimate median differences with 95% confidence intervals
for length-of-stay outcomes. In cases in which the proportional odds assumption was violated in modelling
of the score on the modified Rankin Scale, partial proportional odds models were used. Scores on the
modified Rankin Scale were also analysed as a binary outcome (with scores of 0–3 classified as ‘good’ and
scores of 4–6 classified as ‘poor’). Other secondary outcomes (including quality of life and neurological
and cognitive functions) were summarised by treatment arm. To aid in interpretation, we included a
Bayesian analysis for the primary outcome and for survival with a favourable neurological outcome.
Patient and public involvement
A community engagement event was held prior to the start of the trial to assess the need and
acceptability of the trial and to explore which outcomes were most important to patients. Information
about the trial was disseminated through both health-care and non-health-care settings. Throughout
the trial, we met regularly with patient and public groups, including a patient and public advisory group.
A lay member of the trial team and two independent patient and public representatives served on the
Trial Management Committee and Trial Steering Committee, respectively.
Results
From December 2014 to October 2017, 8014 patients were assigned either to the adrenaline arm
(n = 4015) or to the placebo arm (n = 3999). At 30 days, 130 out of 4012 patients (3.2%) in the
adrenaline arm and 94 out of 3995 patients (2.4%) in the placebo group were arm (adjusted odds
ratio for survival 1.47, 95% confidence interval 1.09 to 1.97). For secondary outcomes, a larger
proportion of participants in the adrenaline arm than in the placebo arm survived to hospital admission
(23.6% vs. 8.0%; adjusted odds ratio 3.83, 95% confidence interval 3.30 to 4.43). The rate of favourable
neurological outcome at hospital discharge was not significantly different between the arms (2.2% in
the adrenaline arm vs. 1.9% in the placebo arm; adjusted odds ratio 1.19, 95% confidence interval 0.85
to 1.68). The pattern of improved survival, but no significant improvement in neurological outcomes,
continued to 6 months. By 12 months, survival in the adrenaline arm was 2.7%, compared with 2.0% in
the placebo arm (adjusted odds ratio 1.38, 95% confidence interval 1.00 to 1.92). A Bayesian analysis
found a 37% probability that the absolute rate of survival was > 1% in the adrenaline arm and a 1.9%
probability for a > 1% improvement in favourable neurological outcome. An adjusted subgroup analysis
did not identify any significant interactions.
Severe neurological impairment (a score of 4 or 5 on the modified Rankin Scale) at discharge was more
common among survivors in the adrenaline arm than among those in the placebo arm [39/126 (31.0%)
vs. 16/90 (17.8%) patients, respectively]. The number of patients with severe neurological impairment
decreased through to 6 months, although evaluation was limited by greater loss to follow-up.
SCIENTIFIC SUMMARY
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Examining health-related quality of life up to 6 months after randomisation and examining cognitive
function, anxiety/depression or post-traumatic stress to 3 months showed that there was significant
functional impairment in cardiac arrest survivors, compared with the normal population. One-third to
half of patients reported that they needed help from someone with everyday activities. For most, this
was a new situation after their cardiac arrest. Fewer than half reported having made a full mental
recovery after their cardiac arrest. Although underpowered, the pattern of impairment suggested
greater disability in the adrenaline group.
The incremental cost-effectiveness ratio for adrenaline was estimated at £1,693,003 per quality-
adjusted life-year gained over the first 6 months after the cardiac arrest event, and £81,070 per
quality-adjusted life-year gained over the lifetime of survivors. The associated adjusted mean
incremental net monetary benefit of adrenaline at cost-effectiveness thresholds of £30,000 per
quality-adjusted life-year was –£1282 (95% confidence interval –£1733 to –£831) at 6 months and
–£1118 (95% confidence interval –£2776 to £487) over the lifetime of survivors.
Conclusions
Findings from this research indicate that adrenaline was effective at restarting the heart and sustaining
circulation to hospital admission following out-of-hospital cardiac arrest. Adrenaline also improved
long-term survival, but did not improve survival with favourable neurological outcome. The incremental
cost-effectiveness ratio per quality-adjusted life-year exceeds the level usually supported by the NHS.
Further research is required to better understand patients’ preferences in relation to survival and
neurological outcome after out-of-hospital cardiac arrest and to aid interpretation of the trial
findings from a patient and public perspective. Further research examining the time to adrenaline
administration and the route of administration (intravenous or intraosseous) may provide additional
insights to the trial’s findings.
Trial registration
This trial is registered as ISRCTN73485024 and EudraCT 2014-000792-11.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 25.
See the NIHR Journals Library website for further project information.
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Out-of-hospital cardiac arrest (OHCA) is defined as the loss of functional cardiac mechanical activity,
in association with an absence of systemic circulation, occurring outside a hospital setting.1
The majority of OHCA events result from cardiac causes such as ischaemic heart disease, myocardial
infarction and rhythm disturbances. Other causes of OHCA include trauma, submersion, drug overdose,
asphyxia, exsanguination or other medical causes such as stroke or pulmonary embolism.2,3
Cardiac arrest occurs through three different mechanisms: (1) lethal arrhythmias [ventricular fibrillation
(VF) or pulseless ventricular tachycardia (VT)] leading to loss of cardiac output, (2) insufficient myocardial
contraction to produce cardiac output [pulseless electrical activity (PEA)] and (3) complete failure of the
electrical conduction system of the heart (asystole).
Manifestation of OHCA is dramatic: blood supply to the brain and vital organs ceases within seconds,
the patient loses consciousness and the process of cell death commences. The window of opportunity to
achieve return of spontaneous circulation (ROSC) is very narrow: a matter of minutes. Delays in attempts
to restart the heart have catastrophic consequences, increasing the likelihood of death or severe
neurological injury. Prolonged duration of resuscitation attempts is associated with poor outcomes.
The Department of Health and Social Care’s Cardiovascular Disease Outcomes Strategy: Improving
Outcomes for People With or at Risk of Cardiovascular Disease,4 published in 2013, estimated that an
increase in the survival rate from OHCA in England of between 10% and 11% could save > 1000 lives
each year. Resuscitation to Recovery: A National Framework to Improve Care of People with Out-of-Hospital
Cardiac Arrest (OHCA) in England,5 was published in 2017, providing a consensus on the optimal
pathway for OHCA in England. Research to improve understanding of resuscitation from OHCA was
identified as a national priority. Similar initiatives have been published in the devolved nations.6–8
Chain of survival
The chain of survival9 concept (Figure 1) is recognised internationally and summarises the key
components of the response to OHCA to optimise the chances of survival. The links in the chain are
discussed in more detail in the following sections.
Chain of survival
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FIGURE 1 The chain of survival.9 CPR, cardiopulmonary resuscitation. Reprinted from Resuscitation, Vol. 71, Nolan J,
Soar J, Eikeland H, The chain of survival, pp. 270–1, Copyright 2006, with permission from Elsevier.
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Early access
The first link in the chain highlights that it is important to identify a patient at risk of cardiac arrest
(e.g. someone with an acute coronary syndrome) or a patient who has suffered a cardiac arrest (signs
of which are loss of consciousness and absence of normal breathing). Rapid identification and calling
for help early allow the ambulance service to send a trained advanced life support team to them as
quickly as possible.
Raising public awareness of OHCA and the steps members of the public can take to increase chances
of survival [calling 999 immediately and commencing cardiopulmonary resuscitation (CPR)] are the
subject of major campaigns led by the British Heart Foundation and Resuscitation Council (UK),
voluntary aid societies such as St John Ambulance and British Red Cross, and NHS ambulance
services. World ‘Restart a Heart’ Day is an annual initiative that aims to train as many people as
possible in CPR in 1 day.10 NHS England has led work on improving ambulance call-taker’s recognition
of life-threatening emergencies such as cardiac arrest, based on information provided by the person
calling 999/111, as a component of the Ambulance Response Programme.11 Ambulance telephone
triage using NHS Pathways to identify OHCA accurately identifies 75% of adult OHCA {sensitivity
0.759 [95% confidence interval (CI) 0.473 to 0.773], specificity 0.986 (95% CI 0.9858 to 0.98647),
positive predictive value 26.80% (95% CI 25.88 to 27.73)}.12 This facilitates despatch of an ambulance
response with the highest priority, and the provision of advice and support to the caller on how to
perform CPR pending arrival of trained personnel. In other countries, such as Singapore, a comprehensive
programme of ambulance dispatcher telephone support was associated with a doubling in bystander CPR
rates.13 When the ambulance service is aware of a nearby defibrillator, there is an opportunity to direct
the caller and/or another responder to retrieve this, provided this does not delay or interrupt bystander
CPR (see High-quality cardiopulmonary resuscitation).
High-quality cardiopulmonary resuscitation
Cardiopulmonary resuscitation is the combination of chest compressions and ventilations, and is
optimally started by those initially at the scene of the collapse (bystander CPR). Bystander CPR
increases the odds of survival by 1.23 (95% CI 0.71 to 2.11) in the studies with the highest baseline
survival rates, to 5.01 (95% CI 2.57 to 9.78) in the studies with the lowest baseline rates.14 When the
emergency medical services (EMS) arrive on scene, they will take over CPR. Current resuscitation
guidelines highlight the importance of high-quality CPR for ensuring optimal outcomes from cardiac
arrest.15 High-quality CPR is CPR that ensures an adequate chest compression depth is achieved
(5–6 cm), that the compression rate is 100–120 per minute, that interruptions are minimised (for
rhythm check/defibrillation and during extrication) and that the chest is allowed to recoil between
chest compressions.
There are no randomised trials evaluating different compression parameters. Nevertheless, high-quality
CPR appears to be important for outcomes.16 Experimental studies show a linear increase in cardiac
output and coronary perfusion pressure with increasing compression depths.17,18 Observational studies
in humans found improved defibrillator shock success19 and trends towards better ROSC rates and
long-term survival with deeper chest compressions.20 Faster chest compression rates (> 100 per
minute) are associated with improved survival21,22 and ensuring that the chest is allowed to recoil
between sequential chest compressions also appears to be important.23
Interruptions in CPR are harmful.24 A particularly critical time to minimise interruptions to CPR is
around the time of attempted defibrillation. Prolonged pre-shock and peri-shock interruptions in CPR
reduce the chances of shock success19 and survival.25
Mechanical chest compression has not been shown in randomised trials to improve the outcome
of OHCA.26
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Early defibrillation
Approximately one-quarter of OHCAs in the UK are due to an arrhythmia either VF or pulseless VT.
These rhythms are referred to as shockable rhythms, as the arrhythmias may be terminated and
cardiac function restored by the successful delivery of defibrillator shocks. The time from the onset
of VF/VT to the delivery of a shock is critical to shock success and the chances of survival. For every
60–90 seconds that a shock is delayed, the chances of survival fall by approximately 10%.27
If a defibrillator is immediately available at the scene of a cardiac arrest, defibrillation should be
attempted without delay. When there is a delay in applying a defibrillator, there is a theoretical
rationale that providing CPR before a shock improves coronary perfusion and, therefore, the chances
of achieving sustained ROSC.28
This concept was evaluated by the Resuscitation Outcomes Consortium (ROC) in a cluster randomised
trial comparing early analysis (30–60 seconds of EMS-administered CPR before initial rhythm analysis)
with later analysis (180 seconds of CPR before the initial electrocardiographic analysis).29 The primary
outcome was survival to hospital discharge with satisfactory functional status [a modified Rankin Scale
(mRS) score of ≤ 3, on a scale of 0–6, with higher scores indicating greater disability]. The trial enrolled
9933 patients (5290 to early analysis and 4643 to late analysis) but found no difference in outcomes
(cluster-adjusted difference of –0.2%, 95% CI –1.1% to 0.7%).
Public access defibrillation (PAD) has the potential to improve outcomes of OHCA. A national scheme
led by the Department of Health and Social Care was launched in England in 1999 and was focused
on busy public places such as railway stations.30 ROSC was reported for 170 out of 437 (39%) patients,
and hospital discharge was reported for 113 out of 437 (26%) patients.31 A systematic review of
observational studies reported an overall median survival of 40% (range 9–83.3%) in OHCA patients
treated by PAD, with defibrillation by bystanders associated with median survival rates of 53%
(range 26–72%).32 In a further systematic review, bystander automated external defibrillator (AED)
use was associated with survival to hospital discharge [odds ratio (OR) 1.66, 95% CI 1.54 to 1.79]
and favourable neurological outcome (OR 2.37, 95% CI 1.58 to 3.57) in patients with shockable
rhythms. However, the quality of the evidence quality was deemed to be low to very low.33
Public access defibrillators are underutilised in OHCA. A retrospective review of OHCA in Hampshire
reported that callers had access to an AED in 44 (4.2%) OHCA cases, and that AEDs were used before
ambulance arrival in only 18 (1.7%) cases.34 A systematic review of barriers to and facilitators of the
use of PADs identified a range of themes, including knowledge and awareness, willingness to use,
acquisition and maintenance, availability and accessibility, training issues, registration and regulation,
medicolegal issues, EMS dispatch-assisted use of AEDs, AED locator systems, demographic factors,
and other behavioural factors. The quality of the evidence was deemed to be very low.35 Deakin et al.36
recently mapped 4012 OHCAs to 2076 AEDs known to the South Central Ambulance Service, and
reported that only 5.9% of the AEDs were within a 100 m radius of OHCA locations during daytime,
falling to 1.59% during out of hours.
Adrenaline
Treatment with adrenaline has been an integral component of advanced life support from the birth
of modern CPR in the early 1960s. In guidelines written originally in 1961, Safar37 recommended the
use of adrenaline: 1 mg intravenously or 0.5 mg intracardiac. Adrenaline has been recommended in
successive guidelines from around the world. An analysis of drug use across 264 EMS agencies in
the USA and Canada reported that 81% (range 57–98%) of patients experiencing an OHCA received
adrenaline.38 The Out-of-Hospital Cardiac Arrest Outcomes (OHCAO) registry reported that 77.5%
of patients in England and Wales received adrenaline as part of their treatment for OHCA.39
Animal studies show that injection of adrenaline during cardiac arrest increases aortic tone, thereby
augmenting coronary blood flow.40,41 However, there are limited reliable data to assess the effects of
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adrenaline on long-term outcomes after cardiac arrest. The International Liaison Committee on
Resuscitation (ILCOR) synthesised the available evidence for adrenaline in 2010 (also reassessed in
October 2012) and noted that, although adrenaline may improve the rate of ROSC and short-term
survival, there is insufficient evidence to suggest that adrenaline improves survival to discharge from
hospital and neurological outcome. ILCOR stated that placebo-controlled trials to evaluate the use of
any vasopressor in adult and paediatric cardiac arrest are needed.42
Post-resuscitation care
The ROSC marks the start of the post-resuscitation care phase of treatment.43 Unless the arrest has
been relatively brief, most patients who achieve ROSC will have an obtunded consciousness level,
necessitating admission to intensive care. The focus of the post-resuscitation care phase of treatment
is stabilising cardiac function to prevent further cardiac arrest and minimising the consequences of the
cardiac arrest on neurological outcome. This involves the use of targeted temperature management,
the avoidance of hyperglycaemia and coronary angiography to guide coronary reperfusion, if required.
Post-resuscitation care treatments are initiated by ambulance clinicians and continue after the patient’s
arrival in the emergency department (ED) and in the intensive care unit (ICU). Patients with ROSC who
have evidence of ST-segment elevation on a 12-lead electrocardiogram (ECG) are transferred directly to
the cardiac catheter laboratory for urgent angiography revascularisation, if appropriate, in accordance
with National Institute for Health and Care Excellence (NICE) guidance.44 A recent randomised clinical
trial suggested no benefit for urgent angiography in post-cardiac arrest patients without ST-segment
elevation on a 12-lead ECG,45 but other trials evaluating the role of urgent coronary angiography in
these patients are ongoing.46–51
Incidence and burden of disease
The societal burden of OHCA has been described as equal to or greater than that of other leading
causes of death.52 Each year, an estimated 275,000 people in Europe experience an OHCA, with
< 30,000 surviving to hospital discharge.53 The UK OHCA outcome project, a prospective observational
study involving all UK NHS ambulance services, reported that 28,729 patients were treated for OHCA
by the 10 ambulance services in England in 2014 (53/100,000 population), with 7.9% surviving to
hospital discharge.2 Globally, estimates of OHCA outcomes vary across countries, with survival to
hospital discharge rates of 7.6% in Europe, 6.8% in North America, 3% in Asia and 9.7% in Australia.54
Out-of-hospital cardiac arrest exerts a major burden on NHS resources (ambulance response,
emergency treatment, post-resuscitation care, rehabilitation) and years of life lost, but treatment
currently has a low chance of success.
Existing evidence
A Cochrane review55 identified a single randomised, placebo-controlled trial of intravenous (i.v.) adrenaline
in OHCA (the search was conducted in December 2012). The Pre-hospital Adrenaline for Cardiac
Arrest (PACA) trial,56 conducted by our co-investigators Judith Finn and Ian G Jacobs, was undertaken
in Western Australia. The study aimed to enrol 5000 patients, but, at the time the study closed, only 601
patients had been randomised. The relatively small numbers led to the results having large uncertainty.
The rate of ROSC (short-term survival) was higher in those receiving adrenaline [64/272 (23.5%) vs.
22/262 (8.4%) patients; OR 3.4, 95% CI 2.0 to 5.6], but there was no clear evidence of a benefit in
survival to hospital discharge (long-term survival) [adrenaline arm, 11 (4.0%) patients, vs. placebo
arm, 5 (1.9%) patients; OR 2.2, 95% CI 0.7 to 6.3]. Two of the survivors in the adrenaline arm, but none
in the placebo arm, had a poor neurological outcome. In addition to the trial’s imprecision, interpretation
of the findings is limited by a large number of post-randomisation exclusions (n = 67, 11%).
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A second randomised study, conducted in Oslo, Norway, compared i.v. cannulation and injection of
drugs (including adrenaline) with no i.v. cannula or drugs among 851 patients experiencing an OHCA.57
The patients in the i.v. arm had better short-term survival rates [ROSC: i.v. arm, 165/418 (40%), vs.
no i.v. arm, 107/433 (25%); OR 1.99, 95% CI 1.48 to 2.67]; however, there was no clear difference
between arms in long-term survival outcomes {survival to hospital discharge: i.v. arm, 44/418 (10.5%),
vs. no i.v. arm, 40/433 (9.2%); OR 1.16, 95% CI 0.74 to 1.82; favourable neurological outcome [measured
using the Cerebral Performance Category (CPC) 1 or 2]: i.v. arm, 9.8%, vs. no i.v. arm, 8.1%; OR 1.24,
95% CI 0.77 to 1.98}. The increase in the rate of ROSC was seen mainly in the patients with initial
non-shockable rhythms (asystole and PEA): 29% in the i.v. arm versus 11% in the no i.v. arm. The rate
of ROSC was 59% in the i.v. arm, compared with 53% in the no i.v. arm, in those patients with an initial
rhythm of VF/VT.
In the post hoc analysis of the i.v. versus no-i.v. trial, outcomes were examined according to whether or
not a patient had actually received adrenaline.58 Treatment with adrenaline (n = 367) was associated
with a greater chance of being admitted to hospital (OR 2.5, 95% CI 1.9 to 3.4). However, long-term
survival outcomes were worse, with reduced survival to hospital discharge [adrenaline arm, 24/367
(7%), vs. no adrenaline arm, 60/481 (13%); OR 0.5, 95% CI 0.3 to 0.8] and reduced neurologically intact
(CPC 1 or 2) survival [adrenaline arm, 19/367 (5%), vs. no adrenaline arm, 57/481 (11%); OR 0.4, 95% CI
0.2 to 0.7]. These effects persisted after adjustment for confounding factors (VF, response interval,
witnessed arrest, sex, age and tracheal intubation).
At the time of developing the Pre-hospital Assessment of the Role of Adrenaline Measuring the
Effectiveness of Drug administration In Cardiac arrest 2 (PARAMEDIC2) trial, three large observational
studies59–61 suggested that adrenaline may cause worse long-term outcomes. The largest observational
study of adrenaline use in cardiac arrest involves 417,188 OHCAs in Japan.59 In propensity-matched
patients, use of adrenaline was associated with an increased rate of ROSC [adjusted odds ratio (aOR)
2.51, 95% CI 2.24 to 2.80], but was also associated with a 1-month survival rate of approximately half
that achieved among those not given adrenaline (aOR 0.54, 95% CI 0.43 to 0.68). In another observational
study from the Osaka group in Japan,60 1013 (32.0%) of 3161 patients who were analysed received
adrenaline. Those patients receiving adrenaline had a significantly lower rate of neurologically intact
(CPC 1 or 2) 1-month survival than those not receiving adrenaline (4.1% vs. 6.1%, respectively; OR 0.69,
95% CI 0.48 to 0.98).
An analysis of registry data had shown reduced survival in those who received adrenaline; The North
American ROC Epistry (n = 16,000) found an inverse association between adrenaline dose and survival
to discharge (survival was > 20% for those not requiring adrenaline, and fell to < 5% for those requiring
more than two doses). This finding persisted after adjustment for age, sex, EMS-witnessed arrest,
bystander-witnessed arrest, bystander CPR, shockable initial rhythm, time from 911 call to EMS arrival,
the duration of OHCA and study site.38 This was similar to a previous analysis of the Swedish Registry
(n = 10,000 patients; OR of long-term survival 0.43, 95% CI 0.27 to 0.66).61
This creates the paradox of better short-term survival at the cost of worse long-term outcomes, in
other words a ‘double-edged sword’.62 However, observational studies are limited by the influence of
confounding variables that may introduce bias, in particular the phenomenon known as resuscitation
time bias, whereby an exposure is more likely to occur the longer the cardiac arrest continues. Because
duration of resuscitation is strongly associated with worse outcome, this will bias the results towards
a harmful effect of the exposure.63 The importance of differences in analytical approaches and the way
they control for resuscitation time bias is illustrated by the discordant findings from the analysis of the
same data set, whereby one study shows benefit64 and the other demonstrates harm.59
Mechanisms by which adrenaline may cause harm
There are a number of mechanisms by which adrenaline may cause harm. These can be considered
under the following headings.
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Reduced microvascular blood flow and exacerbation of cerebral injury
In animal models of cardiac arrest, adrenaline increases coronary perfusion pressure (which predicts
restarting the heart), but impairs macrovascular and microvascular cerebral blood flow. Specifically,
adrenaline was noted to reduce carotid blood flow65 and microvascular blood flow,29 causing worsening
cerebral ischaemia.66
Cardiovascular toxicity
In a further analysis of the Norwegian i.v. versus no i.v. trial,57 adrenaline increased the frequency
of transitions from PEA to ROSC and extended the time window for ROSC, but at a cost of greater
cardiovascular instability after ROSC, with a higher rate of re-arresting. These observations were
consistent with other studies that linked adrenaline with ventricular arrhythmias and increased
post-ROSC myocardial dysfunction.67 In human studies with patients with sepsis68 or acute lung
injury,69 beta-agonist stimulation was similarly linked to cardiovascular instability and reduced
survival.70 A systematic review of beta-blocker treatment in animal models of cardiac arrest found
that fewer shocks were required for defibrillation; that myocardial oxygen demand was reduced; and
that post-resuscitation myocardial stability improved, with less arrhythmia and improved survival.71
Metabolic effects
Adrenaline causes lactic acidosis,72 which is associated with poor outcomes after cardiac arrest.73,74
It also induces stress hyperglycaemia, which is also associated with poorer outcomes.75
Immunomodulation and predisposition to infection
Infective complications, including bacteraemia and early-onset pneumonia, are common after OHCA,
and are associated with worse outcomes.76 The immune-modulatory effects of beta agonists have
been well characterised and may reduce host defence against infection,77 which may contribute to
an increased susceptibility to post-resuscitation sepsis.
Summary of effects
Use of adrenaline in cardiac arrest increases short-term survival (i.e. ROSC), but doubt remained about
whether or not this translated into better long-term outcomes.
Rationale for intervention
Whether or not the practice of giving adrenaline is effective remained an important question that
needed to be answered. Uncertainty about adrenaline has been raised by recent evidence59–61
suggesting that it may be harmful. Resolving this uncertainty was urgent, as adrenaline is used widely
to treat cardiac arrests, and, if harmful, may be responsible for many avoidable deaths. There have
been several precedents whereby treatments have been evaluated after years or decades of use and
had been found to be ineffective or harmful, including pulmonary artery catheters in intensive care,78
beta agonists for acute respiratory distress syndrome69 and corticosteroids for head injury.79 It was
therefore possible that adrenaline for cardiac arrest might be a similar case.
The ILCOR appraised the evidence surrounding adrenaline use for OHCA in 201042 and again in
October 2012. It concluded that there was an urgent need for randomised, placebo-controlled trials
of adrenaline.
We conducted a written survey of 213 attendees (doctors, nurses, paramedics) of the Resuscitation
Council (UK) Annual Scientific Symposium in September 2012 to assess the scientific and clinical
communities’ current perspectives on the role of adrenaline in the treatment of cardiac arrest.
Respondents expressed their agreement to a series of statements on a seven-point Likert scale
(1 = strongly disagree, 7 = strongly agree). Respondents reported that adrenaline increased short-term
survival [median score 6, interquartile range (IQR) 6–7], but disagreed that it improved long-term
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outcomes [median score 2 (IQR 2–3)]. The greatest uncertainty was around the balance of risks and
the benefits of i.v. adrenaline (Figure 2). Respondents felt that the most pressing future research need
for the NHS was a trial comparing adrenaline with placebo (Figure 3).
A trial addressing this question was timely, because of the recent publication of studies questioning the
effectiveness of adrenaline, and calls for a large-scale randomised controlled trials to resolve this issue.
There were no other completed, ongoing or planned trials in the ClinicalTrials.gov [https://clinicaltrials.gov/
(1 January 2012)] or controlled-trials.com (accessed 2012) databases. Moreover, research projects
[e.g. the Prehospital Randomised Assessment of a Mechanical compression Device In Cardiac arrest
(PaRAMeDIC) trial81 in 2010] had shown the feasibility of conducting large-scale OHCA trials in the UK.
The learning from the PaRAMeDIC trial,81 undertaken by this group, helped to ensure efficient and
successful recruitment.
The emerging data suggested that a number of experimental strategies could be considered, including
comparing adrenaline with alpha 2 agonists, comparing adrenaline with beta blockade, lower-dose
adrenaline or adrenaline as a continuous infusion. Preferences of the clinical community are
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FIGURE 2 Perspectives of the UK clinical community on the role of adrenaline for the treatment of cardiac arrest.80
Reprinted from Resuscitation, Vol. 108, Perkins GD, Quinn T, Deakin CD, Nolan JP, Lall R, Slowther A, et al., Pre-hospital
Assessment of the Role of Adrenaline Measuring the Effectiveness of Drug administration In Cardiac arrest (PARAMEDIC-2):































FIGURE 3 Preferences of the UK clinical community.80 Reprinted from Resuscitation, Vol. 108, Perkins GD, Quinn T,
Deakin CD, Nolan JP, Lall R, Slowther A, et al., Pre-hospital Assessment of the Role of Adrenaline Measuring the
Effectiveness of Drug administration In Cardiac arrest (PARAMEDIC-2): trial protocol, pp. 75–81, Copyright 2016, with
permission from Elsevier.
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this was primarily dependent on ambulance response times, which were difficult to control for in
a randomised trial. We suggested that the most pressing need was for a definitive trial comparing
standard-dose adrenaline (1 mg every 3–5 minutes) with placebo. Until there was clarity about the
effect of adrenaline on long-term outcomes, the best comparator agent (placebo or standard-dose
adrenaline) for trials of other agents remained unknown.
This randomised controlled trial of adrenaline had the support of key stakeholders, such as patient
representatives, the College of Paramedics, the National Ambulance Services Medical Directors’ Group,
the Joint Royal Colleges Ambulance Liaison Committee (JRCALC), the Resuscitation Council (UK) and
the British Heart Foundation.
Objectives
Primary objective
The primary objective of this trial was to determine the clinical effectiveness of adrenaline in the
treatment of OHCA, measured as a primary outcome of 30-day survival.
Secondary objective
The secondary objectives of the trial were to evaluate the effects of adrenaline on survival and on
the cognitive and neurological outcomes of survivors, and to establish the cost-effectiveness of
using adrenaline.
INTRODUCTION




This was a pragmatic, randomised, allocation-concealed, placebo-controlled, parallel-group superiority
trial and economic evaluation. Participants were randomised to either adrenaline (intervention) or
placebo (control) in a 1 : 1 allocation ratio. Randomisation took place when a trial-trained paramedic
opened an Investigational Medicinal Product (IMP) pack, which contained either 10 syringes of
adrenaline (1 mg) or a matching placebo (0.9% saline). The primary outcome was survival to 30 days.
Secondary outcomes focused on patient, clinical, resource and economic outcomes. Patients, clinical
teams and those assessing patient outcomes were masked to the treatment allocation.
Figure 4 shows the planned flow of participants through the trial.
Pilot trial
An internal pilot was run to test that the components of this trial worked together. This pilot ran for
6 months. The data from this were included in the main trial. During the pilot, we measured recruitment
rate and compliance with the allocated intervention, and checked that the approach to data collection
and follow-up worked effectively. The pilot phase ran seamlessly into the main trial. The results of the
pilot trial were reviewed with the Trial Steering Committee (TSC), the Data Monitoring Committee
(DMC) and representatives from the Health Technology Assessment (HTA) programme, specifically
considering the achievement of the following targets:
l 25% of ambulance staff trained [i.e. the majority (80%) of participating staff at 25% of stations]
l 181 patients recruited within 6 months of first randomisation
l data available on primary outcome – > 98%
l proportion of patients who are alive agreeing to follow–up – > 75%
l reconcile IMP packs with participants enrolled in the trial
l review of the approach to inform patients and relatives of trial participation
l review of feasibility to collect secondary outcomes.
All pilot objectives were achieved, and the TSC approved continuation to the main phase of the trial on
7 May 2015.
Changes to trial design
There were no substantial changes to the trial design. Table 1 lists all amendments to the trial and
details of the changes made. Reasons for changes to the trial design describes the reason for the change
in exclusion criteria (amendment 6).
Reasons for changes to the trial design
Amendment 4
This amendment updated the Research Ethics Committee (REC) application to confirm that participants
who were prisoners or young offenders in the custody of Her Majesty’s Prison Service or who were
offenders supervised by the probation service in England or Wales would be included in the trial.
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The rationale for not excluding prisoners was as follows:
l There may be practical difficulties in identifying a prisoner in an emergency situation.
l Attempting to establish if someone is a prisoner may lead to confusion and delay of treatment,
which may cause harm.
l Prisoners are not being recruited to the trial because of their position as prisoners, they are being
recruited because of their interaction with the NHS in a cardiac arrest situation.













































OHCA, resuscitation attempted n = 32,000 over five ambulance
services over 3 years
FIGURE 4 Flow chart for PARAMEDIC-2 trial.80 LTFU, lost to follow-up. Reprinted from Resuscitation, Vol. 108, Perkins GD,
Quinn T, Deakin CD, Nolan JP, Lall R, Slowther A, et al., Pre-hospital Assessment of the Role of Adrenaline Measuring the
Effectiveness of Drug administration In Cardiac arrest (PARAMEDIC-2): trial protocol, pp. 75–81, Copyright 2016, with
permission from Elsevier.
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TABLE 1 Amendments to trial







2 August 2018 21 Unblinding response form Unblinding response form updated v2.0; 7 August 2018 N/A 14 August 2018
Unblinding information sheet Unblinding information sheet updated
and separated into three versions
(non-survivor, survivor with poor
neurological outcome, and survivor
with good neurological outcome)
v2.0; 2 August 2018
25 July 2018 20 Protocol l Project end date extended to
31 July 2018
l Change to protocol wording in
sections 3.2.3 and 5.1 to include
the collection of patient-level data
from the UK Transplant Registry
v6.0; 25 July 2018 N/A 13 November 2018
26 March 2018 19 Protocol l Change to protocol wording in
sections 3.2.3 and 5.1 to include
the collection of patient-level data
from the PEDW
l Section 2.9.3 added to include
methods for unblinding treatment
allocation after completion of
the trial
v5.0; 28 March 2018 N/A 3 April 2018
Unblinding information sheet New document to be able to respond
to requests for unblinding
v1.0; 28 March 2018
Unblinding response form New document to be able to respond
to requests for unblinding
v1.0; 28 March 2018
Unblinding cover letter for
response form
New document to be able to respond
to requests for unblinding
v1.0; 28 March 2018
Confirmation of treatment
letter
New document to be able to respond
to requests for unblinding


































































































































































































































































































TABLE 1 Amendments to trial (continued )







28 February 2018 18 Protocol Section 2.6.15.1 added to describe
the process for responding to trial
participation enquiries
v4.0; 28 February 2018 N/A 28 February 2018
Cover letter (patient
enrolled)
New document produced to be able to
respond to trial participation enquiries
v1.0; 28 February 2018
Cover letter (patient not
enrolled)
New document produced to be able to
respond to trial participation enquiries
v1.0; 28 February 2018
Trial participation
information sheet
New document produced to be able to
respond to trial participation enquiries
v1.0; 28 February 2018
13 March 2017 17 N/A Addition of hospital (Medway) N/A N/A 17 March 2017
23 January 2017 16 N/A Addition of general practice surgeries
as sites to allow mRS data collection
under HRA approval
N/A N/A 23 January 2017
13 December 2016 15 N/A Addition of two hospital sites
(Luton and Dunstable, and Bedford)
N/A N/A 20 December 2016
24 November 2016 14 N/A Translations and back translations of
patient information sheet, consent
forms and cover letters into Arabic,
Gujarati, Hindi, Polish, Punjabi, Urdu
and Welsh
N/A N/A 14 December 2016
2 November 2016 13 GP letter (mRS) New letters for GPs to collect mRS
data (two versions – one for consent
and one for passive follow-up)
v1.0; 1 November 2016 N/A 18 November 2016
21 October 2016 12 Protocol Addition of quality of CPR data
collection





































1 June 2016 11 Protocol l Section 2.5.2 (exclusion criteria)
clarification added
l Section 2.9.2 (unblinding) updated
l Section 3.2.4 (quality of CPR)
added
l Section 4.2 (SAEs) clarification
added
l Section 5.1 (data collection)
updated to include Hospital
Episode Statistics and Office for
National Statistics data
l Other minor amendments
v2.0; 4 May 2016 N/A 20 June 2016
Patient information sheets l Separate versions created for
approach in hospital or after
hospital discharge
l Wording updated as required
by NHS Digital to obtain
mortality data
v2.0; 8 April 2016
Patient information sheets
cover letters
Separate versions created for patient
and legal representative and approach
in hospital or after hospital discharge
v2.0; 8 April 2016
Consent forms Wording updated to include reference
to Health and Social Care Information
Centre (former name of NHS Digital)
and Office for National Statistics
v2.0; 8 April 2016
(note that the legal
representative consent
form was amended to
v2.1 because of a
typographical error)
28 October 2015 10 N/A Addition of four hospitals (Burton
Hospitals NHS Foundation Trust,
Western Sussex Hospitals NHS
Foundation Trust, University Hospitals
Bristol and Weston NHS Foundation
Trust, and Countess of Chester
Hospital NHS Foundation Trust)


































































































































































































































































































TABLE 1 Amendments to trial (continued )







28 October 2015 9 GP letter GP letter about survival and mRS
scores for non-responders
v1.0; October 2015 N/A 9 November 2015
8 September 2015 8 IMP dossier Revision of IMP dossier to extend IMP
shelf life to 12 months
4.0 15 October 2015 9 November 2015
10 July 2015 7 N/A Addition of Royal Surrey County
Hospital
N/A N/A 23 July 2014
24 June 2015 6 Protocol Addition of ‘cardiac arrest secondary
to life-threatening asthma’ as
exclusion criterion
1.1; 24 June 2015 13 July 2015 8 July 2015
11 May 2015 5 Poster for public ‘10 Facts
about the PARAMEDIC2
trial’
New document to raise public
awareness of trial
1.0; 12 May 2015 N/A 22 May 2015
Leaflet for general practice
surgeries
New document to raise public
awareness of trial
1.0; 12 May 2015
Communication strategy Revised document 11 May 2015
3 December 2014 4 N/A Clarification that prisoners would not
be excluded from the trial
N/A N/A 4 December 2014
8 October 2014 3 N/A Addition of English hospitals N/A N/A 8 October 2014
4 September 2014 2 N/A Addition of Welsh hospitals: Bronglais
General Hospital, Glan Clwyd Hospital,
Glangwili General Hospital, Morriston
Hospital, Nevill Hall Hospital, Prince
Charles Hospital, Princess of Wales
Hospital, Prince Philip Hospital,
Royal Glamorgan Hospital, Royal
Gwent Hospital, University Hospital of
Wales, Withybush General Hospital,
Wrexham Maelor Hospital, Ysbyty
Gwynedd, Singleton Hospital,
West Wales General Hospital and
Llandough Hospital





































27 August 2014 1 Patient information sheet Updated following feedback from CAG l 1.1; 4 July 2014
l 1.2; 5 September
2014
N/A 10 October 2014
Consent forms (patient and
legal representative)
Updated following feedback from CAG l 1.1; 4 July 2014
l 1.2; 5 September
2014
Cover letter (patient and
legal representative)
Updated following feedback from CAG l 1.1; 4 July 2014
l 1.2; 5 September
2014
Poster for public ‘OK to Ask’ New document to raise public
awareness of trial
l 1.1; 27 August 2014
l 1.2; 4 September
2014
REC form Part C WAST principal investigator corrected
to Nigel Rees
N/A
CAG, Confidentiality Advisory Group; GP, general practitioner; HRA, Health Research Authority; MHRA, Medicines and Healthcare products Regulatory Agency; N/A, not applicable;


































































































































































































































































































Cardiac arrest secondary to life-threatening asthma was added as a trial exclusion criterion following
amendment 6 on 24 June 2015. Although the published literature points to there being equipoise
about the use of i.v. adrenaline in asthma,82–85 there is evidence that adrenaline may be beneficial for
patients with anaphylaxis. The rationale for the change was that, during the pilot trial, ambulance staff
were concerned about potential overlap between the presentation of asthma and anaphylaxis (both
may present with bronchospasm). Therefore, the Trial Management Group (TMG) felt that the safest




Patients were eligible if both the following criteria were met:
l cardiac arrest in an out-of-hospital environment
l advanced life support initiated and/or continued by an ambulance service clinician.
Exclusion criteria
The exclusion criteria at the time of arrest were as follows:
l known or apparent pregnancy
l known to be or apparently aged < 16 years
l cardiac arrest caused by anaphylaxis or life-threatening asthma
l adrenaline given prior to arrival of ambulance service clinician.
In London Ambulance Service, traumatic cardiac arrests were also excluded, in accordance with
local protocols.
Trial setting
Recruitment took place in five NHS ambulance services in the UK (London Ambulance Service NHS
Trust, North East Ambulance Service NHS Foundation Trust, South Central Ambulance Service NHS
Foundation Trust, West Midlands Ambulance Service University NHS Foundation Trust and Welsh
Ambulance Service NHS Trust). These ambulance services serve a mix of urban and rural locations in
England and Wales, covering a population of 24 million people. They collectively attend ≈32,000 cases
of cardiac arrest each year; resuscitation is attempted or continued by ambulance staff in approximately
45% of these cases.
The ambulance services are activated through a central emergency call number (999, 112 or 111), which
directs the caller to the geographically relevant emergency operations and dispatch centre. Calls are
received and processed by trained NHS ambulance dispatch staff. Dispatch staff use one of two dispatch
support systems: NHS Pathways or Advanced Medical Priority Dispatch System. Cases identified as a
cardiac arrest are assigned the highest priority response. At the time of the trial, ambulance services were
expected to provide a defibrillation-capable response within 8 minutes for 75% of these cases. There was
an expectation of having an ambulance on scene within 19 minutes in 95% of cases. A typical first response
could be a community first responder, a rapid response vehicle (e.g. car, motorbike or bicycle) or an air/land
ambulance. Clinically trained staff, such as paramedics or emergency medical technicians, typically attend
cardiac arrests. They are often supported by emergency care assistants. Paramedics can deliver advanced
life support (ALS) interventions (including advanced airway management and i.v. drugs) and, after trial-
specific training, were able to recruit patients to the trial. Technicians, emergency care assistants and many
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community responders dispatched by the NHS ambulance service can deliver CPR and defibrillation, and
some use supraglottic airways.When ambulance staff arrive at a cardiac arrest, one of the first steps is
for them to assess the appropriateness of a full resuscitation attempt. If there is unequivocal evidence of
death (major traumatic injuries, putrefaction, rigour mortis, post-mortem staining, etc.) NHS guidelines86
allow resuscitation to be withheld. Other situations in which resuscitation may be withheld are when
a patient has a ‘do not attempt cardiopulmonary resuscitation’ instruction, if the patient is in asystole,
if no bystander CPR has been performed or if > 15 minutes have elapsed since the time of collapse.87
Ambulance services follow common national guidelines for resuscitation from the Resuscitation Council
UK guidelines,86 which follow those provided by the European Resuscitation Council.88 The overall UK rate
of survival to discharge for all cases of OHCA for which resuscitation is attempted is 7.9%.89
Trial intervention
Patients were enrolled in the trial by the attending ambulance service clinicians, who determined
whether or not a resuscitation attempt was appropriate (according to the JRCALC guidelines87),
and, if it was, whether or not the patient was eligible. Patients who met the eligibility criteria were
randomised to the trial.
Patients received resuscitation according to the Resuscitation Council (UK) and JRCALC ALS
guidelines.86 All standard ALS interventions were provided, including chest compression, defibrillation
and advanced airway management, as required, with the exception that standard adrenaline was
substituted with trial IMP drawn from a single trial treatment pack. Vehicles also carried their standard
supply of adrenaline, for use only with ineligible patients.
If the patient reached the point in the resuscitation protocol where pharmacological treatments were
indicated, they were randomly assigned to receive either parenteral adrenaline or saline placebo by
the opening of a trial drug pack. Each treatment pack contained 10 × 3-ml prefilled syringes, with
each syringe containing either 1 mg of adrenaline (intervention) or 0.9% saline (control). All trial drug
packs were labelled with a unique trial pack number and in accordance with EudraLex Volume 4
Annex 13 requirements.90 The adrenaline and placebo packs and syringes were identical in appearance;
therefore, clinicians, patients and trial personnel were unaware of whether any specific pack contained
adrenaline or placebo.
Single doses of adrenaline or saline were administered every 3–5 minutes by an i.v. or intraosseous
route. Clinicians were instructed to use only one treatment pack per patient (10 × 3-ml syringes).
Treatments were continued until a sustained pulse was achieved, resuscitation was discontinued or
care was handed over to the clinician at the receiving hospital.
Treatment after admission to hospital was not specified in the trial protocol, but was informed by
national guidelines,91 which covered targeted temperature management, haemodynamic and ventilator
criteria and prognostication.
Randomisation
As recruitment took place in an emergency situation, telephone or internet randomisation was
impractical; therefore, the trial used a system of pre-randomised treatment packs. The trial IMP
was packaged in numbered treatment packs. The pre-randomised sequence was prepared by the
programmers at the Warwick Clinical Trials Unit (WCTU). The randomisation sequence was computer
generated by the stratified randomisation method with concealed assignment, using ambulance service
as a strata, with an allocation ratio of 1 : 1.
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Treatment packs were supplied to each ambulance service in a central location, and were distributed
from there to participating ambulance stations and vehicles. When ambulance service personnel
identified an eligible patient, randomisation was achieved by opening one of the packs carried in the
vehicle attending the arrest.
Post-randomisation withdrawals and exclusions
There were three main sources of post-randomisation withdrawal and exclusions. The first was when,
between randomisation (opening the drug pack) and administering the trial intervention, a patient was
identified as ineligible. Examples of this include when a patient achieved ROSC, when a patient was
confirmed to have died or when a trial exclusion became known to the ambulance clinicians before
drug administration. This group would not receive vasopressor drugs in clinical practice. No follow-up
data were collected on this group of patients and they were identified in the Consolidated Standards
of Reporting Trials (CONSORT) flow diagram as post-randomisation exclusions.
The second situation is when, after drug administration, it subsequently became known that the patient
was ineligible for the trial. An example of this would be discovering in hospital that the cause of the
cardiac arrest was anaphylaxis. This group of patients would be exposed to the vasopressor drugs in
clinical practice, as it is not until after drug administration that the exclusion is discovered. This group of
patients were followed up in the normal manner and included in the intention-to-treat analysis.
The third scenario is when a patient or their legal representative withdrew their consent for ongoing
data collection. This group of patients were eligible for and received the trial intervention, but
incomplete data were obtained on their long-term outcomes. This group of patients were included in
the intention-to-treat analysis, up until the point of withdrawal. The information sheet explained the
trial and the data that were collected. The consent form separated out the different data that were
collected, and gave the patient the option to decline. NHS records were continually used unless the
patient explicitly refused permission for this, as were tracking of the patients via NHS Digital to
determine survival to 12 months post cardiac arrest.
In the rare situation in which a patient had neither consented to nor refused follow-up, they were not
included in the face-to-face follow-up, but data collection from NHS records and in-hospital data
sets continued.
Blinding
Methods for ensuring blinding
The packaging and the labelling of the IMP packs did not reveal which IMP was being used; therefore,
the patient, attending clinicians, hospital treating team, research paramedics and trial administration
team were masked to treatment allocation. Only the statistician was able to link the IMP pack number
to the allocation of adrenaline or placebo.
Methods for unblinding the trial
The chief investigator retained the right to break the code for serious adverse events (SAEs) that were
unexpected and suspected to be causally related to an investigational product, and that potentially
required expedited reporting to regulatory authorities. The chief investigator unblinded if requested to
do so by a coroner as part of a death enquiry. In exceptional circumstances, the chief investigator also
considered requests for unblinding from patients or, if they lacked capacity, family members/next of
kin. In this scenario, the trial statisticians made the unblinding on the chief investigator’s request and
the chief investigator was informed accordingly of the allocation. This occurred only if the request
was made after the benefits and harms of disclosing this information to them had been discussed.
Otherwise, treatment codes (IMP pack number) were broken only for the planned interim analyses
of data by the statistician at the request of the DMC.
METHODS
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Methods for unblinding the trial: after trial completion
Requests for unblinding of treatment allocation were received (either from survivors or from the next
of kin of trial participants who were deceased) after completion of the trial. When these requests were
received, the PARAMEDIC2 trial office sent the enquirer (on behalf of the ambulance services) an
information sheet about unblinding and a response form for completion if they wished to continue with
unblinding after having read the information provided. Once a completed response form was received,
requesting unblinding, the PARAMEDIC2 trial office responded, once checks had been performed to
verify the case details, to confirm the treatment allocation on behalf of the ambulance services, with




The primary outcome was survival to 30 days post cardiac arrest.
Secondary outcomes
l Survived event (sustained ROSC, with spontaneous circulation until admission and transfer of care
to medical staff at the receiving hospital).
l Survival to hospital discharge (the point at which the patient is discharged from the hospital acute
care unit, regardless of neurological status, outcome or destination) and to 3, 6 and 12 months.
l Neurological outcome (mRS) at hospital discharge and at 3 and 6 months [assessed at discharge
using the Rankin Focused Assessment (RFA), and completed at 3 and 6 months via the simplified
modified Rankin Scale questionnaire (smRSq)].
l Neurological outcomes [assessed using the Informant Questionnaire on Cognitive Decline in the
Elderly (IQCODE) and ‘Two Simple Questions’] at 3 and 6 months.
l Health-related quality of life at 3 and 6 months [assessed using the Short Form questionnaire-12
items (SF-12) and the EuroQol-5 Dimensions, five-level version (EQ-5D-5L)].
l Cognitive outcome at 3 months [assessed using the Mini Mental State Examination (MMSE)].
l Anxiety and depression at 3 months [assessed using the Hospital Anxiety and Depression Scale (HADS)].
l Post-traumatic stress at 3 months [Post-traumatic stress disorder Checklist – Civilian Version (PCL-C).
l Hospital length of stay.
l Intensive care unit length of stay.
The outcomes defined by the Utstein convention for reporting outcomes from cardiac arrest92
were reported.
Rationale for outcome measures
The mRS was administered at hospital discharge and at 3 and 6 months. The mRS was selected instead
of the CPC as it is more sensitive to detecting mild cognitive impairment. It can be reliably extracted
from medical records and is a predictor of long-term survival. There was emerging international
consensus (Utstein 2012/1393) that the mRS should be the primary measure of neurological outcome in
cardiac arrest trials. The mRS is a seven-point scale ranging from mRS 0 (no symptoms) to 6 (dead). The
RFA was chosen as a framework for assessing the mRS score at discharge, as this could be completed
using a variety of sources of information, such as a patient assessment, via relatives or hospital staff
or using hospital notes, and has been shown to have high inter-rater reliability.94 The smRSq95 was
used to collect the mRS score at 3 and 6 months, as this could be easily self-completed by the patient
or legal representative. The spectrum of impairment of health-related quality of life following cardiac
arrest includes memory and cognitive dysfunction, affective disorders and post-traumatic stress
disorder (PTSD).96 The SF-12 is a standard quality-of-life measure that is short and easy to complete.
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In addition, the EuroQol-5 Dimensions (EQ-5D) questionnaire was used as a health utility measure for
the health economic analysis. Cognitive function was assessed using the MMSE.97 The IQCODE and the
‘Two Simple Questions’ tool98 formed supplementary assessments of cognitive function. The PCL-C99 is
a 17-item self-administered questionnaire measuring the risk of developing PTSD and had been used in
previous studies as a good surrogate for the clinical diagnosis of PTSD, which requires a face-to-face
interview by a suitably trained professional. The HADS is a 14-item self-administered questionnaire
that had been previously used successfully to measure affective disorders in cardiac arrest survivors.100
Two of these measures (PCL-C and HADS) were used as part of a multicentre follow-up for people
surviving a critical illness (Intensive Care Outcome Network study);101 the people from this study were
used as a reference population.
Health economics
Primary economic outcome
The primary economic outcome was the incremental cost per quality-adjusted life-year (QALY) gained
with use of adrenaline compared with the incremental cost per QALY gained with use of placebo from
the perspective of the NHS and Personal Social Services (PSS) over a 6-month time horizon. QALYs
were calculated using area-under-the-curve methods, assuming linear interpolation between baseline
utility (set to zero) and utility values derived from a combination of mRS and EQ-5D-5L assessments at
hospital discharge and at 3 and 6 months post randomisation.
Secondary economic outcomes
l Incremental cost per QALY gained from the perspective of the NHS and PSS with 1-year and
lifetime (via decision-analytic modelling) time horizons.
l Incremental cost per unit increase in the proportion surviving to 6 months post cardiac arrest,
estimated from an NHS/PSS perspective.
l Incremental cost per unit increase in the proportion surviving with good neurological outcome at
6 months post cardiac arrest, estimated from an NHS/PSS perspective.
l Cost of critical care stay, cost of hospital stay, use of NHS and PSS resources after discharge and
broader resource use after discharge. Resource use and costs were estimated over the 6-month
period from randomisation/cardiac arrest event onwards.
Sample size
Incidence of primary outcome
Most existing data refer to survival to hospital discharge rather than survival to 30 days, but as most
mortality will occur in the first few days after cardiac arrest, we expect these two measures to be
very similar. Estimates of long-term survival of patients who receive adrenaline during a resuscitation
attempt vary between about 3.5% and 12%. From national data for England, overall survival to hospital
discharge of patients for whom resuscitation is attempted is 7%.89 However, this will include a small
number of patients who achieve ROSC immediately and would not receive adrenaline, and hence
would not be recruited to the trial. As these patients have much better outcomes, we expected that
the survival among the trial population would be slightly lower. Estimates from the Norwegian trial
of i.v. drugs and the Australian trial of adrenaline were 9%57 and 4%,56 respectively. We therefore
expected a rate of survival to 30 days of ≈ 6% in the adrenaline group.
The trial’s primary aim was to estimate the treatment effect of adrenaline and the uncertainty around this;
we therefore based the target sample size primarily on the precision of the estimate of the risk ratio (RR).40
Figure 5 shows the precision that is achievable (width of the 95% CI for the RR) with different total sample
sizes, for RRs (placebo vs. adrenaline) of 1.25 and 1.00. A RR of 1.25 corresponds to an increase in 30-day
survival from 6% in the adrenaline group to 7.5% in the placebo group.
METHODS
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Sample size
The target sample size was 8000 participants, which was expected to give a width of the 95% CI for
the RR of approximately 0.4 or slightly less; for a RR of 1.25, the 95% CI would be 1.07 to 1.46, and
for a RR of 1.0 the 95% CI would be 0.84 to 1.19. There was a trade-off between precision and
practicality in setting a target sample size at > 8000, there was only a small improvement in precision,
but the difficulty and time needed to recruit this number increased significantly. We expected a very
small number of missing data for survival outcomes. In the PaRAMeDIC trial,102 we ascertained survival
status for > 99% of randomised patients; therefore, we have not adjusted the sample size estimates
to account for missing data.
Using a conventional sample size calculation based on a significance test, a sample size of 8000 would
have 93% power to achieve a statistically significant (p < 0.05) result if the true treatment difference is
a RR of 1.33 (increase from 6% in the adrenaline group to 8% in the placebo group), or 75% power if
the true treatment difference is a RR of 1.25 (increase from 6% in the adrenaline group to 7.5% in the
placebo group).
Reconsideration of sample size after low survival rate
In July 2016, the DMC raised concerns regarding a lower than anticipated survival rate. We explored
additional data sources and the current literature to assess if the original assumption was correct.
Since the inception of the trial, we had access to two contemporary sources of information for the
epidemiology and outcome of this patient group in the UK.
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FIGURE 5 Width of 95% CI for the RR against sample size. (a) RR 1.25; and (b) RR 1.0, with 6% survival in the adrenaline arm.
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The first was a secondary analysis of the PaRAMeDIC trial.102 The PaRAMeDIC trial102 enrolled adult
patients experiencing OHCA in three English and the Welsh ambulance service regions. Patients were
eligible for enrolment if they had an OHCA attended by a trial vehicle and resuscitation was continued
by the EMS team. Patients who were pregnant or who sustained a traumatic cardiac arrest were
excluded. We collected information on whether or not a patient received i.v. cardiac arrest medications
per se, rather than specifically adrenaline. As resuscitation algorithms recommend that adrenaline and
amiodarone (the only other recommended i.v. drug for cardiac arrest) are given together, we believed
that this was a reasonable surrogate to the patient requiring i.v. adrenaline. For the PaRAMeDIC
trial,102 this group comprised 3621 patients, with an overall 30-day survival rate of 2.8%.
The second source of data was the national OCHA registry (OHCAO) hosted by the University of
Warwick.103 This registry collects process and outcome information from all English ambulance services.
Data were available covering the period from 2013 to 2015. These data were analysed for patients aged
> 16 years who were given i.v. adrenaline (n = 28,939). In this group, 3.1% survived to discharge.
We extended the initial review of the literature to include studies that included standard-dose adrenaline
as control, rather than limiting to intervention. Table 2 gives a brief detail of these studies, together with
the percentage rates for survival to discharge for patients receiving standard-dose adrenaline (1 mg).
This identified 10 studies in which high-dose adrenaline or vasopressin were given as comparator.
In one trial, placebo was given as comparator.56 The median rate of survival to discharge was 2.8%,
and the weighted mean was 3.5%.
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IHCA, in-hospital cardiac arrest.
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Considering this information and the survival outcomes for PARAMEDIC2 at the time of our review,
we concluded, as a trial team, that our initial estimates of survival to discharge/30-day survival, as
detailed in the protocol, were overly optimistic. An adjusted sample size calculation based on the
collected data indicated that, if we assumed a rate of survival to 30 days of 2% in the control arm,
we would need > 24,000 patients for a RR of 1.33 at 90% power.
In addition, we estimated treatment effects detected by the sample size of 8000, as seen in Table 3.
We believed that revising the sample size to 24,000 was unachievable (and unaffordable) at that point
in the trial.
We noted that the Jacobs et al.56 trial showed an OR of 2.2 in the survival to discharge outcome,
but with wide CIs (95% CI 0.7 to 6.3). Furthermore, a threshold of 1% in absolute risk reduction for
outcomes has been used widely in resuscitation science as the threshold that defines the minimal
clinically important difference.114,115 We therefore believed that the trial would still yield valuable
information about the safety and effectiveness of adrenaline if the observed survival rates continued
to the end of the trial.
Consent
Obtaining consent
The ambulance service research teams received training on informed consent and assessing
capacity, good clinical practice (GCP) guidelines, relevant legislation, and the trial-related procedures
around consent.
Informing the patient about participation in the trial
For all patients who were transported to hospital for further treatment, ambulance service research
teams conducted checks with local hospitals to determine whether or not a patient had survived.
The first attempt to contact the patient and inform them of their enrolment in the trial was during
their stay in hospital. The ambulance service research paramedics made contact with the patient
as soon as practicable after the initial emergency had passed, taking the utmost care and sensitivity
in doing so. Following our experience from an OHCA study of 4400 patients (PaRAMeDIC trial),81
and from discussions with fellow researchers from the REVIVE AIRWAYS cardiac arrest study116 and
discussions with patient and public representatives, we believed that the earliest practicable time to
approach patients and relatives was once the patient was discharged from the ICU and was on a
hospital ward. This allowed sufficient time for the research team to be made aware of enrolment, to
identify who the patient was, to check which hospital the patient was transferred to and whether or
not they were still alive and to verify with the hospital team where the patient was in the hospital.
Transfer to a ward indicated that the initial emergency had passed and the patient’s condition had
stabilised. It was also considered more likely that the patient had regained consciousness and it would
avoid any confusion or additional distress of making an approach while the patient remained critically
ill in intensive care.
TABLE 3 Scenarios of estimable effect size based on current trial parameters
Power (%) Proportion on control (%) Proportion on intervention (%) ARR (%) RR
80 2 2.98 0.98 1.49
90 2 3.15 1.15 1.57
93 2 3.23 1.23 1.62
ARR, absolute risk reduction.
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For patients or legal representatives who did not speak English, patient information sheets and consent
forms were translated into some common languages. When printed translations were not available
in the required language, Language Line Services (now known as LanguageLine Solutions, Monterey,
CA, USA) was used to translate the patient information sheets and consent forms for the patient or
their legal representative.
Procedure for taking consent
The research paramedic assessed if the patient had capacity to consent, with advice from the hospital
team. If the patient had capacity, they were provided with the information sheet explaining the trial
and the options for their involvement. The patient was allowed time to consider the information
provided and had the opportunity to ask questions and discuss with others. The research paramedic
or hospital team then asked when the patient would like someone to come back to discuss participation
further and potentially take consent. The patient could decide that it was not an appropriate time to
discuss the trial or they could decide that they did not want to be involved, in which case their feelings
were respected and their decision about continuing in the trial was recorded.
The consent form listed the different sorts of information that were collected. Specific consent was
not sought to use the data already collected. If the patient did not want the trial team to continue to
collect data about survival, or to access the patient’s health records, then they indicated this on the
consent form by not initialling the corresponding boxes or told the trial team verbally.
Research paramedics confirmed with the patient or legal representative their willingness to continue
with the trial at each contact point.
In the event that a patient lacked capacity to consent, the research paramedic worked with the
hospital team to identify a legal representative, defined as:
l personal legal representative – a person independent of the trial, who, by virtue of their relationship
with the potential study participant, is suitable to act as their legal representative for the purposes
of that trial, and who is available and willing to so act for those purposes.
Or, if there is no such person:
l professional legal representative – a person independent of the trial, who is the doctor primarily
responsible for the medical treatment provided to that adult
l a person nominated by the relevant health-care provider.
The legal representative was approached and provided with the information sheet explaining the trial
and the options for their and the patient’s involvement, including the need for them to give consent
on behalf of the patient and complete questionnaires on behalf of the patient. The legal representative
was given time to consider the information provided. The research paramedic or hospital team then
asked when the legal representative would like someone to come back to discuss participation further
and potentially take consent.
The legal representative could decide that it was not an appropriate time to discuss the trial or they
could decide that the patient would not want to take part, in which case their feelings were respected
and their decision about taking part was recorded.
In exceptional circumstances, if consent was not obtained during the hospital stay, the patient or
their legal representative was sent an invitation letter by post and written consent was taken at the
3-month follow-up visit, if the patient or legal representative agreed.
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It is possible that the patient could have regained capacity by the time the 3-month visit was due. When
contacting the legal representative to arrange the 3-month visit, the ambulance service research team
asked if they could speak with the patient. If, on assessment of the patient, either on the telephone or at
the visit, it was found that the patient still lacked capacity, the legal representative was asked to complete
the questionnaires on behalf of the patient. If the patient had regained capacity, then information was
provided about the trial and consent for further data collection was sought.
General information about the trial and contact details for further information was made freely available
throughout the trial. Information about the trial was placed on ambulance trust and University of Warwick
websites, ambulance service public newsletters, posters and information leaflets were shared with general
practices, pharmacies, hospital accident and EDs and waiting areas, totalling 6500 mail-outs, which included
2356 general practices and 3181 pharmacies. Prior to the start of the trial, a press release was issued
providing information about the trial. This was followed by periodic regional press releases as the trial
progressed. The trial website was updated with information throughout the trial [www.warwick.ac.uk/
paramedic2 (accessed 1 August 2019)], and was accessed > 178,000 times during the trial.
Although not required by the relevant regulations, the trial team developed a system to allow a patient
to decline participation in the trial in the event that they sustained a cardiac arrest.
Requests not to participate were sent to and managed by the WCTU trial team. An online form could
be completed on the website or the team could be contacted by telephone or e-mail. A stainless steel
‘No Study’ bracelet was issued to the person’s home address and, with the person’s permission, their
home address was passed to the ambulance service to register the person’s wishes by placing an
address flag on dispatcher systems. Those requesting a ‘No Study’ bracelet were also told to tell those
close to them their wishes and told that those wishes would be respected by the treating paramedics.
Paramedics were trained to look for the bracelet when attending a cardiac arrest.
Enquiries regarding trial participation
The following process was introduced at the end of the trial to deal with trial participation enquiries
from members of the public.
If a member of the public enquired as to whether or not their next of kin was enrolled in the
PARAMEDIC2 trial, they completed a trial participation enquiry form. On receipt of a completed trial
participation enquiry form, the PARAMEDIC2 trial office worked with the appropriate site to check
whether or not the next of kin of the enquirer was enrolled in the PARAMEDIC2 trial. Once it was
confirmed, a letter was sent from the appropriate ambulance service to confirm whether or not the
enquirer’s next of kin was enrolled in the trial, along with an information sheet about the trial, which
included contact details for the PARAMEDIC2 trial office.
Serious adverse events
Events that were related to cardiac arrest and that were expected in patients undergoing attempted
resuscitation were not reported. These included:
l death
l hospitalisation
l persistent or significant disability or incapacity
l organ failure.
All events categorised as serious [SAE/serious adverse reaction (SAR)/suspected unexpected serious
adverse reaction (SUSAR)] were required to be reported to the WCTU within 24 hours of becoming
aware of the event. All reports of SAEs/SARs/SUSARs were reviewed on receipt by the chief investigators
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or delegated clinical members of the TMG; the main REC, the Medicines and Healthcare products
Regulatory Agency (MHRA) and the sponsor were notified within 7 or 15 days of receipt of those that
were considered to satisfy the criteria for being related to the IMP and unexpected, in accordance with
regulatory requirements. Reports of SAEs/SARs/SUSARs were also reviewed by the DMC at its regular
meetings, or more frequently if requested by the DMC chairperson.
Procedures in case of pregnancy
Known pregnancy at the time of the cardiac arrest was an exclusion criterion for this trial. However,
should the patient later be known to have been pregnant at the time of cardiac arrest and trial
intervention, the protocol specified that the outcome of the pregnancy would be followed up
and documented, even if the subject was discontinued from the trial. All reports of congenital
abnormalities or birth defects were to be reported and followed up as a SAE.
Protocol non-compliances
Any deviations from or violations of the trial protocol or GCP were reported to the WCTU trial team
promptly via a paper case report form (CRF) or an electronic case report form (eCRF). Any reports
were assessed by the trial team on the day of receipt, or the following working day if received on a
weekend, and escalated to the chief investigator (or their delegate), the quality assurance team and the
WCTU manager if the non-compliance was a new or an exceptional event. All non-compliances, including
cumulative numbers, trends and frequency over time, were reviewed at monthly trial management
meetings. All violations and serious breaches were reported to the sponsor, and serious breaches
were reported to the MHRA within 7 days (Figure 6). The ambulance service trial teams put in place
corrective and preventative actions to mitigate the risk, and these actions were reviewed by the WCTU
trial team to ensure that all had been completed.
A protocol deviation was defined as a change or departure from the clinical trial protocol and/or GCP
that did not result in harm to the trial participants or significantly affect the scientific value of the
reported results of the trial.
CRF 05 or SAE
received from site
Assessed by trial team


















FIGURE 6 Process for receipt of a non-compliance report. CTU, Clinical Trials Unit.
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A protocol violation was defined as a serious non-compliance with the approved protocol resulting
from error, fraud or misconduct.
A serious breach was defined as a breach (deviation or violation) that was likely to affect, to a
significant degree, either the safety or physical or mental integrity of the participants of the trial,
or the scientific value of the trial.
Data collection
Screening data
Data were collected on a screening log of all cardiac arrests, which were attended by a trial-trained
paramedic in the trial areas. These data consisted of the case identifier, the age and sex of the patient
and the reason why the patient was not enrolled in the trial. This allowed assessment of the proportion
of missed enrolments and the reasons, to ensure that the trial sample was representative of the trial
population. The reasons for missed enrolments were established either from reviewing the patient’s
clinical record, or from speaking to the attending clinician. Several strategies were used during the
trial to reinforce the message that all eligible patients should be enrolled in the trial, and data on the
numbers and reasons for missed enrolments were reviewed throughout the trial and fed back to sites.
Patient enrolment
All cardiac arrests for which a trial pack was opened were reported to the ambulance service trial
teams by the recruiting clinician. The method for notification of enrolled patients was specific to each
research site, but was usually done via telephone to the control centre or to a dedicated telephone
number. Once ambulance service research teams were notified of an enrolled patient, the patient
details were registered promptly on the trial database via an online web application hosted by the
University of Warwick.
Baseline cardiac arrest data
Baseline cardiac arrest data were obtained retrospectively from ambulance service clinical records and
the OHCAO registry (University of Warwick) and transcribed directly onto eCRFs via the PARAMEDIC2
web application. All ambulance service staff were trained on how to collect and enter trial data, and all
data definitions followed Utstein recommendations.92 Follow-up data were then obtained from hospitals,
general practitioner (GP) surgeries, NHS Personal Demographics Service and patient follow-up
questionnaires and were entered into the PARAMEDIC2 web application as they became available.
Hospital
Patients were taken to any hospital in the trial regions. Although hospital clinicians did not have a role
in delivering the trial interventions, they were informed about the trial and were provided with
information about the trial for any clinicians or patients who needed it.
Hospitals were contacted initially to ascertain survival of patients handed over from ambulance
services to the ED. If the patient had survived, the research paramedics liaised with the hospital
clinicians to visit the patient and seek consent for continuation in the trial (see Consent).
For any patient taken to hospital, data were collected on survival, length of stay in hospital and ICU,
targeted temperature management, adrenaline use and mRS score at discharge, as well as discharge
address and GP details. As some patients were found in a public place without any identifiers, or only
part of their details were known to the ambulance service at the time of arrest, hospitals also, when
necessary, provided missing information such as name, address and date of birth.
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Survival checks
Survival checks were completed by the ambulance service research teams or the WCTU trial team
using a variety of sources:
l hospital data
l Summary Care Record/Welsh Demographic Service
l GP surgeries.
Follow-up
Survivors willing to take part were followed up approximately 3 months and 6 months after their
cardiac arrest, as per Figure 4. Whenever possible, the 3-month assessments were a home visit, but,
if the patient preferred postal questionnaires or to go through the questionnaires over the telephone,
this was arranged, although the MMSE was not completed over the telephone. Questionnaires at the
6-month time point were sent by the WCTU and returned by post.
Following the approach to the patient, in the unlikely event that we had not obtained a response from
the patient, the WCTU trial team approached the patient’s GP or hospital or ambulance service for
information on their mRS score as close to the 3- and 6-month time points as possible. If the 3-month
booklet had not been completed by the time the 6-month visit was due, the patient was sent the
3-month booklet to complete instead, so that outcomes that are only collected at 3 months were
not missed.
Data linkage with other data sets
Data on each patient’s stay in hospital were collected retrospectively from the following electronic
data sets to provide data on length of stay in hospital and hospital interventions:
l Intensive Care National Audit and Research Centre (ICNARC).
l Patient Episode Database for Wales (PEDW).
l Hospital Episode Statistics (HES).
l UK Transplant Registry (UKTR).
An application was made to receive data from the National Institute for Cardiovascular Outcomes
Research data set. However, the application was not approved in time for data to be received in time
for analysis.
Quality of cardiopulmonary resuscitation
Information on CPR quality is increasingly being viewed as an international reporting standard for
cardiac arrest research.
The executive summary of the European Resuscitation Council Guidelines for Resuscitation 201088
identifies four critical components of high-quality CPR: minimise interruptions in chest compressions
(as measured by chest compression fraction), provide compressions of adequate rate, provide
compressions of adequate depth and allow full chest recoil between compressions.
Because a way to measure chest recoil was unavailable, the first three parameters were measured:
1. chest compression fraction, also known as chest compression ratio
2. chest compression rate
3. chest compression depth.
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A preliminary review of existing literature showed that these three variables are typically studied using
measurements covering two time periods:
1. initial 5 minutes of recorded CPR treatment
2. whole episode of recorded CPR treatment.
To measure these indicators of the quality of CPR for PARAMEDIC2 trial cases, data were downloaded
from defibrillators, when possible. Three models of defibrillators were used across two ambulance services:
l London Ambulance Service –
¢ LIFEPAK® 15 monitor/defibrillator (Physio-Control, Inc., Redmond, WA, USA)
¢ LIFEPAK® 1000 defibrillator (Physio-Control, Inc.).
l North East Ambulance Service –
¢ X Series® monitor/defibrillator (ZOLL Medical Corporation, Chelmsford, MA, USA).
When it was not possible to download quality of CPR data using existing means, a CPR card was used as
a substitute. These Conformité Européenne-marked CPR cards, supplied by Laerdal Medical (Stavanger,
Norway), measured compression fraction, compression rate and depth. CPR cards were operated by
being switched on and placed centrally on a patient’s chest. Chest compressions were then performed as
usual. Quality of CPR data were recorded during the resuscitation attempt, but the card did not provide
real-time feedback to the paramedics.
In total, 1000 CPR cards were distributed to South Central Ambulance Service, the Welsh Ambulance
Service and the West Midlands Ambulance Service. Trial-trained paramedics were taught how to use
the CPR cards. Trial sites used site-specific processes to return used CPR cards from paramedics to site
research teams. Site research teams downloaded data from the returned used CPR cards and provided
the quality of CPR data securely to the WCTU. Data from both the defibrillators and CPR cards were
entered into the trial database for analysis.
Table 4 compares the feasibility of acquiring the needed parameters and measurement periods from
the devices used for the PARAMEDIC2 trial. The X Series defibrillator records all three parameters;
TABLE 4 Parameters and measurement periods feasible for devices used to acquire data indicating the quality of CPR














Compression depth 1-minute intervals Not feasible Not feasible Feasible
Whole episode Feasible Not feasible Feasible
Compression rate 1-minute intervals Not feasible Feasible Feasible
Whole episode Feasible Feasible Feasible
Compression
fraction or ratio
1-minute intervals Not feasible Feasible Feasible
Whole episode Feasible Feasible Feasible
LAS, London Ambulance Service; NEAS, North East Ambulance Service; SCAS, South Central Ambulance Service;
WAST, Welsh Ambulance Service; WMAS, West Midlands Ambulance Service.
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an arithmetic mean (or average) value is given for the whole treatment episode and arithmetic mean
values are also given for 1-minute intervals. The CPR cards record all three parameters, with an arithmetic
mean value given for the whole treatment episode only; 1-minute intervals are not possible. The LIFEPAK 15
and LIFEPAK 1000 defibrillators record compression rate and compression fraction only (compression depth
is not possible without an additional puck-sized sensor). Instead of the arithmetic mean, a ‘trimmed mean’
value (namely a mean that removes the extreme observations) is given by the LIFEPAK defibrillators for
the whole treatment episode, and also for each 1-minute interval.
Statistical analyses
Primary and secondary outcomes
The primary analysis was performed with and without adjustment in the modified intention-to-treat
population, which included all the patients who had undergone randomisation and were confirmed to
have received the assigned intervention.
Other approaches, for instance per protocol and complier-average causal effect, were not considered
because of the negligible proportion of non-compliance. For data with a normal distribution, means and
standard deviations (SDs) are presented. For data that were non-normally distributed, medians and
IQRs are presented. Categorical data are summarised as frequency and percentage.
Fixed-effect regression models were used to examine survival outcomes with and without adjustment.
Variables included in adjusted analyses were age, sex, the time between the 999 call and the ambulance
arriving at the scene, the time between the ambulance arriving and trial drug administration, the suspected
aetiology of the cardiac arrest, the initial heart rhythm, whether or not the event was witnessed and
whether or not a bystander undertook CPR.
Length-of-stay outcomes were examined by the Hodges–Lehmann117 method, and were reported as
estimated median differences with 95% CIs. When modelling the mRS, scores of 0–3 were classified
as ‘good’ and scores of 4–6 were classified as ‘poor’; that is scores of 0–3 were regarded as a ‘good’
outcome and scores of 4–6 were regarded as a ‘poor’ outcome. If the proportional odds assumption
was violated in modelling the mRS, partial proportional odds models118,119 were used. Other secondary
outcomes (including quality of life and neurological and cognitive functions) were summarised by
treatment arm.
Sensitivity
A sensitivity analysis was prespecified for mRS scores at discharge and at 3 and 6 months if > 10% of
the data of survivors at each time point were missing. We used last observation carried forward and
best- and worst-case scenarios for imputation. For the best-case scenario, missing data are considered
as having no symptoms. For the worst-case scenario, missing data are considered as having severe
disability in those confirmed to be alive at follow-up, and dead in those with confirmed death or missing
survival status at follow-up. Post hoc sensitivity analyses were conducted for survival at 30 days,
survival at hospital discharge, and survival with a good neurological outcome at discharge and at
3 and 6 months. Best-case and worst-case scenarios and multiple imputation were used.
Unadjusted and adjusted analyses were conducted for the primary and secondary outcomes, apart
from the Two Simple Questions tool. Unadjusted and adjusted ORs with 95% CIs and mean differences
with 95% CIs were reported for categorical and continuous outcomes, respectively. The number
needed to treat and its 95% CI were calculated for survival at 30 days.
Quality of cardiopulmonary resuscitation
We used only the data on quality of CPR collected by London Ambulance Service because insufficient
data were collected from the other sites. The Mann–Whitney U-test was used to compare treatment
differences in hospital- and ICU-free survival because of their non-normal distributions.
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Subgroups
Prespecified subgroup analyses included a patient’s age, cause of cardiac arrest, initial cardiac rhythm,
whether or not the cardiac arrest was witnessed, whether or not CPR was performed by a bystander,
interval between the emergency call and ambulance arrival at the scene, interval between ambulance
arrival and the trial-agent administration, and the interval between the emergency call and trial-agent
administration. A p-value for interaction was reported in each analysis.
Reporting of analyses followed CONSORT guidelines.
Additional analyses
Interim analyses
Prior to the start of the trial, we used the Lan–DeMets,120 O’Brien–Fleming and Pocock alpha spending
methods to determine the upper and lower stopping boundaries for the primary outcome, with no
adjustment in the final analysis. Interim analyses were carried out 10 times on a quarterly basis during
the trial recruitment. Reports were delivered confidentially to the DMC. The DMC reviewed these
results and made recommendations to the TSC about continuation of recruitment or any modification
to the trial that may have been necessary.
The DMC monitored the accumulating outcome data; one of its roles was to recommend cessation of
recruitment if a clear result had been reached (i.e. if either adrenaline or placebo was clearly superior).
We suggested that different thresholds of evidence for early termination were adopted if adrenaline
or placebo was being more effective, as it was probable that stronger evidence would be needed to
change current practice (adrenaline use) if adrenaline was found to be inferior. We therefore proposed
that interim analyses were conducted frequently in the early stages of the trial, so that, if adrenaline
was superior, this was detected earlier. Thus, we minimised any risks to patients while producing robust
evidence that will change practice if adrenaline is inferior.
The outcomes of primary interest for the interim analyses were 30-day survival and neurological
status. We prepared reports for the DMC initially every 3 months. The exact schedule of interim
analyses and the nature of any early-stopping rules were determined by the DMC, in discussion with
the investigators, before the start of recruitment.
Bayesian analysis
To aid in interpretation, we included a Bayesian analysis for the primary outcome and for survival with
a favourable neurological outcome. The Bayesian statistical analyses were performed using RStan. All
other statistical analyses were performed with the use of SAS® software, version 9.4 (SAS Institute Inc.,
Cary, NC, USA).
We performed unadjusted Bayesian analyses for two outcomes, 30-day survival and survival with
favourable neurological outcome, to enable us to quantify the probability of treatment effects of
different sizes. We modelled the adrenaline and placebo arms separately, with the outcome for each
participant being a Bernoulli (0/1) variable, with treatment arm-specific probabilities of ‘success’.
Non-informative beta(1, 1) priors (Figure 7) were used for both groups, initially. We also performed
a sensitivity analysis assuming more realistic, informative priors. These were beta(5, 150) for the
adrenaline group (Figure 8), reflecting previous knowledge that survival in the adrenaline group was
very unlikely to exceed 10%, and was most likely to be around 3%, and beta(2, 20) for the placebo
group (Figure 9), because a survival rate exceeding 20% in the placebo group was very unlikely.
We calculated the 95% and 80% highest-density intervals, and, for risk differences, the probability that
the treatment effect exceeded 0%, 1% and 2% (which have been suggested as representing clinically
important differences).
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FIGURE 7 Beta(1, 1).
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FIGURE 8 Beta(5, 150).
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FIGURE 9 Beta(2, 20).
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We present the results for the analyses of risk differences for both outcomes with the non-informative
prior. The informative priors made only very minor differences to the results.
Economic evaluation
A within-trial economic evaluation and decision-analytic model that extrapolated economic outcomes
beyond the trial-follow-up period were based on the trial design. The economic evaluation was
conducted from the recommended NHS and PSS perspective.121 Further details of the economic
evaluation methods are presented in Chapter 4.
Quality control of protocol non-compliances
Protocol violations were monitored using statistical process control charts. The monthly number of
violations and the proportion as a percentage of recruitment were plotted. The moving range, defined
as the absolute value of month-to-month change, was plotted against the recruitment month. Any out-
of-control conditions, defined as outside the prespecified limits, were investigated for quality control.
Ethics and regulatory approvals
The trial was approved by the South Central Oxford C REC (reference number 14/SC/0157) and the
MHRA (EudraCT number 2014-000792-11). The trial was sponsored by the University of Warwick and
was conducted in accordance with the Directive 2001/20/EC122 of the European Parliament and of the
Council of 4 April 2001 and The Medicines for Human Use (Clinical Trials) Regulations act,123 statutory
instrument 2004 No. 1031 and amendment (No. 2) statutory instrument 2006 No. 2984.
The Confidentiality Advisory Group provided approval under regulation 5 of the Health Service
(Control of Patient Information) Regulations 2002124 to process patient-identifiable information without
consent (reference number 14/CAG/1009).
Several changes to the protocol and procedures were made during the trial (see Table 1). When these
fulfilled the definition of substantial amendments according to the Medicines for Human Use (Clinical
Trials) Regulations act,123 they were reviewed and approved by the REC, the MHRA (when applicable)
and ambulance trusts. Approvals were not sought at hospital level, but those trusts were notified of all
amendments via the Clinical Research Network.
The funders had no role in the trial design, in the collection or analysis of the data, or in the writing of
the manuscript.
Ethics considerations
In designing and conducting this trial, a number of specific ethics issues were identified that required
careful consideration.
Conducting a placebo-controlled trial
As adrenaline is currently part of standard clinical treatment in cardiac arrest, a placebo controlled trial
necessitates some patients not receiving standard treatment. To justify the use of a placebo in place of
standard treatment, it was necessary to demonstrate that current evidence on the use of adrenaline in
cardiac arrest raised sufficient doubt about its efficacy and concern about its potential harm to patients,
to justify a trial that involved withholding adrenaline from some participants. There is an ethical
obligation for health-care professionals to provide treatment that imparts the most benefit and least
harm for the patient, based on the best available evidence. Our review of the available evidence
concluded that adrenaline, as currently used, improves the rate of ROSC), but increases the likelihood of
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neurological damage in those patients who survive and leave hospital. Thus, adrenaline can cause benefit
and harm, and it was not clear from available evidence whether or not it caused more harm than benefit.
Given the uncertainty of the evidence, and the potential life-threatening nature of the condition being
treated, it is ethically important to obtain the best evidence we can to justify treatment, while ensuring
that the interests of the research participants remain paramount. Based on available evidence, the risks
and benefits from participating in the trial were reasonably balanced (if a participant was randomised to
placebo, they may have a reduced chance of immediate survival, but an increased chance of surviving
to leave hospital neurologically intact). Our initial patient and public involvement (PPI) work suggested
that members of the public value long-term survival more than short-term recovery of spontaneous
circulation, so it would seem reasonable to assume that potential participants might agree to take part
in a placebo-controlled trial, if they were able to do so.
Using a model of deferred consent
Enrolment in a clinical trial of a medicinal product normally requires informed consent from the
participant or, if the participant lacks capacity, their legal representative. A decision about participating in
a trial with potentially life or death consequences is particularly challenging, and, when treatment is not
urgently required, the consent process may take considerable time. The unpredictability and immediately
incapacitating nature of cardiac arrest (sudden loss of consciousness) means that it is not possible to
obtain prospective informed consent from participants. Because of the need for immediate treatment,
it is also not possible to obtain consent from the patient’s legal representative. This situation is ethically
challenging as it is not possible to respect the participant’s autonomy by enabling them to make an
informed choice regarding participation. The ethical justification for over-riding the usual requirement
for consent must therefore be substantial with regard to the potential for the research to provide
future benefit to patients or to protect them from future harm. All clinical trials of IMPs in the UK are
governed by the EU Clinical Trials Directive (2001/20/EC)122 and the Statutory Instrument 2004/1031
[The Medicines for Human Use (Clinical Trials) Regulations 2004].123 In designing and conducting this trial,
we also complied with the 2006 amendment to these regulations, relating to emergency care research that
permits enrolment without consent in the emergency situation, subject to approval by an appropriate REC,
and with a requirement that consent is obtained once it is no longer necessary to take action as a matter
of urgency (deferred consent). Our approach was based on the template outlined at the Health Research
Authority Workshop 2012 on conducting emergency research in patients who lack capacity.125
The ethics implications of the deferred consent model [referred to as ‘exception from informed
consent’ (EFIC) in the USA] in relation to the constraints on the principle of respect for autonomy,
and approaches to mitigate these, have been discussed in the academic literature.126–130 Providing
information to, or undertaking consultation with, the relevant population prior to the research taking
place can assist in the assessment of whether or not the research is sufficiently important in terms
of the clinical benefit to patients to warrant the use of deferred consent. In the initial stages of trial
design, we consulted PPI members from the first PARAMEDIC trial, and held a community engagement
event where the rationale of the trial was presented to 280 lay people with an interest in first aid
(see Patient and public involvement).
Providing information prior to and during the trial also allows the opportunity for potential participants to
register their wish not to participate, and for researchers to respect their autonomous prior refusal. In the
USA, some RECs (Institutional Review Boards) require researchers in EFIC studies to provide a mechanism
for potential participants to opt out.131 In the UK, it is rare for trials in emergency care to provide this
option. For the PARAMEDIC2 trial, we developed a substantial public communications policy and included
a mechanism for members of the public to register their wish not to participate, which included provision
of ‘opt-out’ bracelets to be worn during the trial period (see Procedure for taking consent).
Approaching patients or their relatives (or legal representative) to inform them about enrolment in
the trial and to seek consent for continuation in the trial also required careful thought in balancing
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the importance of providing information as soon as possible following the emergency and minimising
distress caused by approaching relatives of patients critically ill in intensive care. Many patients lacked
capacity to consent to participation in the early stages of recovery and some patients regained capacity
over the period of the trial. Our consent processes were responsive to these complexities within the
legal framework of the European Directive122 (see Procedure for taking consent).
Informing families of patients who do not survive cardiac arrest
The sad reality of an OHCA is that fewer than 1 in 10 people survive. Experiencing the sudden
unexpected loss of a loved one because of cardiac arrest is a traumatic event that frequently leads
to symptoms of anxiety, depression and post-traumatic distress. Careful consideration therefore
needed to be given to how, when and if the relatives of non-survivors were to be informed about
participation in the trial. By the time a patient’s death occurred, the trial intervention would have
been implemented and no further follow-up would occur. Thus, there would be no requirement to
seek consent to continue, and nor would it be useful to do so. The purpose of any communication with
the family/next of kin of the deceased would be to inform them about the patient’s involvement in
the trial, demonstrating that the process of trial recruitment is open and transparent. In addition, it
mitigates any potential harm to family members from discovering at a later date that their relative or
friend had been involved in a trial without their knowledge. However, knowledge of trial participation
after the event may also place a significant burden on the next of kin at a time of heightened emotional
distress due to the loss of their relative or friend. Any strategy to inform the family or next of kin following
a patient’s death needs to balance the need for transparency with the need to minimise this distress.
The research team, including the trial ethicist, considered this issue with great care and discussed different
approaches with patient representatives, clinicians caring for patients who had experienced a cardiac
arrest and their families, the Resuscitation Council, and the REC. Approaches to informing the relatives of
participants who do not survive can be broadly categorised as passive or active. Passive methods include
placing information about the trial in publicly accessible places (e.g. websites, newsletters) and targeted
sites likely to be attended by relatives of the deceased (e.g. hospitals, general practice surgeries, Registrar
of Births and Deaths offices), with a contact telephone number and address for further information.
This approach allows people to make a choice about whether or not and when they wish to seek further
information. However, it is uncertain whether or not relatives of participants will see them. Discussion
with investigators of previous UK trials in emergency of life-threatening conditions suggested that passive
strategies, although not formally evaluated, had been used successfully.
Active strategies involve making direct contact with relatives through a face-to-face meeting, a
telephone call or written communication. To our knowledge, this approach has not been used in previous
UK OHCA trials, so we were unable to draw on relatives’ or researchers’ experiences of this process.
There are practical barriers to providing information actively. The sudden and unpredicted nature of
cardiac arrest mean that the relatives/next of kin are neither universally present nor identifiable at the
time of the cardiac arrest. Information on the identity of the relatives/next of kin are also not held by
ambulance services, so follow-up at a later date or time may not be possible. For people for whom
resuscitation efforts are terminated in the home (≈ 40% of total cases), it is not possible for the
attending paramedic to spend the necessary time to explain about the trial, answer questions and
provide support to relatives who will be extremely distressed. Alternatively, providing unsolicited
written information by post could exacerbate an already traumatic and stressful experience.
Having assessed the balance of benefits and burdens for relatives of the different strategies, and taking
into account the importance of transparency, we concluded that the burden to families of adopting
an active information strategy outweighed the potential benefits. We therefore developed a passive
information strategy with a clear process for responding to enquiries from relatives of participants
(and the general public) (see Procedure for taking consent and Enquiries regarding trial participation).
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Patient and public involvement
During the planning and development phase, we worked with the PPI members of the PaRAMeDIC
trial, who contributed to the trial design and proposed follow-up processes. Specific contributions
related to the selection of outcome measures and a summary/presentation of the research in plain
English. We held a community engagement event (supported by West Midlands South Comprehensive
Local Research Network) in late November 2012, at which we presented the scientific rationale behind
this trial to a group of 280 lay people who were interested in first aid. After preparing the talk in
collaboration with one of our PPI representatives (John Long), to ensure that concepts were presented
in plain, understandable English, we delivered the presentation and addressed any questions from
the group. We explained the concept of short-term and longer-term outcomes and briefly sought
community views about priorities for outcomes and their views on a trial of adrenaline for OHCA.
We received responses from 243 participants. Ninety-five per cent of respondents indicated that
long-term survival was important to them, whereas short-term survival was not. Participants broadly
agreed that there was a need for further research about adrenaline as a treatment for cardiac arrest
(86% agreed, 8% neither agree nor disagreed and 6% disagreed).
Prior to ethics approval for the trial being obtained, the views of the Resuscitation Council (UK)
Patient Advisory Group were sought on the appropriateness of our approach to informing relatives of
patients who do not survive. These views and comments supported the approach described in the
protocol and ethics application.
John Long, our PPI co-applicant, with extensive experience of working with charities dedicated to
reducing death from cardiac arrest, was a member of the TMG and lead PPI representative. John Long
attended the REC meeting and provided important input from a patient perspective on the ethics of
the trial. Since then, he has been heavily involved in TMG meetings, developing the trial procedures and
processes, and reviewing public-facing information (e.g. website text and press releases) for readability
and relevance. John Long has volunteered on several occasions to present the concept of the trial to
several interested user groups/conferences. For example, on request by the Patient Voice Group, NHS
North and West Reading Clinical Commissioning Group, John Long, one of our co-investigators and a local
research fellow attended its meeting on 10 March 2015. John Long also presented the trial at several
Lifesaving Foundation conferences during the trial. We also included two PPI representatives in the TSC.
In addition, the WCTU team formed a PPI group comprising eight members of the public, and chaired
by John Long, to give advice on the content and distribution of patient- and public-facing documents.
The group was put together through the University of Warwick’s Universities/User Teaching and
Research Action Partnership (UNTRAP) group and included a cross section of age, sex, religion and
experience. The group have met on six occasions throughout the trial, on at least an annual basis,
and have provided input on the following:
l the patient information sheet and consent forms
l process for informing patients or their relatives of their involvement in the trial
l the trial communication strategy (ways in which information about the trial can be shared in
relevant communities)
l wording and layout of the trial website, trial posters, information leaflets and press releases
l issues regarding seeking/obtaining consent
l co-enrolment of participants
l end-of-trial communications, including how to communicate the results to trial participants.
Following the completion of the trial, the results were presented to the trial investigators group, and our
PPI representatives were invited to attend this meeting. Here, an infographics leaflet summarising the
results of the trial for patients and members of the public was presented and the PPI representatives
provided feedback. Our PPI representative, John Long, also attended a Science Media Centre briefing in
London to present the results of the trial to journalists and to be on hand to answer any questions from
a patient or public perspective.
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Recruitment took place between 23 December 2014 and 17 October 2017. The trial team assessed
10,623 patients in regions served by the London Ambulance Service NHS Trust, the West Midlands
Ambulance Service University NHS Foundation Trust, the North East Ambulance Service NHS
Foundation Trust, the South Central Ambulance Service NHS Foundation Trust and the Welsh
Ambulance Service NHS Trust. A total of 8103 (76.3%) patients met the inclusion criteria and were
randomised to the adrenaline or placebo arm by ambulance service paramedics. Within a short period
of randomisation (confirming eligibility) and administration of the trial drug, 87 patients were found to
be ineligible after the trial drug pack was opened, and were thus excluded post randomisation. Another
two patients had an unknown allocation because of missing trial drug packs. Therefore, 4015 patients
were allocated to the adrenaline arm and 3999 were allocated to the placebo arm. Details of the
CONSORT flow diagram are presented in Figure 10. Patient flow in hospital is presented in Figure 11.
Losses and exclusions
Of all patients approached for the eligibility assessment, 2520 (23.7%) met the exclusion criteria.
Having adrenaline before EMS’ arrival was the major reason for exclusion, accounting for 1192 (47.3%)
exclusions.
In practice, administration of the trial drug occurred shortly after randomisation. Within this short
period, 87 patients were found to be ineligible for various reasons after the trial drug pack had been
opened (see Figure 10). Another two patients were given the drug, but were excluded from the analysis
because the drug pack number could not be verified.
After survival to hospital ward admission, patients might become lost to follow-up (LTFU) because of
consent decline/withdrawal or because they were lost track of in the trial. For the primary outcome,
seven patients were LTFU. A further 10 patients became LTFU within 6 months follow-up, leaving
14 and 17 with missing survival status at 3 and 6 months, respectively.
After survival to hospital ward admission, patients might become LTFU if they declined consent,
withdrew consent or could not be traced by the research paramedics. Ten patients were LTFU before
hospital discharge. This number cannot be compared directly with other survival outcomes measured,
as the discharge time is not a fixed time point and hospital stay varied from days to months. Nine
patients survived for > 30 days in hospital and died before discharge, whereas seven were discharged
from hospital and later died before reaching 30 days post randomisation. In addition, six patients were
LTFU in the period from 30 days to hospital discharge, and three were LTFU in the period from
discharge to 30 days.
Trial participation enquiries and unblinding requests
Warwick Clinical Trials Unit received five enquiries from members of the public asking whether they
or their relative had been enrolled in the trial. Of the five enquiries, two patients or their relatives
were confirmed to have been enrolled.
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• LTFU of survival at 3 months, n = 6
• LTFU of survival with favourable
    neurological outcome at 3 months, n = 29
• LTFU of survival at 6 months, n = 9
• LTFU of survival with favourable
    neurological outcome at 6 months, n = 24
LTFU at hospital dischargeb
• LTFU of survival at hospital discharge, n = 6
• LTFU of survival with favourable





• Known to be/apparently aged < 16 years, n = 268
• Known to be/apparently pregnancy, n = 17
• ROSC before randomisation, n = 615
• Cardiac arrest secondary to anaphylaxis, n = 17
• Cardiac arrest secondary to life-threatening
    asthma, n = 183
• Adrenaline had been given prior to EMS’ arrival,
    n = 1192
• Traumatic arrest excluded by London
    Ambulance Service, n = 228
Meeting exclusion criteria
(n = 2520)
• DNAR in place, n = 4
• Asthma, n = 6
• ROSC before drug given, n = 22
• Pregnant, n = 2
• Syringes broken or contaminated, n = 4
• Unable to obtain i.v. access, n = 2
• Unknown, n = 47
Post-randomisation exclusions
(n = 87)
• LTFU of survival at 30 days, n = 4
• LTFU of survival at 3 months, n = 8
• LTFU of survival with favourable
    neurological outcome at 3 months, n = 20
• LTFU of survival at 6 months, n = 8
• LTFU of survival with favourable
    neurological outcome at 6 months, n = 28
LTFU at hospital dischargeb
• LTFU of survival at hospital discharge, n = 4
• LTFU of survival with favourable
    neurological outcome at discharge, n = 5
LTFU at 30 days and at 3 and 6 monthsa
FIGURE 10 The CONSORT flow diagram. a, Cumulative loss to follow-up; b, hospital discharge was not a fixed
time point, compared with the other survival outcomes and hence it was listed separately. DNAR, do not attempt
resuscitation; LTFU, lost to follow-up.
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During the recruitment phase of the trial, we received six requests for unblinding (two from HM
coroners, two from relatives of deceased patients as part of complaints investigations and two as part
of non-compliance investigations). In all cases, requests occurred after collection of primary outcome
data. Following closure of recruitment, we received nine requests from patients or their relatives.
Overview of recruitment
Recruitment began in a staggered fashion in five ambulance services. Figure 12 shows the cumulative
recruitment at each ambulance service, as well as funder (i.e. HTA programme) targets for recruitment.
The HTA programme recruitment targets were revised in July 2015 to allow a more gradual increase
in recruitment, following delays in starting recruitment. Table 5 shows the number of patients at each
ambulance service who were randomised and received the trial drug (not including post-randomisation
exclusions).
Enrolled in the trial
(pack opened, drug given)
(n = 8016)
Placebo
(n = 3999; 49.9%)
Unknown




(n = 7; 0.2%)
Still in ED
(n = 0; 0.0%)
Still in ICU
(n = 0; 0.0%)
Died in ICU
(n = 176; 4.4%)
ICU
(n = 270; 6.8%)
Ward
(n = 147; 3.7%)
Hospital discharged
(n = 91; 2.3%)
Still in ward
(n = 4; 0.1%)
Died in ward
(n = 54; 1.4%)
Died in EDa
(n = 902; 22.6%)
ED          Ward
(n = 55; 1.4%)
ICU           Ward
(n = 92; 2.3%)
Ward           discharge
(n = 89; 2.2%)ICU           discharge
(n = 2; 0.1%)
ICU            discharge
(n = 4; 0.1%)
Not admitted
(n = 11; 0.3%)
Admitted




(n = 4; 0.1%)
Still in ED
(n = 0; 0.0%)
Still in ICU
(n = 0; 0.0%)
Died in ICU
(n = 414; 10.3%)
ICU
(n = 566; 14.1%)
Ward
(n = 242; 6.0%)
Hospital discharged
(n = 128; 3.2%)
Still in ward
(n = 6; 0.1%)
Died in ward
(n = 114; 2.8%)
Died in EDa
(n = 1379; 34.3%)
ED           Ward
(n = 94; 2.3%)
ICU           Ward
(n = 148; 3.7%)
ED          discharge
(n = 2; 0.1%)
Ward             discharge
(n = 122; 3.0%)
Not admitted
(n = 21; 0.5%)
Admitted
(n = 2016; 50.2%)
Unknown
(n = 0; 0.0%)
Deceased on scene
(n = 2772; 69.3%)
Deceased on scene
(n = 1974; 49.2%)
Transported to hospital
(n = 2041; 50.8%)
Transported to hospital
(n = 1227; 30.7%)
Adrenaline
(n = 4015; 50.1%)
Missing allocation
(n = 2; < 0.1%)
ED          discharge
(n = 0; 0.0%)
FIGURE 11 Patient flow through the trial from recruitment to hospital discharge. Note that percentages of
transportation to in-hospital status are based on enrolled patients in each arm. a, A total of 213 and 391 patients are
included in placebo and adrenaline boxes, respectively, as a result of unknown ICU/ward admission information.
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Baseline data
Baseline data were collected for 8016 patients. Two patients had missing allocation and were not
included in the analysis. Baseline patient and event characteristics (summarised in Tables 6 and 7) were


































































































FIGURE 12 Cumulative recruitment from December 2014 to October 2017.
TABLE 5 Recruitment by region
Site Start date Number of recruited patients
London 23 December 2014 2058
South Central 17 February 2015 2456
North East 10 April 2015 1049
West Midlands 16 June 2015 1163
Wales 14 July 2015 1290
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TABLE 6 Baseline patient and event characteristics
Characteristic Adrenaline arm (N= 4015) Placebo arm (N= 3999)
Age (years), mean (SD) 69.7 (16.6) 69.8 (16.4)
Sex, n (%)
Male 2609 (65.0) 2584 (64.6)
Female 1406 (35.0) 1415 (35.4)
Initial rhythm, n (%)
Shockable rhythm 770 (19.2) 748 (18.7)
VF 716 (17.8) 684 (17.1)
Pulseless VT 25 (0.6) 20 (0.5)
Not otherwise identified with AED 29 (0.7) 44 (1.1)
Non-shockable rhythm 3149 (78.4) 3181 (79.5)
Asystole 2135 (53.2) 2194 (54.9)
PEA/EMD 955 (23.8) 937 (23.4)
Bradycardia 20 (0.5) 16 (0.4)
Not otherwise identified with AED 39 (1.0) 34 (0.9)
Undetermined 96 (2.4) 70 (1.8)
Not identified 4 (0.1) 1 (< 0.1)
Missing 92 (2.3) 69 (1.7)
Initial aetiology, n (%)
Medical (presumed cardiac) 3656 (91.1) 3691 (92.3)
Traumatic cause 66 (1.6) 57 (1.4)
Drowning 10 (0.2) 10 (0.3)
Drug overdose 74 (1.8) 72 (1.8)
Electrocution 0 (0.0) 1 (< 0.1)
Asphyxia 117 (2.9) 81 (2.0)
Not identified 1 (< 0.1) 2 (0.1)
Missing 91 (2.3) 85 (2.1)
Witness, n (%)
None 1498 (37.3) 1505 (37.6)
Paramedic 452 (11.3) 470 (11.8)
Bystander 2013 (50.1) 1967 (49.2)
Not identified 1 (< 0.1) 1 (< 0.1)
Missing 51 (1.3) 56 (1.4)
Bystander commenced CPR, n (%)
Bystander CPR 2382 (59.3) 2349 (58.7)
No bystander CPR 1111 (27.7) 1094 (27.4)
By paramedic during witnessed event 452 (11.3) 470 (11.8)
Not identified 1 (< 0.1) 1 (< 0.1)
Missing 69 (1.7) 84 (2.1)
EMD, electromechanical dissociation.
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Pre-hospital treatment data
The summaries of pre-hospital treatments and the quality of EMS CPR are presented in Tables 8 and 9,
respectively.
TABLE 7 Intervals between key events and initial response to resuscitation
Adrenaline arm (N= 4015) Placebo arm (N= 3999)
Time from 999 call to EMS’ arrival at scene (minutes)a,b
Median (IQR) 6.7 (4.3–9.7) 6.6 (4.2–9.6)
Missing, n 0 0
Time from 999 call to administration of drug (minutes)a,b
Median (IQR) 21.5 (16.0–27.3) 21.1 (16.1–27.4)
Missing, n 40 50
Time from EMS’ arrival at scene to leaving scene (minutes)
Mean (SD) 50.1 (21.8) 44.5 (18.3)
Missing, n 1976 2773
Time from EMS leaving scene to arrival at hospital (minutes)
Mean (SD) 12.9 (9.8) 12.4 (8.9)
Missing, n 1977 2774
Time from starting ALS to cessation of resuscitation efforts (minutes)b
n 1027 1457
Median (IQR) 47.5 (35.1–64.0) 43.1 (33.5–56.1)
Missing, n 947 1315
ROSC, n (%)
Yes 1457 (36.3) 468 (11.7)
No 2518 (62.7) 3492 (87.3)
Missing 40 (1.0) 39 (1.0)
Patients transported to hospital, n (%)
Yes 2041 (50.8) 1227 (30.7)
No 1974 (49.2) 2772 (69.3)
Patient declared deceased by ED staff, n (%)
Yes 988 (24.6) 689 (17.2)
No 614 (15.3) 290 (7.3)
Not applicable (not transported) 1974 (49.2) 2772 (69.3)
Missing 439 (10.9) 248 (6.2)
a Time from 999 call to witness time from EMS; witnessed cases were defined as 0.
b Time interval was calculated only for patients who died on scene.
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TABLE 8 Concurrent pre-hospital treatments
Pre-hospital treatment Adrenaline arm (N= 4015) Placebo arm (N= 3999)
i.v. access, n (%) 2739 (68.2) 2763 (69.1)
Missing 5 (0.1) 3 (0.1)
Unknown 76 (1.9) 66 (1.7)
Intraosseous access, n (%) 1340 (33.4) 1,319 (33.0)
Missing 5 (0.1) 4 (0.1)
Unknown 76 (1.9) 64 (1.6)
Number of trial drug doses
Mean (SD) 4.9 (2.5) 5.1 (2.3)
Unknown 7 9
Administration of amiodarone, n (%) 584 (14.5) 368 (9.2)
Missing 11 (0.3) 14 (0.4)
Unknown 47 (1.2) 39 (1.0)
Supraglottic airway used, n (%) 2844 (70.8) 2847 (71.2)
Unobtainable 5 (0.1) 3 (0.1)
Unknown 176 (4.4) 164 (4.1)
Tracheal tube used, n (%) 1206 (30.0) 1125 (28.1)
Missing 5 (0.1) 4 (0.1)
Unknown 167 (4.2) 157 (3.9)
Number of shocks after randomisation (n) 3980 3962
Mean (SD) 1.4 (3.0) 0.9 (2.4)
Compression rate in the first 5 minutes (per minute)a (n) 149 137
Mean (SD) 106.8 (14.4) 106.5 (13.3)
Compression fraction in the first 5 minutes (%)b (n) 149 137
Mean (SD) 76.2 (11.2) 78.4 (13.0)
a Compression rate is derived by including only compressions in the periods of uninterrupted compression (no pause
or a pause of < 3 seconds).
b Compression fraction is defined as the proportion of time of uninterrupted chest compression.
TABLE 9 Quality of EMS CPR
Quality of CPR
Trial arm, mean (SD)
Adrenaline (n= 149) Placebo (n= 137)
Compression rate in the first 5 minutes (per minute)a 106.8 (14.4) 106.5 (13.3)
Compression fraction in the first 5 minutes (%)b 76.2 (11.2) 78.4 (13.0)
a Compression rate is derived by including only compressions in the periods of uninterrupted compression (no pause
or a pause of < 3 seconds).
b Compression fraction is defined as the proportion of time of uninterrupted chest compression.
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Numbers of patients analysed
The number analysed for each outcome is listed in Table 10.
Outcomes and estimations
Short- to medium-term outcomes are presented in Table 11. The survival rate at 30 days post
randomisation was significantly higher in the adrenaline arm than in the placebo arm. The treatment
difference of survival rate then decreased over time. Fewer patients who survived had a favourable
neurological outcome, and differences between groups were smaller than for survival alone [0.3%
(95% CI –0.3% to 0.9%) difference at discharge; 0.5% (95% CI –0.1% to 1.1%) difference at 3 and
6 months]. The number of patients with an unknown neurological outcome increased from discharge
(n = 13) to 3 months (n = 49) and to 6 months (n = 51).
Intensive care unit- and hospital-free survival are summarised in Figures 13 and 14, respectively.
TABLE 10 Number analysed for primary and secondary outcomes
Outcome Number analysed
Survival at 30 days 8007
Survival until hospital admission 7955
Survival to hospital discharge 8002
Survival at 3 months 8000
Survival at 6 months 7997
Survival at 12 months 7997
mRS at hospital discharge 8001
mRS at 3 months 7965
mRS at 6 months 7963
IQCODE at 3 months 132
IQCODE at 6 months 121
Two Simple Questions at 3 months 154
Two Simple Questions at 6 months 126
EQ-5D-5L at 3 months 154
EQ-5D-5L at 6 months 126
SF-12 at 3 months 137
SF-12 at 6 months 116
MMSE at 3 months 123
HADS (anxiety) at 3 months 144
HADS (depression) at 3 months 142
Post-traumatic stress at 3 months 137
Hospital length of stay (discharged) 218
Hospital length of stay (deceased) 7785
Intensive care length of stay (discharged) 238
Intensive care length of stay (deceased) 590
Free of hospital stay 8000
Free of intensive care 7999
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TABLE 11 Results of survival, hospital stay and mRS outcomes




Primary outcome, n/N (%)
30-day survival status 130/4012 (3.2) 94/3995 (2.4) 0.9% (0.2% to 1.6%) 1.39 (1.06 to 1.82) 1.47 (1.09 to 1.97)
Secondary outcomes, n/N (%)
Survived to hospital admissiona 947/3973 (23.8) 319/3982 (8.0) 15.8% (14.3% to 17.4%) 3.59 (3.14 to 4.12) 3.83 (3.30 to 4.43)
Survived to hospital discharge 128/4009 (3.2) 91/3995 (2.3) 0.9% (0.2% to 1.6%) 1.41 (1.08 to 1.86) 1.48 (1.10 to 2.00)
Survived at 3 months 121/4009 (3.0) 86/3991 (2.2) 0.9% (0.2% to 1.6%) 1.41 (1.07 to 1.87) 1.47 (1.08 to 2.00)
Survived at 6 months 117/4006 (2.9) 85/3991 (2.1) 0.8% (0.1% to 1.5%) 1.38 (1.04 to 1.83) 1.43 (1.05 to 1.96)
Survived at 12 months 107/4006 (2.7) 80/3991 (2.0) 0.7% (0.0% to 1.3%) 1.34 (1.00 to 1.80) 1.38 (1.00 to 1.92)
Hospital stay, median (IQR)
ICU length of stay of survivors 7.5 (3.0–15.0) 7.0 (3.5–12.5) 0.0 (–1.0 to 2.0) – –
ICU length of stay of deceasedb 2.0 (1.0–5.0) 3.0 (1.0–5.0) 0 (0 to 0)
Hospital length of stay of survivors 21.0 (10.0–41.0) 20.0 (9.0–38) 1.0 (–3.0 to 6.0) – –


































































































































































































































































































TABLE 11 Results of survival, hospital stay and mRS outcomes (continued )





Neurological outcome (mRS) at hospital discharge,c n (%)
0 – No symptoms 12 (0.3) 15 (0.4) – 0.80 (0.37 to 1.70) 0.80 (0.36 to 1.77)
1 – No significant disability 17 (0.4) 10 (0.3) – 1.16 (0.68 to 1.98) 1.16 (0.66 to 2.03)
2 – Slight disability 23 (0.6) 29 (0.7) – 0.96 (0.65 to 1.41) 0.98 (0.65 to 1.48)
3 – Moderate disability 35 (0.9) 20 (0.5) – 1.18 (0.86 to 1.61) 1.23 (0.88 to 1.73)
4 – Moderately severe disability 12 (0.3) 8 (0.2) – 1.21 (0.90 to 1.63) 1.26 (0.91 to 1.75)
5 – Severe disability 27 (0.7) 8 (0.2) – 1.41 (1.07 to 1.85) 1.51 (1.12 to 2.04)
6 – Dead 3881 (96.7) 3904 (97.6) – 1 1
Unknown 8 (0.2) 5 (0.1) –
Favourable neurological outcome at hospital discharge
(0–3 vs. 4–6), n/N (%)
87/4007 (2.2) 74/3994 (1.9) 0.3% (–0.3% to 0.9%) 1.18 (0.86 to 1.61) 1.19 (0.85 to 1.68)
Neurological outcome (mRS) at 3 months,c n (%)
0 – No symptoms 20 (0.5) 20 (0.5) – 1.33 (0.98 to 1.80) 1.20 (0.62 to 2.33)
1 – No significant disability 30 (0.7) 20 (0.5) – 1.39 (0.89 to 2.18)
2 – Slight disability 10 (0.2) 11 (0.3) – 1.27 (0.84 to 1.90)
3 – Moderate disability 22 (0.5) 12 (0.3) – 1.41 (0.99 to 2.02)
4 – Moderately severe disability 6 (0.1) 5 (0.1) – 1.41 (0.99 to 1.99)
5 – Severe disability 10 (0.2) 6 (0.2) – 1.45 (1.04 to 2.02)
6 – Dead 3888 (96.8) 3905 (97.6) – 1
Unknown 29 (0.7) 20 (0.5) –
Favourable neurological outcome at 3 months
(0–3 vs. 4–6), n/N (%)




























Outcome Adrenaline arm Placebo arm Difference (95% CI)
OR (95% CI)
Unadjusted Adjusted
Neurological outcome (mRS) at 6 months,c n (%)
0 – No symptoms 25 (0.6) 19 (0.5) – 1.51 (1.11 to 2.06) 1.38 (0.73 to 2.62)
1 – No significant disability 22 (0.5) 13 (0.3) – 1.63 (1.01 to 2.65)
2 – Slight disability 10 (0.2) 9 (0.2) – 1.47 (0.95 to 2.26)
3 – Moderate disability 21 (0.5) 17 (0.4) – 1.40 (0.96 to 2.03)
4 – Moderately severe disability 7 (0.2) 2 (0.1) – 1.49 (1.04 to 2.15)
5 – Severe disability 16 (0.4) 7 (0.2) – 1.62 (1.15 to 2.28)
6 – Dead 3889 (96.9) 3906 (97.7) – 1
Unknown 25 (0.6) 26 (0.7) –
Favourable neurological outcome at 6 months
(0–3 vs. 4–6), n/N (%)
78/3990 (2.0) 58/3973 (1.5) 0.5% (–0.1% to 1.1%) 1.35 (0.96 to 1.90) 1.35 (0.93 to 1.97)
a Survival to hospital admission was defined as a sustained ROSC until admission and transfer of care to medical staff at the receiving hospital.
b Hospital length of stay for deceased included all patients who died before hospital discharge; ICU length of stay for deceased included patients who were admitted to and died
in ICU. Unknown cases are not used in the difference or OR calculation. Adjustment covariates include age, sex, time from 999 call to arrival at scene, time from arrival at scene
to drug administration, initial rhythm, aetiology, who witnessed the arrest and bystander CPR. All treatment comparisons are made by comparing treatment adrenaline with
treatment placebo.
c Proportional odds assumption was valid only in the 3- and 6-month unadjusted mRS models. The 95% CIs have not been adjusted for multiplicity; therefore, inferences based on
the intervals may not be reproducible. In total, nine patients died and six were LTFU from 30 days to hospital discharge, and seven patients died and three patients were LTFU

































































































































































































































































































Longer-term neurocognitive and health-related quality-of-life outcomes among surviving patients are
presented in Figures 15–17. Figure 15 summarises outcomes whereby a higher score is better. Figure 16
summarises outcomes whereby a lower score indicates a better health outcome. Figure 17 presents
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Days alive and free of hospital stay (n)
FIGURE 14 Hospital-free survival (days) in the 30 days post randomisation, by trial arm. a, Mann–Whitney U-test
was used.
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FIGURE 15 Summary of longer-term neurocognitive and health-related quality-of-life outcomes for the MMSE, the
EQ-5D-5L and the SF-12 physical and mental health components. (a) Number of survivors; (b) mean (SD) MMSE score;
(c) mean (SD) EQ-5D-5L score; (d) mean (SD) EQ-VAS score; (e) mean (SD) SF-12 physical health score; and (f) mean (SD)
SF-12 mental health score. VAS, visual analogue scale. Note that error bars are ± 95% CIs of means. Frequency (rate) and
mean (SD) are shown on top of the bars for categorical and continuous outcomes, respectively. Normal range or value of
the outcomes: MMSE, 25–30 (122); HADS, 0–7 (123). The population mean is 50 (SD 10) for SF-12 and 0.86 (SD 0.23)
for EQ-5D-5L index score. VAS, visual analogue scale. (continued )
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Time point
FIGURE 15 Summary of longer-term neurocognitive and health-related quality-of-life outcomes for the MMSE, the
EQ-5D-5L and the SF-12 physical and mental health components. (a) Number of survivors; (b) mean (SD) MMSE score;
(c) mean (SD) EQ-5D-5L score; (d) mean (SD) EQ-VAS score; (e) mean (SD) SF-12 physical health score; and (f) mean (SD)
SF-12 mental health score. VAS, visual analogue scale. Note that error bars are ± 95% CIs of means. Frequency (rate) and
mean (SD) are shown on top of the bars for categorical and continuous outcomes, respectively. Normal range or value of
the outcomes: MMSE, 25–30 (122); HADS, 0–7 (123). The population mean is 50 (SD 10) for SF-12 and 0.86 (SD 0.23)
for EQ-5D-5L index score. VAS, visual analogue scale.
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FIGURE 16 Summary of longer-term neurocognitive and health-related quality of life for (a) IQCODE; (b) PCL-C;
(c) HADS anxiety; and (d) HADS depression. Note that error bars are ± 95% CIs of means. Frequency (rate) and mean
(SD) are shown on top of the bars for categorical and continuous outcomes, respectively. Normal range or value of the
outcomes: PCL-C, no optimal range; IQCODE, < 3.04 (124).
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The treatment effect on survival to 30 days was further assessed in the prespecified subgroups. Survival
rate was consistently higher in the adrenaline arm, but the results indicated no evidence of significant
treatment difference across subgroups in both unadjusted (Figure 18) and adjusted analyses (Figures 19)
(interaction p > 0.05).
Data linkage
Patients who survived on the scene and were transported to hospital were included for data linkage
(Figure 20). Data linkage to HES, the PEDW, the ICNARC data set and the UKTR was conducted for the
health economic analysis. The overall match rate of the ICNARC data set and the UKTR are 22.9% and
5.5%, respectively.
The linkage rates for the HES data sets are 96.4% for the PEWD (Welsh HES), 82.1% for NHS Digital
and 92.2% across both data sets.
Sensitivity analysis
Four scenarios were evaluated in the analysis, including best-case scenario in both arms (A), worst-case
scenario in both arms (B), best-case scenario in the placebo arm and worst-case scenario in the adrenaline
arm (C), best-case scenario in the adrenaline arm and worst-case scenario in the placebo arm (D), and
multiple imputation assuming missing at random (E). Best cases were defined as patients surviving and
worst cases were defined as patients dying. Results were presented in Table 12. The longer-term outcomes
are more affected by the individual imputation scenarios (C and D), but the majority of the results, including














































20Yes answers (n) 42 17 35 32 34 16 36 10 30 25 35
FIGURE 17 Summary of Two Simple Questions. Q1: In the last 2 weeks, did you require help from another person for
your everyday activities? Q1a: If yes, is this a new situation following your cardiac arrest? Q2: Do you feel that you have
made a complete mental recovery from your cardiac arrest? The Q1 and Q2 bars show the proportion of yes answers
among all followed-up patients at 3 and 6 months. The Q1a bars show the proportion of patients giving a yes answer of
those who answered yes to Q1. Q, question.
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Harms, serious adverse events
Serious adverse events
No events fulfilling the criteria for SAEs, SARs or SUSARs were reported during the trial.
Protocol deviations and violations
Table 13 shows the type and frequency of protocol deviations and violations throughout the trial,
and Figure 21 shows the number of violations over time as a proportion of recruitment in each month.
Overall, the proportions were small. The peak in October 2015 was mainly as a result of the small
number of participants recruited by this early stage. The dotted line shows the decreasing trend of
violations over time. Figure 22 is the statistical process control chart of the change of protocol
violations over time, as a percentage of recruitment, from June 2015 to October 2017. The violation
had large variation at the early stage, due to the peak in October 2015 (see Figure 22). The change
then stabilised and was mostly limited to the upper one-sigma (SD) limit.
Serious breaches
Two serious breaches occurred during the trial, as outlined in the following sections.
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FIGURE 18 Unadjusted subgroup analysis.
DOI: 10.3310/hta25250 Health Technology Assessment 2021 Vol. 25 No. 25
Copyright © 2021 Perkins et al. This work was produced by Perkins et al. under the terms of a commissioning contract issued by the Secretary of State for Health and
Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
53
0.1 1 10
Favours placebo Favours adrenaline















Mean age (69.7 years)
999 call to at scene
Mean time (7.4 minutes)
At scene to drug administration
Mean time (15.2 minutes)
999 call to drug administration
Mean time (22.6 minutes)
2.621 (1.153 to 5.958)
1.352 (0.946 to 1.930)
1.258 (0.603 to 2.621)
1.453 (1.019 to 2.071)
1.845 (0.816 to 4.173)
1.325 (0.945 to 1.857)
2.148 (1.129 to 4.088)
1.462 (1.082 to 1.975)
1.197 (0.179 to 8.011)
1.303 (0.934 to 1.818)
1.461 (1.067 to 1.999)
1.444 (1.038 to 2.010)
1.429 (1.014 to 2.014)
0.319
































FIGURE 20 Data linkage to UKTR and ICNARC.
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TABLE 12 Sensitivity analysis of short- to medium-term survival and mRS outcomes
Scenario
Trial arm, n (%)
Difference (95% CI) (%) Unadjusted OR (95% CI)Adrenaline (N= 4015) Placebo (N= 3999)
30-day survival status
A 133 (3.3) 98 (2.5) 0.9 (0.1 to 1.6) 1.36 (1.05 to 1.78)
B 130 (3.2) 94 (2.4) 0.9 (0.2 to 1.6) 1.39 (1.06 to 1.82)
C 130 (3.2) 98 (2.5) 0.8 (0.1 to 1.5) 1.33 (1.02 to 1.74)
D 133 (3.3) 94 (2.4) 1.0 (0.2 to 1.7) 1.42 (1.09 to 1.86)
E – – – 1.38 (1.06 to 1.81)
Survived to hospital discharge
A 134 (3.3) 95 (2.4) 1.0 (0.2 to 1.7) 1.42 (1.09 to 1.85)
B 128 (3.2) 91 (2.3) 0.9 (0.2 to 1.6) 1.41 (1.08 to 1.86)
C 128 (3.2) 95 (2.4) 0.8 (0.1 to 1.5) 1.35 (1.03 to 1.77)
D 134 (3.3) 91 (2.3) 1.1 (0.3 to 1.8) 1.48 (1.13 to 1.94)
E – – – 1.41 (1.07 to 1.85)
90-day survival status
A 127 (3.2) 94 (2.4) 0.8 (0.1 to 1.5) 1.36 (1.04 to 1.78)
B 121 (3.0) 86 (2.2) 0.9 (0.2 to 1.6) 1.41 (1.07 to 1.87)
C 121 (3.0) 94 (2.4) 0.7 (–0.0 to 1.4) 1.29 (0.98 to 1.70)
D 127 (3.2) 86 (2.2) 1.0 (0.3 to 1.7) 1.49 (1.13 to 1.96)
E – – – 1.41 (1.07 to 1.87)
180-day survival status
A 126 (3.1) 93 (2.3) 0.8 (0.1 to 1.5) 1.36 (1.04 to 1.79)
B 117 (2.9) 85 (2.1) 0.8 (0.1 to 1.5) 1.38 (1.04 to 1.83)
C 117 (2.9) 93 (2.3) 0.6 (–0.1 to 1.3) 1.26 (0.96 to 1.66)
D 126 (3.1) 85 (2.1) 1.0 (0.3 to 1.7) 1.49 (1.13 to 1.97)
E – – – 1.38 (1.04 to 1.83)
Survival with good neurological outcome at discharge (mRS score of ≤ 3)
A 95 (2.4) 79 (2.0) 0.4 (–0.2 to 1.0) 1.20 (0.89 to 1.63)
B 87 (2.2) 74 (1.9) 0.3 (–0.3 to 0.9) 1.17 (0.86 to 1.61)
C 87 (2.2) 79 (2.0) 0.2 (–0.4 to 0.8) 1.10 (0.81 to 1.50)
D 95 (2.4) 74 (1.9) 0.5 (–0.1 to 1.1) 1.29 (0.95 to 1.75)
E – – – 1.18 (0.86 to 1.61)
Survival with good neurological outcome at 3 months (mRS score of ≤ 3)
A 111 (2.8) 83 (2.1) 0.7 (0.0 to 1.4) 1.34 (1.01 to 1.79)
B 82 (2.0) 63 (1.6) 0.5 (–0.1 to 1.1) 1.30 (0.94 to 1.81)
C 82 (2.0) 83 (2.1) –0.0 (–0.7 to 0.6) 0.98 (0.72 to 1.34)
D 111 (2.8) 63 (1.6) 1.2 (0.6 to 1.8) 1.78 (1.30 to 2.43)
E – – – 1.30 (0.93 to 1.81)
continued
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Investigational Medicinal Product management
During scheduled reconciliation of the IMP (batches 6.2 and 6.3), the number of unaccounted packs in
one ambulance service reached 4.4%. An investigation was instigated and the results were reviewed
by the TMG. It was concluded that the risk to trial subjects, the public and to the scientific value of
the trial was low. However, it was discussed with the MHRA and classified as a serious breach due to
non-compliances associated with IMP management. A corrective and preventative actions plan was
put in place, which included several communications to paramedic crews, thorough tracking of the drug
pack journey for unaccounted packs and more regular drug audits. The rate of unaccounted-for packs
reduced to 3.3% for future batch reconciliation and 2.7% overall. The serious breach was considered
closed by the MHRA on 27 July 2017.
TABLE 12 Sensitivity analysis of short- to medium-term survival and mRS outcomes (continued )
Scenario
Trial arm, n (%)
Difference (95% CI) (%) Unadjusted OR (95% CI)Adrenaline (N= 4015) Placebo (N= 3999)
Survival with good neurological outcome at 6 months (mRS score of ≤ 3)
A 103 (2.6) 84 (2.1) 0.5 (–0.2 to 1.1) 1.23 (0.92 to 1.64)
B 78 (2.0) 58 (1.5) 0.5 (–0.1 to 1.1) 1.35 (0.96 to 1.90)
C 78 (2.0) 84 (2.1) –0.1 (–0.8 to 0.5) 0.92 (0.68 to 1.26)
D 103 (2.6) 58 (1.5) 1.1 (0.5 to 1.7) 1.79 (1.29 to 2.48)
E – – – 1.36 (0.97 to 1.92)
A, Best-case scenario in both arms; B, worst-case scenario in both arms; C, best-case scenario in the placebo arm and
worst-case scenario in the adrenaline arm; D, best-case scenario in the adrenaline arm and worst-case scenario in the
placebo arm; E, multiple imputation assuming missing at random.
TABLE 13 Frequency of protocol deviations and violations
Frequency (n)
Type of deviation
Expired trial drug pack used (used within 12-month shelf life) 6
Two trial packs opened for one patient (when all 10 doses from the first pack had been administered) 4
Open-label adrenaline given after 10 doses of the IMP 19
No active notification of patient enrolment to research team (no effect on follow-up of patient) 359




Expired trial drug pack used (used after end of 12-month shelf life) 3
Paramedic enrolled patient without completing trial training 19
Two trial packs opened for one patient (when < 10 doses had been administered from the first pack) 10
Ineligible patient enrolled (known to be ineligible at the point of randomisation) 8
Open-label adrenaline given after < 10 doses of the IMP 40
Other (IMP administered post ROSC; trained paramedic did not travel to A&E with untrained crew;
patient’s relatives contacted after they had declined consent for follow-up)
3
Total 83
A&E, accident and emergency.
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A single point outside the control limits
Two of three points outside the two-sigma limit
Four of f ive points outside the one-sigma limit
Eight in a row on the same side of centre line

































































































































































































































































































Enrolment error, trial number 7398
A patient was enrolled who met one of the trial exclusion criteria. The HM Coroner inquest found that
the error did not contribute to the patient’s death. A root-cause analysis found that the paramedic
did not adequately check the contents of the syringe before administering it; therefore, incorrect
medicines were selected and given. This was reported to the MHRA as a potential serious breach,
and was considered closed on 28 August 2018.
Corrective and preventative actions
The following preventative measures were in place prior to this incident occurring:
l Face-to-face trial refresher training had been provided to clinicians on an ongoing basis.
l Paramedics were provided with aide memoires detailing inclusion and exclusion criteria.
l Eligibility criteria stickers had been added to all IMP packs to act as a reminder.
l A question-and-answer exercise was undertaken at South Central Ambulance Service giving
examples of non-compliances and checking that teams were aware of the correct course of action.
The following additional actions were put in place following the incident:
l The enrolling paramedic was prevented from enrolling further patients in the trial until retraining
had taken place.
l A communication was sent on two separate occasions to all paramedics in the ambulance service to
act as a reminder of eligibility criteria.
l A message was sent to all ambulance service dashboards reminding clinicians to check patient
eligibility before administering the PARAMEDIC2 trial IMP.
l Refresher training slides were updated to emphasise eligibility criteria.
Assessment of impact of protocol non-compliances
It is the assessment of the TMG that the trial complied with GCP and that the deviations, violations
and serious breaches did not have any material impact on the trial findings.
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Chapter 4 Economic evaluation
Overview
A prospective within-trial economic evaluation was conducted to estimate the cost-effectiveness of
adrenaline, compared with placebo, for OHCA. Costs are expressed in Great British pounds (2017 price
year) and health outcomes are expressed in terms of QALYs, 6-month overall survival and 6-month
survival with good neurological function (mRS score of ≤ 3). The base-case analysis used intention-to-
treat data covering the 6-month period from randomisation and was conducted from the perspective
of the UK NHS and PSS.132
A decision-analytic model was used to extrapolate outcomes beyond the trial follow-up and to
assess the cost-effectiveness of adrenaline over a lifetime time horizon. Costs and outcomes were
discounted to present values at 3.5% per annum only when the time horizon of the analyses was
> 1 year (i.e. the lifetime decision-analytic model). Sensitivity analyses explored the probable impact
of alternative data inputs (e.g. as a result of adopting a broader societal perspective) and assumptions
on cost-effectiveness outcomes. Subgroup analyses were conducted to estimate heterogeneity in
cost-effectiveness outcomes. Findings are reported in accordance with the Consolidated Health
Economic Evaluation Reporting Standards (CHEERS) guidelines.133
Measurement and valuation of resource use
Economic costs were calculated using estimates of resource inputs associated with pre-hospital
emergency response, including treatment costs, and using estimates of broader utilisation of hospital-
and community-based health and social care services.
Initial emergency response
Resource inputs associated with the initial pre-hospital emergency response were extracted from the
trial CRFs completed by research paramedics. These data included the number of emergency response
staff/ambulance crew and vehicles in attendance, the duration of the emergency response and the
cumulative adrenaline doses administered. Emergency response duration was defined as (1) the interval
between the at-scene time (i.e. the time at which the emergency response team arrived at scene) and
the left-scene time (or the time at which CPR was stopped if the left-scene time was not recorded) if
the cardiac arrest occurred at home and the patient was pronounced dead at scene, or (2) the interval
between at-scene time and arrival-at-hospital time if the patient survived and was taken to hospital.
It was assumed that one vehicle transported the patient to hospital if multiple vehicles were in attendance,
with the remaining vehicles standing down and available for the next assignment. Consequently, a 1-hour
stand-down time was added to the emergency response time for each patient to account for ambulance
crew stand-down and restock time following discussions with the trial paramedics about duration of these
activities under current UK clinical practice. Sensitivity analyses (see Table 14, sensitivity analyses 11 and 13)
explored the impact of excluding the cost of emergency response crew stand-down and restock time on
cost-effectiveness outcomes.
Initial emergency response data were generally collected for trial participants up to the point of death
or hospital admission. This meant that trial data were not available to estimate some resource inputs
for patients who died at scene. In particular, the trial CRFs did not record post-death ambulance crew
activity, such as whether or not the deceased person was transported to a mortuary. Thus, it was
assumed that patients pronounced dead at the scene of the cardiac arrest would be left at the scene
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if the location of the cardiac arrest was the patient’s home, and would be transported by emergency
ambulance to the nearest hospital or public mortuary if the location of the cardiac arrest was a public
place. Google Maps (Google Inc., Mountain View, CA, USA) [called from within R (The R Foundation
for Statistical Computing, Vienna, Austria) via packages ‘gmapsdistance’ and ‘googleway’] was then
used to estimate ambulance travel time to the nearest hospital mortuary for the subgroup of patients
whose arrest occurred in a public place. Sensitivity analyses explored the impact of variations in this
assumption on the base-case cost-effectiveness results (see Table 14, sensitivity analyses 12 and 13).
Hospital- and community-based health and social care service use
Data on the use of hospital- and community-based health and social care services covering the
6-month period from randomisation were collected for trial participants by three principal means:
1. Trial CRFs completed by research paramedics provided details of the initial hospitalisation episode,
including ED assessment and treatment and inpatient length of stay in the ICU and cardiac and
general adult wards.
2. Hospital Episode Statistics134 were requested for trial participants, covering the period from each
participant’s cardiac arrest event to 31 March 2018. This provided a complete profile of resource
use associated with all hospital episodes for all participants over the trial time horizon, including ED
attendances, outpatient attendances, day-case admissions and critical care and other inpatient
admissions covering procedures undertaken and lengths of stay. When HES data were not available,
data collected using the trial CRFs and patient self-reports of hospital-based service use were
used instead.
3. Economic questionnaires completed by trial participants or their proxies at the 3- and 6-month
post-randomisation assessment points provided details of hospital re-admissions and use of hospital
outpatient services, community health and social care services, prescribed medications, NHS supplies,
child-care costs, time off work and out-of-pocket medical expenses.
Valuation of hospital resource use collected through trial case report forms
Hospital resource inputs were estimated for trial participants using the trial CRFs and valued by
attaching unit costs drawn largely from secondary sources. Hospital-based services included inpatient
admissions, outpatient visits and diagnostic tests and scans. Unit costs for these services were obtained
primarily from the 2016/17 NHS reference costs main schedules,135 and acted as an alternative source
of hospital cost values to the HES-generated data. Average daily unit costs were calculated for hospital-
based services using a costing methodology previously described in a HTA report that informed an
economic evaluation of a mechanical versus manual CPR for OHCA.136 The costing method involves
assigning identifying Healthcare Resource Group (HRG) codes for clinical care most likely to be
received following OHCA and calculating a per diem cost weighted by the level of activity.
Valuation of Hospital Episode Statistics data
The HRG4+ 2016/17 Reference Costs Grouper137 was used to generate HRG codes for each record of
admitted care and critical care episode, ED attendance, and outpatient visit extracted from HES for
each trial participant. Records were matched to grouper costs in the 2016/17 NHS Reference Costs
main schedules135 based on the HRG and combination variables describing the level of resource use
associated with each episode of care. ED and outpatient attendances were matched to averaged
reference costs based on the HRG code only. Admitted care episodes were matched at the full
consultant episode level based on the HRG, patient classification (admitted vs. day case), type of
admission (elective vs. non-elective) and length of stay (short stay vs. long stay). Inpatient length of
stay was defined as short stay if the episode duration was 1 day and was described as long stay for
episodes lasting ≥ 2 days, in line with national reference cost calculations (see pages 47 and 48 of the
National Cost Collection guidance 2018138).
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Unbundled HRGs associated with high-cost drugs, devices and investigations and excess bed-days were
automatically generated by the Grouper software for each admitted care record. Reference costs were
attached to unbundled HRGs and excess bed-day costs generated by multiplying the duration of excess
bed-days by respective excess bed-day unit costs in the 2016/17 reference cost schedules.135 Costs
were summed across full consultant episodes within spells to generate total costs per admitted care
spell covering the total time period between admission and hospital discharge. Critical care records
were matched to reference costs based on the critical care HRG, and critical care unit function code
describing type of critical care activity. Non-specific general adult critical care patients and the maximum
number of organ systems supported at any one time during the critical care period predominate in the
algorithms were used to cost critical care episodes.139
Resource use and economic costs extracted from participant-completed questionnaires
Economic questionnaires completed by trial participants or their proxies at the 3- and 6-month
post-randomisation assessment points provided resource use data that complemented the resource
use data extracted from the trial CRFs and HES data sets. Details of hospital re-admissions, by type
and duration of hospital admission and hospital outpatient service, by type and volume, were extracted
from the economic questionnaires and valued using 2016/17 NHS reference costs main schedules.135
Primary and community health and social care services included face-to-face or telephone contacts
and/or home visits by a general practice doctor, practice nurse, community physiotherapist or other
community health or social care professionals. Consultation costs were derived from the Personal
Social Services Research Unit’s Unit Costs of Health and Social Care 2017.140 The cost of prescribed
medication was obtained primarily from the prescription cost analysis 2017 database141 and electronic
searches of the British National Formulary (BNF) 2017 edition.142 Typical dosages and durations of
treatment reported in the BNF for each medication were used in calculating quantities of individual
preparations if the daily dose and/or duration of a course of medication was not reported in the
trial documentation.
The quantities of over-the-counter medicines were rounded to the nearest pack and unit costs were
obtained from online sources. Costs of aids and supplies (e.g. walking aids, heart monitors) were either
provided by the trial participants themselves (if self-purchased) or derived from the NHS supply chain
catalogue for aids and supplies provided by health providers during the trial follow-up period. Unit costs
for health-care resource inputs were inflated/deflated to 2016/17 prices when necessary using the
NHS Hospital and Community Health Services Pay and Prices Index, and the Consumer Prices Index.140
The economic questionnaires completed by trial participants or their proxies at the 3- and 6-month
post-randomisation assessment points also provided details of broader societal (non-NHS/PSS) resource
input and costs, such as out-of-pocket medical expenses (e.g. privately purchased medication, travel
costs as a result of hospital and medical appointments), child-care costs, income lost, housework help
and laundry services costs. Out-of-pocket medical expenditure (e.g. medication purchased by patients
themselves and travel costs) were either provided in monetary terms or valued by attaching unit costs
to resource inputs provided. Non-health-care costs such as child-care costs and lost income were
generally provided by participants and/or their proxies in monetary terms; therefore, no requirement
to value these outcomes was necessary.
Estimation of costs for the total 1-year period after randomisation
Hospital Episode Statistics134 were requested for trial participants covering the period from the cardiac
arrest event to 31 March 2018. This meant that patients followed up after this date had incomplete
HES records covering the 1-year period after the cardiac arrest event. The following methodology was
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used to calculate 1-year hospital costs estimates for all inpatients, including those with < 1 year of
complete HES data:
l Hospital Episode Statistics data were available for 1833 (45.7%) participants in the adrenaline group
and 1094 (27.4%) participants in the placebo group. Of these, complete records of hospital resource
use up to 1 year were available for 1802 (98.3%) of the 1833 in the adrenaline group and 1068
(97.6%) of the 1094 in the placebo group. These data were used to estimate costs of hospital care
(initial hospitalisation episode, re-admissions and use of non-admitted hospital care services such as
day-case admissions, ED attendances and outpatient attendances) covering the period between the
cardiac arrest event to 1 year post event. The remaining 31 (1.7%) patients in the adrenaline group
and 26 (2.4%) in the placebo group had HES-based records of hospital resource use for < 1 year.
The 1-year costs of hospital resource use for these patients were treated as missing data.
l Of the remaining 2182 (54.3%) trial participants in the adrenaline group and 2905 (72.6%) trial
participants in the placebo group who did not have HES data, 1984 (90.9%) in the adrenaline group
and 2778 (95.6%) in the placebo group died at the scene of the cardiac arrest or were not taken
to hospital. We assigned zero hospitalisation costs to these patients. The remaining 198 (8.1%)
and 127 (4.4%) participants in the adrenaline and placebo groups, respectively, who were taken to
hospital but had no HES records were either treated as missing data (if they declined consent to
continued participation) or assigned 1-year hospitalisation costs based on the CRFs and data
collected through the economic questionnaires completed by trial participants or their proxies.
l The cost of hospital resource use covering the 0–6 months post-randomisation period was estimated
based on resource use extracted from the CRF and economic questionnaire data. The costs of hospital
re-admissions and non-admitted care services in the 6- to 12-month window were estimated by
extrapolating costs incurred in the 3- to 6-month period to 6–12 months. This essentially multiplied
the 3- to 6-month costs by three for the calculation of 1-year hospital costs.
l Finally, 1-year costs associated with the use of non-hospital-based health and social care services
and societal costs were estimated by extrapolating costs incurred at 3–6 months post randomisation
(derived from participant-completed questionnaires) to 6–12 months post randomisation for all
trial participants.
Measurement of outcomes
Health-related quality of life and survival
Health-related quality of life was assessed using generic instruments (i.e. the EQ-5D-5L and SF-12
version 2) completed at 3 and 6 months post randomisation and the mRS instrument completed at
hospital discharge and at 3 and 6 months post randomisation. Responses to the EQ-5D-5L descriptive
system were converted into health utility (or preference-based health-related quality-of-life) values,
based on the UK EuroQol-5 Dimensions, three-level version (EQ-5D-3L), tariff143 using the van Hout
et al.144 interim cross-walk algorithm, in line with current NICE recommendations.145 The mRS scores
were converted into health utility (or preference-based health-related quality-of-life) values, based on the
UK EQ-5D-3L tariff,143 using a published mapping function developed by Rivero-Arias et al.146 The SF-12
scores were converted into health utility values using the Short Form questionnaire-6 Dimensions
(SF-6D) utility tariff for the UK published by Brazier et al.147 Survival outcomes following cardiac
arrest were also collected to 12 months post cardiac arrest for trial participants.
Quality-adjusted life-years
Quality-adjusted life-year profiles were generated for each trial participant using area-under-the-curve
methods, assuming a baseline health utility value of zero and linear interpolation between utility
measurements, taking into account survival over the 6-month time horizon of interest (base case). In
the base-case analysis, we combined utility values from the mRS scores at hospital discharge and utility
values derived from the EQ-5D-5L at 3 and 6 months to calculate QALY profiles over 6 months.We used
mRS-derived health utilities in place of EQ-5D-5L values if the latter were missing at the 3- or 6-month
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post-randomisation assessment points.146 Health utility values generated from the mRS were available
at hospital discharge and at all assessment points over the 6-month base-case time horizon. Thus, the
impact of combined EQ-5D-5L-/mRS-generated QALYs on the base-case cost-effectiveness results was
assessed in a sensitivity analysis that used QALYs generated solely from the mRS scores. Patients who
died were assigned a utility value of zero onwards from time of death for the calculation of QALYs.
We did not assess health-related quality of life at baseline, as the clinical context precluded collecting
any patient-reported outcome data around the time of randomisation: patients were either unconscious
or too critically ill to complete questionnaires.148 Alternative assumptions around health-related quality
of life at baseline explored the impact on the cost-effectiveness of adrenaline of setting the baseline
utility value to zero. In the first of these, the baseline utility value in the adrenaline and placebo groups
was set to –0.402, reflecting UK population preferences for an unconscious health state within the
EQ-5D-3L A1 tariff set.149
We also calculated QALY profiles over 12 months, under the assumption that patients’ health-related
quality of life at 12 months was the same as their health-related quality of life at 6 months, if they
had survived, and we used this information to inform a sensitivity analysis exploring longer-term
cost-effectiveness.
Statistical analysis of economic data
Summary of resource use and costs
Patient-level costs were generated for each resource variable by multiplying the quantity reported by
the respective unit cost, weighted by length of stay or duration of contact when appropriate. Summary
statistics (means, standard errors and completion rates) were generated for the whole trial population
and for those surviving to hospital discharge by treatment allocation and assessment point. Between-
group differences in mean resource use and mean costs at each assessment point were compared
using the two-sample t-test. Statistical significance was assessed at the 5% significance level. A non-
parametric bootstrap routine was implemented, generating 1000 replications of the data. Estimates of
standard errors surrounding mean resource use (or cost) estimates and 95% CIs surrounding between-
group differences in mean resource use (or costs) were obtained from the bootstrapped samples.
Summary of health-related quality-of-life data
Responses to each health dimension of the EQ-5D-5L and SF-12 are presented by level of function.
Comparisons of responses were conducted on the basis of optimal level of function (e.g. ‘no problem’ on
the EQ-5D-5L) versus suboptimal level of function (indicating any functional impairment). Between-group
differences in optimal versus suboptimal level of function for each health dimension were compared
for each outcome measure using chi-squared (χ2) tests at each assessment point for each health-related
quality-of-life instrument. Summary statistics (means, standard errors and completeness rates) for health
utilities were generated for the whole trial population and for survivors to hospital discharge by treatment
allocation, assessment point and health-related quality-of-life instrument. Estimates of between-group
difference in mean health utility values and 95% bootstrapped CIs surrounding mean group differences
were generated based on 1000 bootstrapped resamples of the data.
Missing data
In addition to trial-specific protocols and procedures to minimise missing data, a strategy was
employed prior to commencement of recruitment to identify and collect resource use and health
outcomes data from multiple sources, with the specific aim of reducing the level of missingness for
the economic outcomes of interest. Participants were assumed to incur no health-care costs beyond
the initial emergency response costs if cardiac arrest occurred at home and the patient was declared
deceased at the scene of arrest. Costs associated with use of hospital-based services were generated
primarily from HES data; information obtained through trial-specific procedures (trial CRFs and
participant questionnaires) was used when HES data were not available.
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Health-related quality of life was assessed using multiple instruments, including the mRS completed at
hospital discharge and the mRS, EQ-5D-5L and SF-12 completed by trial participants at 3 and 6 months
post randomisation. Survival information was collected through trial-specific procedures and Office for
National Statistics data. This process of using multiple data sources to systematically fill in missing data
provided a more complete profile of the main economic outcomes of interest, compared with relying on
a single data source.
Nevertheless, multiple imputation by chained equations (MICE), implemented through the R package
MICE,150 was used to predict values for any remaining missing items, assuming data were missing at
random. Missing costs and health utility values were imputed at the level of resource category and
health-related quality-of-life assessment, stratified by survival status at hospital discharge and
treatment allocation in accordance with good-practice recommendations outlined in Faria et al.151
Imputation was achieved using predictive mean matching, which has the advantage of preserving
non-linear relationships and correlations between variables within the data. Twenty imputed data sets
were generated and used to inform the base-case and subsequent sensitivity and subgroup analyses.
Parameter estimates were pooled across the 20 imputed data sets using Rubin’s rules to account for
between- and within-imputation components of variance terms associated with parameter estimates.
Base-case cost-effectiveness
The base-case cost-effectiveness analysis used the intention-to-treat data to estimate the cost–utility
of adrenaline, compared with placebo, from the perspective of the UK NHS and PSS.132 Economic costs
and QALYs were calculated for each patient over a 6-month post-randomisation time horizon. Total
costs were calculated by summing costs associated with the initial emergency response (including the
cost of the intervention) and costs of broader hospital- and community-based health and social care
services. QALYs were generated based on health utility data generated from the mRS score at hospital
discharge and the EQ-5D-5L score at the 3- and 6-month assessments.
Two seemingly unrelated normal error regressions were fitted to imputed data using the systems fit
implementation in R,152 which accounts for the correlation between patient-level costs and QALYs.
The regressions controlled for treatment allocation, age, sex, time to first dose administration, cause
of cardiac arrest, whether or not the cardiac arrest was witnessed, bystander CPR and rhythm.
The base-case analyses were replicated using the Stata® version 15 (StataCorp LP, College Station,
TX, USA) MICE and seemingly unrelated regressions SUR REG functions.
The incremental cost-effectiveness ratio (ICER) was calculated for adrenaline, compared with placebo,
by dividing the between-group difference in adjusted mean total costs by the between-group difference
in adjusted mean QALYs. Cost-effectiveness was assessed by comparing the ICER to cost-effectiveness
thresholds of between £15,000 and £30,000 per QALY gained, in line with NICE guidance132 and the
recent empirical threshold of £13,000 per QALY estimate suggested by Claxton et al.153 Estimates were
also generated assuming £50,000 and £100,000 values for the cost-effectiveness threshold for a QALY,
reflecting potentially higher willingness-to-pay thresholds for a life-saving intervention. The incremental
net (monetary) benefit of adrenaline compared with placebo was calculated for cost-effectiveness
thresholds ranging from £15,000 to £200,000 per QALY gained. Net monetary benefit values reflect the
opportunity cost of (or the benefits forgone from) adopting a new treatment when resources could be
put to use elsewhere. A positive net monetary benefit suggests that, on average, adrenaline provides a
net gain, compared with placebo, for the health service and can be considered cost-effective at the
given cost-effectiveness threshold.
Uncertainty around the mean cost-effectiveness estimates was characterised through a Monte Carlo
method.154 This involved simulating 1000 replicates of the ICER from a joint distribution of the incremental
costs and QALYs and plotting the simulated ICERs on the cost-effectiveness plane. A sensitivity analysis
explored an alternative characterisation of uncertainty based on generating 1000 bootstrap replications
of the ICER instead of the Monte Carlo method (see Table 14, sensitivity analysis 4). Cost-effectiveness
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acceptability curves (CEACs) were also plotted to give graphical display of the probability that adrenaline
is cost-effective across a wide range of cost-effectiveness thresholds. A sensitivity analysis explored
the impact of embedding the imputation model within the non-parametric bootstrap to simulate 1000
replicates of the ICER to calculate the probability that adrenaline is cost-effective at the cost-effectiveness
thresholds specified previously.
Analysis of secondary health economic outcomes
Secondary health economic outcomes were analysed using logistic regression models that were
embedded in the bootstrap and imputation models. The regression models estimated adjusted overall
survival and neurologically intact survival probabilities for adrenaline and placebo at 6 months post
randomisation. This preserved the correlation between patient-level costs and effects and allowed us
to express the cost-effectiveness of adrenaline as incremental costs per unit increase in the proportion
of patients surviving to 6 months post cardiac arrest.
Sensitivity analyses
Table 14 summarises methods and assumptions underlying the base-case and the sensitivity analyses
conducted to explore the impact of alternative modelling assumptions and methods on the cost-
effectiveness of adrenaline.
TABLE 14 Prespecified and post hoc sensitivity analyses exploring the impact of various modelling assumptions on
base-case cost-effectiveness
Sensitivity
analysis Base-case methods/assumptions Changes implemented in sensitivity analyses
Prespecified
1 Adjusted multiple imputation Unadjusted multiple imputation
2 Adjusted multiple imputation Adjusted complete-case analysis
3 Adjusted multiple imputation Unadjusted complete-case analysis
4 Parameter estimates via seemingly unrelated
linear regression
Parameter estimates via linear regression
implemented within a boostrap
5 QALYs based on EQ-5D-5L/mRS data QALYs based on mRS data only
6 QALYs derived assuming baseline utility of 0
(equivalent to dead)
QALYs derived assuming baseline utility of –0.042
(equivalent to unconscious health state)
7 QALYs based on EQ-5D-5L and mRS data,
NHS/PSS costs
QALYs based on EQ-5D-5L and mRS data,
6 months’ societal costs
8 6-month time horizon (QALYs based on EQ-5D-5L
and mRS data, NHS/PSS costs)
12-month time horizon (QALYs based on
EQ-5D-5L and mRS data, NHS/PSS costs)
9 QALYs based on EQ-5D-5L and mRS data,
6-month time horizon
12-month time horizon (QALYs based on mRS
data, NHS/PSS costs)
10 QALYs based on EQ-5D-5L and mRS data,
6-month time horizon
12-month time horizon (QALYs based on
EQ-5D-5L and mRS data, societal costs)
Post hoc analyses
11 1 hour added to emergency response cost
calculations to account for stand-down and
restock time
Excluded stand-down and restock time in
emergency response cost calculations
12 Accounts for cost of transporting deceased
patients to nearest hospital or local authority
mortuary if patient died at scene of cardiac arrest
and in a public place
Excluded estimated cost of transporting deceased
patients to nearest hospital mortuary if patient
died at scene of cardiac arrest and in a public place
13 Accounts for stand-down/restock time and
transportation costs to nearest mortuary if
patients died in a public place in emergency
response cost calculations
Excluded stand-down/restock time and cost of
transporting patients to nearest mortuary in
emergency response cost calculations
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Subgroup analysis
Prespecified subgroup analyses were also conducted based on specifications in the PaRAMeDIC trial81
statistical analysis plan to explore whether or not there are subgroups of patients for whom adrenaline
is likely to be cost-effective. In addition, one post hoc subgroup explored the treatment dose–response
relationship and estimated the dose at which adrenaline is likely to be most cost-effective. Our subgroup
analyses were as follows:
l Cardiac arrest witnessed by paramedic versus cardiac arrest witnessed by bystander versus cardiac
arrest not witnessed.
l Bystander CPR versus no bystander CPR for bystander-witnessed and not-witnessed OHCAs.
l Type of initial rhythm: shockable (VT/VF) versus non-shockable (PEA/asystole).
l Aetiology of cardiac arrest (medical vs. non-medical).
l Age (≤ 60 years vs. > 60 years).
l Time interval from 999 call to EMS arrival (≤ 10 minutes vs. > 10 minutes) among those with a
witnessed arrest.
l Time interval from EMS arrival to administration of trial drug (≤ 10 minutes vs. > 10 minutes)
among those with a witnessed arrest.
l Time interval from 999 call to administration of trial drug (≤ 10 minutes vs. > 10 minutes) among
those with a witnessed arrest.
l The time to emergency treatment variables were categorised based on previous studies reporting
that administration of adrenaline within 10 minutes following cardiac arrest is associated with
neurologically improved survival outcomes.155
Extrapolating beyond trial follow-up
A simple Markov state-transition model was built in R using the package heemod156 to extrapolate
the within-trial results over the lifetimes of cardiac arrest survivors. The model as shown in Figure 23
comprises four health states (OHCA state, post-OHCA survival with good neurological function,
post-OHCA survival with poor/impaired neurological function and death). The cycle length is 1 year













FIGURE 23 Model to extrapolate cost-effectiveness beyond the PARAMEDIC2 trial follow-up. C, complement (probability
of remaining in good or poor neurological functional states); good, good neurological function; poor, poor neurological
function; pGood2Dead, annual probability of death among survivors with good neurological function; pPoor2Dead, annual
probability of death among survivors with poor neurological function; pOHCA2Dead, probability of death within first year
post cardiac arrest/from randomisation; pOHCA2Good, probability of surviving to 1 year with good neurological function;
pOHCA2Poor, probability of surviving to 1 year with poor neurological function.
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from this state represent 1-year survival with good or poor neurological function and death. This implies
that the OHCA state captures all the economic costs and benefits in the first year after randomisation
and so corresponds to the within-trial cost-effectiveness analysis with a 1-year time horizon. In the
PARAMEDIC2 trial, neurological function was assessed at hospital discharge and at 3 and 6 months post
randomisation. This information was used to categorise post-OHCA survival as good if the score of the
mRS assessment closest to the 1-year time point after the cardiac arrest was ≤ 3 and to categorise it
as poor for scores of > 3. Probabilities governing these transitions were estimated separately for the
adrenaline and placebo groups, based on these categorisations, and are summarised in Table 15.
TABLE 15 Extrapolating beyond trial follow-up; data inputs
Parameter Mean (SE) Distribution Source
Cohort characteristics
Mean age (years), 1-year post-cardiac arrest survivors 60 PARAMEDIC2 data
Percentage of males among 1-year post-cardiac arrest
survivors
78 Beta PARAMEDIC2 data
Probabilities
1-year survival with good function (mRS score of ≤ 3),
adrenaline
0.023 (0.0024) Multinomial PARAMEDIC2 data
1-year survival with good function (mRS score of ≤ 3),
placebo
0.019 (0.0021) Multinomial PARAMEDIC2 data
1-year survival with poor function (mRS score of > 3),
adrenaline
0.005 (0.0011) Multinomial PARAMEDIC2 data
1-year survival with poor function (mRS score of > 3),
placebo
0.003 (0.0019) Multinomial PARAMEDIC2 data
3-month mortality given alive with good function at
9 months post arrest
0.029 (0.013) Binomial PARAMEDIC2 data
3-month mortality given alive with poor function at
9 months post arrest
0.061 (0.042) Binomial PARAMEDIC2 data
Annual mortality rate given survival to 1 year with
good function
0.111 (0.0457) Derived 0.111/UK mortality
2015157
Annual mortality rate given survival to 1 year with
poor function
0.215 (0.1213) Derived 0.215/UK mortality
2015157
Costs (£, 2017 prices)
OHCA, adjusted mean costs, 1 year post randomisation,
adrenaline
3741 (536) Gamma PARAMEDIC2 data
OHCA, adjusted mean costs, 1 year post randomisation,
placebo
2330 (541) Gamma PARAMEDIC2 data
Good functional state 7907 (718) Gamma PARAMEDIC2 data
Poor functional state 24,457 (2275) Gamma PARAMEDIC2 data
Utilities (EQ-5D-5L)
OHCA, adjusted mean utility, first year post
randomisation, adrenaline
0.0038 (0.0051) Beta PARAMEDIC2 data
OHCA, adjusted mean utility, first year post
randomisation, placebo
0.0061 (0.0051) Beta PARAMEDIC2 data
Good functional state 0.707 (0.019) Beta PARAMEDIC2 data
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Possible transitions beyond the first year after the cardiac arrest event were restricted to movement
from the good and poor functional states to death. The probabilities governing these movements were
assumed to be independent of treatment allocation and were estimated from two sources. First, we
estimated the conditional probability of surviving to 12 months, given that an individual had survived
the first 9 months with good or poor function, and converted these estimates to 1-year probabilities
using standard formulae.158 Second, we obtained age- and sex-adjusted UK mortality statistics,157
assuming a starting age of 60 years and 78% probability of being male, reflecting the average cohort
characteristics of survivors at 1 year post randomisation. We used this information to extrapolate
survival beyond the first year post cardiac arrest to a lifetime horizon by assigning individuals a
probability of death equivalent to the larger of the two estimates.
We assumed that patients surviving beyond the first year after the cardiac arrest event either died or
remained alive in the same functional state at each modelled cycle (functional status cannot improve
or deteriorate after first year post cardiac arrest). The assumption that neurological function cannot
improve or deteriorate after the first year post cardiac arrest was made because of a lack of robust
data to estimate the between-state transitions, and is consistent with recent economic models
evaluating the cost-effectiveness of intervention in cardiac arrest.159
Patients in the OHCA state were assigned cost and utility values obtained from the within-trial
sensitivity analysis in which the time horizon was extended to 1 year. This covered the full spectrum
of costs and QALYs incurred in the first year after the cardiac arrest event, adjusted for demographic
and clinical characteristics. Costs associated with the good and poor functional states were estimated
from resource use estimates covering the 3- to 6-month post-randomisation period collected for trial
participants. Utility values associated with good and poor functional states were collected through the
EQ-5D-5L reported by trial participants and stratified by functional status at the 6-month assessment
point (see Table 15). Costs generated from resource use covering the 3- to 6-month period after
randomisation were converted to 1-year costs assuming that the rate of resource use in this 3-month
window is maintained over a period of 1 year. Costs and utilities were discounted at 3.5% per annum
over the lifetime of cardiac arrest survivors.
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A total of 8014 participants were randomised in the PARAMEDIC2 trial: 4015 to the adrenaline group
and 3999 to the placebo group (see Figure 24). Of these, 219 participants survived to hospital discharge:
128 in the adrenaline group and 91 in the placebo group.
In our estimation of economic outcomes of interest, we assigned a nominal value of zero to resource
use, costs and health utility for patients who died at the scene of the cardiac arrest or prior to the
collection of health-related quality-of-life data (in which case zeros were assigned to QALYs, but not
resource use and costs). Thus, for all participants based on HES and CRF sources, approximately 98.9%
and 99.2% of all health resource use data (including the zero service utilisation and utility assigned to
deaths) were available at 3 months for the adrenaline and placebo groups, respectively; this dropped to
98.7% and 98.8%, respectively, by 6 months (see Appendix 1, Tables 26 and 27). Similarly, a complete
QALY profile over the 6-month time horizon was estimated for 7939 of the 8014 (99.1%) trial
participants, based on utility weights derived from the EQ-5D-5L and mRS assessments at hospital
discharge and at 3 and 6 months post randomisation (see Table 22).
When looking at the completeness rates for survivors (see Table 23), approximately 72.7% and 71.4%
of all health resource use data reported on the CRFs were complete at 3 months for the adrenaline
and placebo groups, respectively; this declined to 63.3% and 51.6%, respectively, by 6 months
(see Appendix 1, Tables 30 and 31). A complete QALY profile based on the EQ-5D-5L and mRS
utility scores was available for 132 out of 219 (60.3%) survivors at 6 months post randomisation.
Overall, approximately 1% of QALY data and between 1% and 2% of costs (at the component level)
were missing (and subsequently imputed) for the primary analysis.
Resource use and costs extracted from Hospital Episode Statistics
Figure 24 displays the flow chart of data sources used to inform estimates of resource use and costs.
HES data were requested for 2023 (50.4%) of the 4015 patients in the adrenaline arm and for 1214
(30.4%) of the 3999 patients in the placebo arm. This represented data for trial participants who
survived to hospital admission and who did not withdraw consent to participate in the trial. Of those
requested, HES records covering the 6-month (1 year for some patients) period from the cardiac arrest
event were provided by NHS Digital and PEDW for 1833 patients in the adrenaline arm and 1094 in
the placebo arm, generating linkage rates of 90.6% and 90.1% for the adrenaline and placebo arms,
respectively. This represented 45.7% of the 4015 patients randomised to adrenaline and 27.4% of the
3999 patients randomised to placebo. For the remaining 2182 (54.3%) patients in the adrenaline arm
who did not have HES data provided, 2171 (99.5%) died prior to hospital admission (and therefore
incurred no costs beyond the initial emergency response costs) and 11 (0.5%) had no linkage records
or survived to decline consent to continued participation in the trial. For the placebo arm, 2905
(72.6%) of the 3999 patients did not have HES data provided: 2893 (99.6%) died before they could
be admitted to hospital and 12 (0.4%) either declined consent or had no linked records for analysis.
Summaries of hospital resource use (length of stay in a hospital inpatient ward and ICU admissions,
day-case admissions, and ED and outpatient attendances), by trial arm and follow-up period, extracted
from the HES records are presented in Appendix 1, Table 26. Summary statistics were generated based
on the available HES records at each level of hospital resource use, and therefore excluded trial
participants who were not admitted to hospital (e.g. those who died at home), those who declined
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continued consent and those admitted to hospital but who had no record for a particular category or
level of hospital resource use variable.
During the initial hospitalisation event among the 1833 (45.7%) and 1094 (27.4%) patients with HES
data in the adrenaline and placebo arms, respectively (see Appendix 1, Table 26), there were no noticeable
differences between the adrenaline and placebo arms in mean hospital length of stay (6.63 vs. 7.84 days,
respectively; unadjusted mean difference –1.2 days, 95% bootstrapped CI –3.5 to 0.91 days) and ICU
length of stay (5.75 vs. 6.29 days, respectively; mean difference –0.54 days, 95% CI –2.13 to 1.07 days).
There were no noticeable differences between the adrenaline and placebo groups in length of stay in a
general ward (18.55 vs. 16.69 days, respectively; mean difference 1.86 days, 95% CI –9.84 to 13.71 days)
or an ICU (9.8 vs. 13.29 days, respectively; mean difference –3.49 days, 95% CI –12.96 to 6.31 days) for
hospital re-admissions over the 6-month period after the cardiac arrest. Similarly, there were no differences
between the adrenaline and placebo arms in ED attendances (1.05 vs. 1.04 visits, respectively; mean
difference 0.01 visits, 95% CI –0.02 to 0.03 visits), day-case attendances (5.93 vs. 1.06 visits, respectively;
mean difference 4.87 visits, 95% CI –0.12 to 15.8 visits) and outpatient attendances (5.12 vs. 6.07 visits,
respectively; mean difference –0.95, 95% CI –2.58 to 0.68 visits).
Thirty-one (1.7%) of the 1833 trial participants with HES data in the adrenaline arm and 26 (2.4%)
of the 1094 patients with HES data in the placebo arm who had their cardiac arrest event after
31 March 2017 were alive 1 year after arrest; therefore, these patients had partially incomplete
1-year records of hospital resource use based on the HES data. We assumed that hospital resource use
data covering the 6- to 12-month period after the cardiac arrest event are missing for these patients
because of incompleteness of follow-up. For the remaining 1802 (98.3%) of the 1833 patients in the
adrenaline arm and 1068 (97.6%) of the 1094 in the placebo arm, complete records of hospital
resource use were available for the 1-year period after the cardiac arrest event and are summarised in
Appendix 1, Table 26. There were no noticeable differences between the adrenaline and placebo arms
in hospital length of stay or ICU length of stay during hospital re-admissions in the 6- to 12-month
period after the cardiac arrest event. Similarly, there were no differences between the two groups in
ED attendance and day-case attendances, but the adrenaline arm had significantly more outpatient
consultations, on average, than the placebo arm (7.45 vs. 4.3 visits, respectively; unadjusted mean
difference 3.15 visits, 95% CI 0.31 to 6.74 visits).
Appendix 1, Table 27, presents hospital-related costs based on HES-only data for the 0- to 6-month and
0- to 12-month post-cardiac arrest periods by trial arm and resource category. As explained in Chapter 4,
Valuation of hospital resource use collected through trial case report forms, these costs were derived by
mapping HRG codes generated using the HRG4+ 2016/17 Reference Costs Grouper137 to national
reference costs.135 Across all categories of hospital services, the mean total cost per patient estimated
from the HES data was £5224 for the adrenaline arm and £4777 for the placebo arm, generating
a mean cost difference of £448 (95% CI –£718 to £1483; p = 0.412) during the 0- to 6-month period
following the cardiac arrest event.
Costs of hospital-based services covering the period of 0–12 months after the cardiac arrest event
are also summarised in Appendix 1, Table 27. As explained previously, only participants with complete
1-year HES records are included in the calculation of these costs. The mean total cost of hospital
resource use over 12 months was £4913 for the adrenaline arm and £4350 for the placebo arm,
generating a mean 1-year cost-difference of £563 (95% CI –£660 to £1644; p = 0.314).
Summaries of the NHS and PSS resource use values by trial allocation, resource category and trial
period for complete cases collected through trial CRFs and participant-completed questionnaires
are presented in Appendix 1, Table 28, for all patients and in Appendix 1, Table 30, for survivors. The
equivalent summaries for non-NHS and PSS resource use information are also presented in Appendix 1,
Table 29, for all patients and in Appendix 1, Table 31, for survivors. Resource use values are presented
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for subcategories of resource use, including emergency response, intervention doses administered,
hospital inpatient and outpatient care, primary health care (residential care, community health and
social care), prescribed medications, and equipment and aids. Broader societal resource inputs and
costs included privately purchased medications, travel costs, child care, income lost, help with
housework and laundry service costs (see Appendix 1, Tables 29 and 31).
In terms of specific resource use values from an NHS and PSS perspective for adrenaline versus
placebo for all participants at 3 months (see Appendix 1, Table 28), notable differences were observed
for number of syringes given (mean difference for adrenaline vs. placebo –0.152 syringes, 95%
bootstrapped CI –0.266 to –0.052 syringes), ED stays (mean difference 0.201 days, 95% CI 0.179 to
0.224 days), general ward stays (mean difference 0.296 days, 95% CI 0.078 to 0.536 days) and ICU
stays (mean difference 0.438 days, 95% CI 0.298 to 0.592 days). When looking at the equivalent
information for survivors to hospital discharge at 3 months (see Appendix 1, Table 28), there were
no noticeable differences between the trial arms.
Between 3 and 6 months post cardiac arrest, for all participants (see Appendix 1, Table 28), evidence
of noticeable differences in resource use from an NHS and PSS perspective between adrenaline and
placebo was observed for district nurse contacts (mean difference 0.055, 95% CI 0.003 to 0.141) and
use of other aids and adaptations (mean difference 0.004, 95% CI 0.001 to 0.007). For survivors to
hospital discharge (see Appendix 1, Table 30), there were noticeable differences in resource use for
district nurse contacts (mean difference 2.494, 95% CI 0.013 to 6.315) only. For all other resource use
items, no differences between the trial arms were apparent.
In terms of non-NHS/PSS resource use, encompassing expenditure incurred by patients, family members
and lost income due to ill health as a result of the cardiac arrest, for all participants at 3 months (see
Appendix 1, Table 27), no significant differences were observed during this time period. There were also
no significant differences in non-NHS/PSS resource use for survivors to hospital discharge over this
period (see Appendix 1, Table 31).
Between 3 and 6 months post randomisation, and for all participants (see Appendix 1, Table 29),
differences in resource use from a broader perspective were observed for reliance on child care
(mean difference 0.004 occurrences, 95% CI 0.001 to 0.007 occurrences), travel costs (mean difference
0.01, 95% CI 0.000 to 0.019) and other additional costs (mean difference 0.014, 95% CI 0.000 to 0.027).
For survivors to hospital discharge (see Appendix 1, Table 31), there were no noticeable differences
between the two trial arms for all other resource use items.
Unit costs
Unit costs, and data sources from which they were derived, of resource use variables are presented in
Appendix 1, Table 32. The unit cost of emergency ambulance (including vehicle and crew) support was
estimated at £8.80 per minute in 2017 prices. This was based on a 2008 estimate of £6.80 per minute
of emergency ambulance response reported in the Unit Costs of Health and Social Care 2008160
compendium, published by the Personal Social Services Research Unit, and inflated to reflect the
Hospital and Community Health Service pay and price inflation reported in the Unit Costs of Health and
Social Care 2017.140 The total cost of prehospital emergency response was calculated for each patient
using the following formula:
(Number of vehicles in attendance × time spent at scene + time taken to hospital and/or
mortuary + 60) × cost per minute of emergency ambulance.
(1)
Unit cost values and their sources are reported for all other resource inputs in Appendix 1, Table 32.
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Economic cost estimates at level of resource use variable and category,
trial data collection instruments
Tables 16 (all patients) and 17 (survivors) summarise the estimated economic costs for hospital- and
community-based health and social care services (NHS/PSS costs), based on the CRF data by trial
allocation, resource category and trial period. The equivalent, more disaggregated, information at the
level of resource variables is presented in Appendix 1 (see Table 33 for NHS/PSS costs for all patients
and Table 35 for NHS/PSS costs for survivors; see Table 34 for non-NHS/PSS costs for all patients
and Table 36 for non-NHS/PSS costs for survivors). Economic costs from an NHS and PSS perspective
for all participants are presented in Table 16 by trial arm, trial period and cost category. Between
randomisation and 3 months post randomisation, the mean total emergency response costs were, on
average, higher for the adrenaline arm than for the placebo arm: £1716 versus £1660, respectively
(mean cost difference £56.41, 95% bootstrapped CI £18.54 to £94.42). Similarly, total inpatient
costs were higher, on average, for the adrenaline arm than for the placebo arm: £2094 versus £1082
(mean cost difference £1011.78, 95% bootstrapped CI £729.39 to £1325.13). This was driven by
higher costs for ED costs, general ward stays (£129 vs. £80 for the adrenaline vs. placebo arms,
respectively; mean difference £49.19, 95% CI £13.40 to £87.45) and ICU stays (£1924 vs. £998 for
the adrenaline vs. placebo arms, respectively; mean difference £926.88, 95% CI £629.78 to £1250.56)
(see Appendix 1, Table 33). There were no significant differences in costs from an NHS and PSS
perspective for survivors to hospital discharge at 3 months (see Table 17).
Between 3 and 6 months, for all participants (see Table 16), the mean total primary health-care costs
were significantly higher for the adrenaline arm (£6.54) than for the placebo arm (£1.55) (mean cost
difference £4.99, 95% bootstrapped CI £1.36 to £9.26). Medications costs were, on average, significantly
higher for the adrenaline arm (£3.68) than for the placebo arm (£1.03) (mean cost difference £2.65,
95% bootstrapped CI £0.71 to £5.61). For survivors to hospital discharge (see Table 17), the mean total
primary health-care costs were significantly higher for the adrenaline arm (£312) than for the placebo
arm (£125) (mean cost difference £187, 95% bootstrapped CI £29.94 to £378.04).
Economic costs from a broader societal perspective are presented in Appendix 1 (see Table 34 for all
participants and Table 36 for survivors) by trial arm, trial period and cost category. There were no
significant differences in costs for the period between randomisation and 3 months (see Appendix 1,
Table 34). There were also no noticeable differences in the costs when looking at the information for
survivors to hospital discharge (see Appendix 1, Table 36). Between 3 and 6 months post randomisation,
for all participants (see Appendix 1, Table 34), mean total additional health-care-related costs (out-of-pocket
medical expenditure on items such as over-the-counter medications, travel to medical appointments and
aids) and non-health-care costs (e.g. child care and lost income as a result of the cardiac arrest) were,
on average, significantly higher for the adrenaline group (£18.52) than for the placebo group (£5.02)
(mean cost difference £13.50, 95% bootstrapped CI £0.43 to £33.45).
Total economic cost estimates over trial follow-up, and trial data
collection instruments
Total costs estimated based on the trial data collection instruments for all participants are presented
in Table 18 by trial arm, trial period and aggregate cost category. Based on total costs, adrenaline was,
on average, more costly. Between randomisation and 3 months, the total mean cost was higher, from
an NHS and PSS perspective, for the adrenaline arm than for the placebo arm: £3765 versus £2687,
respectively (mean cost difference £1078, bootstrapped 95% CI £790 to £1406). This was also the case
when costs were considered from a broader societal perspective: £3774 versus £2698 for the adrenaline
and placebo arms, respectively (mean cost difference £1076, bootstrapped 95% CI £782 to £1403).
There were no significant differences between the trial arms in total mean costs for survivors to hospital
discharge (Table 19). Between 3 and 6 months, for all participants, the total mean non-NHS/PSS costs
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TABLE 16 Total NHS and PSS costs (2017 prices) by trial arm, all participants, based on resource use collected through trial CRF data only
Post-randomisation
assessment period Category
Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean cost (SE) (£)
Participants with
complete data (n) Mean cost (SE) (£)
Mean difference in costs
(95% CI) (£) p-value
0–3 months Emergency response costs 4010 1716.03 (17.05) 3992 1659.61 (10.41) 56.41 (18.54 to 94.42) < 0.001
Intervention costs 4008 33.82 (0.27) 3990 0 (0) 33.82 (33.27 to 34.32) < 0.001
Inpatient costs 3964 2093.96 (128.43) 3967 1082.18 (88.63) 1011.78 (729.39 to 1325.13) < 0.001
Outpatient costs 3967 18.62 (5.63) 3961 10.63 (3.38) 8 (–3.77 to 21.61) 0.196
Community care costs 3976 10.69 (4.76) 3969 5.42 (1.67) 5.27 (–2.75 to 17.05) 0.308
Medication costs 3975 6.8 (1.7) 3970 4.98 (1.68) 1.82 (–2.96 to 6.61) 0.45
Aids and adaptations costs 3967 1.78 (1.29) 3964 1.75 (1.29) 0.02 (–3.8 to 3.88) 0.972
Total NHS and PSS costs 3937 3764.73 (127.92) 3936 2686.9 (90) 1077.83 (790.49 to 1406.45) < 0.001
3–6 months Inpatient costs 3961 83.1 (50.84) 3949 37.36 (19.5) 45.73 (–37.8 to 172.54) 0.388
Outpatient costs 3960 18.59 (6.93) 3949 9.25 (4.02) 9.34 (–4.73 to 25.67) 0.218
Community care costs 3964 6.54 (2.03) 3953 1.55 (0.33) 4.99 (1.36 to 9.26) < 0.001
Medication 3961 3.68 (1.2) 3952 1.03 (0.26) 2.65 (0.71 to 5.61) 0.002
Aids and adaptations costs 3959 4.78 (2.18) 3954 1.24 (1.09) 3.54 (–1 to 8.89) 0.12
Total NHS and PSS costs 3948 93.75 (50.8) 3940 47.62 (20.86) 46.13 (–38.68 to 169.18) 0.382
0–6 months Total NHS and PSS costs 3919 3641.84 (149.13) 3914 2548.36 (84) 1093.49 (800.43 to 1442) < 0.001
SE, standard error.
Note




























TABLE 17 NHS and PSS costs (2017 prices) by trial arm, survivors to hospital discharge, CRF data
Assessment
period Category
Adrenaline arm (N= 128) Placebo arm (N= 91) Adrenaline vs. placebo
Participants
with complete
data (n) Mean cost (SE) (£)
Participants
with complete
data (n) Mean cost (SE) (£)
Mean difference in costs




Emergency response costs 127 1535.32 (45.62) 91 1455.87 (53.8) 79.45 (–51.87 to 222.5) 0.242
Intervention costs 128 14.38 (0.99) 91 0 (0) 14.38 (12.44 to 16.33) < 0.001
Inpatient costs 88 29,425.72 (3032.74) 65 24,356.65 (3055.72) 5069.07 (–3985.61 to 13,777.15) 0.244
Outpatient costs 86 859.01 (241.89) 57 738.40 (214.69) 120.61 (–494.23 to 763.48) 0.7
Community care costs 95 447.36 (204.33) 65 330.81 (89.27) 116.55 (–250.21 to 580.86) 0.684
Medications 94 287.66 (64.88) 66 299.49 (93.53) –11.83 (–250.68 to 183.9) 0.97
Aids and adaptations costs 86 81.91 (63.42) 60 115.82 (84.33) –33.91 (–263.39 to 159.46) 0.736




Inpatient costs 80 4114.25 (2466.27) 45 1916.46 (957.58) 2197.79 (–2031.75 to 8385.56) 0.44
Outpatient costs 79 932.02 (328.67) 45 812.04 (331.92) 119.97 (–835.56 to 1002.03) 0.736
Community care costs 83 312.26 (86.32) 49 125.27 (19.78) 187 (29.94 to 378.04) 0.02
Medications 80 182.04 (54.94) 48 84.86 (18.07) 97.18 (2.60 to 225.3) 0.044
Aids and adaptations costs 78 242.69 (104.76) 50 97.99 (87.6) 144.7 (–117.87 to 409.13) 0.296
Total NHS and PSS costs 67 5524.18 (2914.88) 36 3508.31 (1334.03) 2015.87 (–3297.29 to 8742.91) 0.598
0–6 months Total NHS and PSS costs 54 33,385.85 (7293.82) 29 29,144.43 (4609.34) 4241.42 (–9982.79 to 22,538.49) 0.698
SE, standard error.
Note

































































































































































































































































































TABLE 18 Total costs (2017 prices) by trial arm, all participants, CRF data
Assessment
period Category
Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean cost (SE) (£)
Participants with
complete data (n) Mean cost (SE) (£)
Mean cost difference
(bootstrap 95% CI) (£) p-value
0–3 months post
randomisation
Total NHS and PSS costs 3937 3764.73 (127.92) 3936 2686.9 (90) 1077.83 (790.49 to 1406.45) < 0.001
Total non-NHS and PSS costs 3973 37.34 (10.32) 3970 19.93 (6.45) 17.4 (–6.71 to 40.77) 0.156
Total societal costs 3936 3774.22 (127.5) 3936 2698.06 (91.12) 1076.16 (782.48 to 1403.42) < 0.001
3–6 months post
randomisation
Total NHS and PSS costs 3948 93.75 (50.8) 3940 47.62 (20.86) 46.13 (–38.68 to 169.18) 0.382
Total non-NHS and PSS costs 3962 18.51 (8.13) 3953 4.95 (2.25) 13.56 (0.49 to 33.62) 0.038
Total societal costs 3948 110.4 (52.28) 3939 46.22 (20.39) 64.18 (–21.67 to 188.32) 0.192
0–6 months post
randomisation
Total NHS and PSS costs 3919 3641.84 (149.13) 3914 2548.36 (84) 1093.49 (800.43 to 1442) < 0.001
Total non-NHS and PSS costs 3956 50.84 (14.62) 3952 15.07 (5.59) 35.77 (8.1 to 68.61) 0.01
Total societal costs 3919 3671.5 (150.28) 3913 2535.36 (82.89) 1136.14 (840.32 to 1484.33) < 0.001
SE, standard error.
Note




























TABLE 19 Total costs (2017 prices) by trial arm, survivors to hospital discharge, CRF data
Assessment
period Category
Adrenaline arm (N= 128) Placebo arm (N= 91) Adrenaline vs. placebo
Participants
with complete
data (n) Mean cost (SE) (£)
Participants
with complete
data (n) Mean cost (SE) (£)
Mean cost difference




Total NHS and PSS costs 72 32,669.22 (3589.54) 50 27,956.52 (3795.11) 4712.7 (–5527.48 to 14,967.31) 0.382
Total non-NHS and PSS costs 92 1612.33 (420.67) 66 1199 (372.51) 413.33 (–686.8 to 1566.93) 0.444




Total NHS and PSS costs 67 5524.18 (2914.88) 36 3508.31 (1334.03) 2015.87 (–3297.29 to 8742.91) 0.598
Total non-NHS and PSS costs 81 905.61 (372.83) 49 399.36 (174.22) 506.25 (–196.78 to 1464.21) 0.204




Total NHS and PSS costs 54 33,385.85 (7293.82) 29 29,144.43 (4609.34) 4241.42 (–9982.79 to 22,538.49) 0.698
Total non-NHS and PSS costs 75 2681.64 (703.79) 49 1215.1 (432.91) 1466.54 (–171.05 to 3200.25) 0.082
Total societal costs 54 35,538.15 (7286.24) 28 28,277.49 (4592.94) 7260.66 (–6800.38 to 24,616) 0.422
SE, standard error.
Note
The CIs were obtained via the bootstrapped percentile method. This table contains NHS Digital data. Copyright © 2019, the Health and Social Care Information Centre. Re-used with

































































































































































































































































































were significantly higher for the adrenaline arm (£18.51) than for the placebo arm (£4.95) (mean cost
difference £13.56, bootstrapped 95% CI £0.49 to £33.62). There were no significant differences between
the trial arms in total mean costs for survivors to hospital discharge (see Table 19). Over the trial
time horizon of the first 6 months post randomisation, for all participants, adrenaline was, on average,
more costly (see Table 18). The total mean cost from an NHS and PSS perspective was higher for the
adrenaline arm than for the placebo arm: £3642 versus £2548, respectively (mean cost difference
£1093, bootstrapped 95% CI £800 to £1442). This was also the case when costs were considered from
a broader societal perspective: £3672 versus £2535 for the adrenaline and placebo arms, respectively
(mean cost difference £1136, bootstrapped 95% CI £840 to £1484). There were no differences between
the groups for total mean costs for survivors to hospital discharge (see Table 19).
Economic cost estimates, combined Hospital Episode Statistics and trial
instrument data in the 0–6 months post-randomisation period
Economic costs from an NHS and PSS perspective for all participants based on combining resource
use data from HES and trial instrument sources are presented in Table 20 by trial arm, cost period and
cost category. For the whole trial population, HES data were used to estimate only the cost of hospital-
based services (inpatient admissions and ED and outpatient attendances) during the period 0–6 months
after randomisation for 1833 (45.7%) of the 4015 participants in the adrenaline arm and 1094 (27.4%) of
the 3999 participants in the placebo arm. Hospitalisation costs for the remaining participants were either
set at zero (primarily as a result of patients dying at the scene of cardiac arrest: adrenaline, n = 1985;
placebo, n = 2768) and trial CRFs completed by paramedics and trial participants (adrenaline, n = 188
and placebo, n = 126), with any remaining hospitalisation costs classed as missing (adrenaline, n = 9 and
placebo, n = 11). Non-hospital-based costs of health and social care services were estimated from
resource use data collected using economic questionnaires completed by trial participants.
Between randomisation and 6 months (see Table 20), the total mean cost estimates based on the
combined HES and trial data collection instrument data were higher, from an NHS and PSS perspective,
for the adrenaline arm (£3789) than for the placebo arm (£2698) (mean cost difference £1091,
bootstrapped 95% CI £807 to £1398). This was also the case when costs were considered from a
broader societal perspective: £3829 versus £2687 for the adrenaline and placebo arms, respectively
(mean cost difference £1143, bootstrapped 95% CI £861 to £1451).
There were no significant differences in total mean costs for survivors to hospital discharge between
trial arms (Table 21). Over the trial time horizon of 6 months, for all participants, the adrenaline
intervention was, on average, more costly, but the difference in total costs was not statistically
significant. The mean total cost was higher, from an NHS and PSS perspective, for the adrenaline
arm (£33,554) than for the placebo arm (£33,348) (mean cost difference £205, bootstrapped 95% CI
–£10,849 to £10,159). This was also the case when costs were considered from a broader societal
perspective: £34,994 versus £31,557 for the adrenaline and placebo arms, respectively (mean cost
difference £3438, bootstrapped 95% CI –£7222 to £13,343).
Economic costs, combined Hospital Episode Statistics and trial data collection
form based resource use data, 12-month period from randomisation
Cost estimates covering the 1-year period from randomisation are also presented in Table 20 (whole
trial population) and Table 21 (survivors to hospital discharge) by trial allocation and resource category.
These costs were derived using the methodology described in Chapter 4, Estimation of costs for the total
1-year period after randomisation, taking into account the fact that not all patients had complete
HES-derived hospital care data covering the 1-year period from randomisation.
RESULTS
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TABLE 20 Total costs (2017 prices) by trial arm, combined HES and CRF data, all participants
Assessment period Category
Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean cost (SE) (£)
Participants with
complete data (n) Mean cost (SE) (£)
Mean cost difference
(bootstrap 95% CI) (£) p-value
0–6 months Hospitalisation costs
(NHS and PSS)
4006 2669 (179) 3988 1460 (129) 1209 (804 to 1660) < 0.001
Non hospitalisation costs
(NHS and PSS)
3934 1785 (21) 3926 1678 (13) 107 (61 to 155) < 0.001
Non-NHS and PSS costs 3956 51 (15) 3952 15 (6) 36 (8 to 69) 0.01
Total NHS and PSS costs 3934 3789 (121) 3926 2698 (94) 1091 (807 to 1398) < 0.001
Total societal costs 3933 3829 (124) 3925 2687 (92) 1143 (861 to 1451) < 0.001
0–12 monthsa Hospitalisation costs
(NHS and PSS)
3971 2419 (173) 3961 1322 (131) 1096 (692 to 1537) < 0.001
Non hospitalisation costs
(NHS and PSS)
3922 1822 (32) 3915 1677 (13) 145 (87 to 215) < 0.001
Non-NHS and PSS costs 3941 63 (26) 3939 16 (8) 47 (2 to 111) 0.042
Total NHS and PSS costs 3921 3748 (126) 3915 2651 (95) 1096 (804 to 1415) < 0.001
Total societal costs 3920 3793 (132) 3915 2662 (96) 1131 (820 to 1473) < 0.001
SE, standard error.
a The 12-month costs for patients with < 12 months of complete HES data (adrenaline arm, n = 31; placebo arm, n = 26) were treated as missing observations.
Note
This table contains NHS Digital data. Copyright © 2019, the Health and Social Care Information Centre. Re-used with the permission of the Health and Social Care Information

































































































































































































































































































TABLE 21 Total costs (2017 prices) by trial arm, survivors to hospital discharge, combined HES and CRF data
Assessment
period Category
Adrenaline arm, (N= 128) Placebo arm, (N= 91) Adrenaline vs. placebo
Participants with
complete data (n) Mean cost (SE) (£)
Participants with
complete data (n) Mean cost (SE) (£)
Mean cost difference
(bootstrap 95% CI) (£) p-value
0–6 months Hospitalisation costs
(NHS and PSS)
123 37,153 (3780) 83 33,258 (3162) 3894 (–5364 to 14,798) 0.408
Non-hospitalisation costs
(NHS and PSS)
64 3467 (686) 39 3011 (645) 456 (–1357 to 2388) 0.58
Non-NHS and PSS costs 75 2682 (716) 49 1215 (429) 1467 (–91 to 3115) 0.07
Total NHS and PSS costs 64 33,554 (2956) 39 33,348 (4263) 205 (–10,849 to 10,159) 0.9
Total societal costs 63 36,522 (3211) 38 32,988 (4153) 3534 (–7106 to 13,535) 0.49
0–12 monthsa Hospitalisation costs
(NHS and PSS)
89 39,577 (5273) 57 38,447 (4801) 1130 (–11,842 to 15,807) 0.856
Non-hospitalisation costs
(NHS and PSS)
52 6671 (1978) 28 3432 (927) 3240 (–656 to 7924) 0.11
Non-NHS and PSS costs 60 4150 (1641) 36 1756 (799) 2394 (–748 to 6580) 0.152
Total NHS and PSS costs 51 37,962 (4448) 28 38,868 (6258) –906 (–17,196 to 13,318) 0.982
Total societal costs 50 42,204 (5143) 28 40,401 (6340) 1804 (–15,835 to 16,999) 0.766
SE, standard error.
a The 12-month costs for patients with < 12 months of complete HES data (adrenaline arm, n = 31; placebo arm, n = 26) were treated as missing observations.
Note
The CIs were obtained via the bootstrapped percentile method. This table contains NHS Digital data. Copyright © 2019, the Health and Social Care Information Centre. Re-used with




























Between randomisation and 12 months, and for the whole trial population, the estimated total mean
costs based on complete cases from the combined HES and trial data collection instrument data were
higher, from an NHS and PSS perspective, for the adrenaline arm (£3748) than for the placebo arm
(£2651) (mean total cost difference £1096, bootstrapped 95% CI £804 to £1415). This was also the
case when costs were considered from a broader societal perspective: £3793 versus £2662 for the
adrenaline and placebo arms, respectively (mean total cost difference £1131, bootstrapped 95% CI
£820 to £1473). There were no significant differences in total mean costs between the trial arms for
survivors to hospital discharge (see Table 21) during the first 12 months after randomisation. During
this period, adrenaline was, on average, associated with increased costs, but the difference in total costs
was not statistically significant.
Health-related quality-of-life and quality-adjusted life-year outcomes
The distribution of the responses to the EQ-5D-5L and SF-12 health-related quality-of-life questionnaires
by trial arm and trial period for survivors to hospital discharge are presented in Appendix 1, Tables 37 and
38, respectively. The comparisons of responses were conducted on the basis of optimal level of function
(e.g. ‘no problem’ on the EQ-5D-5L) versus suboptimal level of function (indicating any functional
impairment). At the 3-month assessment point, the only statistically significant differences in levels of
function in health-related quality of life was for the self-care dimension of the EQ-5D-5L (p = 0.020).
There were no statistically significant differences in levels of function in health-related quality of life
for participant-reported dimensions of the EQ-5D-5L or SF-12 measures between the adrenaline and
placebo groups at the 6-month assessment point (see Appendix 1, Tables 37 and 38).
The mean health utility scores from alternative sources [mRS mapped to the EQ-5D, EQ-5D-5L and SF-6D
(derived from the SF-12)] by trial arm and trial period for all participants are presented in Tables 22
and 23, and displayed in Appendix 1, Figure 25 (utility generated via the mRS and EQ-5D-5L). There were
no statistically significant differences in mean utility scores between the adrenaline arm and placebo arm
for the health utility scores from different sources at the trial assessment points. However, the mean
health utility scores, based on mRS mapping to the EQ-5D-3L for survivors to hospital discharge (see
Table 23), were statistically significantly lower at hospital discharge for the adrenaline arm (0.48) than for
the placebo arm (0.60) (unadjusted mean difference –0.118, 95% CI –0.196 to –0.032).
Cost-effectiveness results
Base-case analysis
The incremental cost-effectiveness of adrenaline is shown in Table 24 for the participants with costs and
health outcomes data subject to multiple imputation.When an NHS and PSS perspective was adopted
(i.e. that adopted for the baseline analysis), and health outcomes were measured in terms of QALYs
based on the EQ-5D and mRS measures, the adjusted mean total cost was £3591 for the adrenaline arm,
and £2285 for the placebo arm, generating a mean incremental cost of £1306 (95% CI £837 to £1774)
over the first 6-month post-randomisation period. The adjusted mean QALYs was 0.0025 in the adrenaline
arm and 0.0017 in the placebo arm, generating a mean difference in QALYs of 0.0008 (95% CI –0.0014 to
0.003). The ICER was £1,693,003. The probability that adrenaline was cost-effective at a cost-effectiveness
threshold of £30,000 per QALY gained was zero. Extending the within-trial analysis to cover the 1-year
period from randomisation by extrapolating costs and utilities measured at 6 months to 12 months
reduced the base-case ICER from £1,693,003 per QALY gained to £644,308 per QALY gained for
adrenaline, compared with placebo (mean incremental costs of £1411 and mean incremental QALYs of
0.0022). Extrapolating the within-trial analysis to cover the lifetime of survivors (see the model described
in Chapter 4, Extrapolating beyond trial follow-up) reduced the ICER further to £81,070 per QALY gained
(mean incremental costs of £1775 and mean incremental QALYs of 0.022).
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TABLE 22 Health utilities: all patients
Assessment period Category












Hospital discharge mRS mapped to EQ-5D 4009 0.015 (0.002) 3994 0.013 (0.002) 0.002 (–0.002 to 0.006) 0.582
0–3 months after
randomisation
EQ-5D-5L 3976 0.013 (0.002) 3970 0.011 (0.001) 0.002 (–0.002 to 0.006) 0.472
mRS mapped to EQ-5D 3991 0.016 (0.002) 3981 0.012 (0.002) 0.003 (–0.001 to 0.008) 0.228
SF-12 (SF-6D) 3968 0.013 (0.002) 3968 0.011 (0.001) 0.002 (–0.002 to 0.007) 0.406
3–6 months post randomisation
assessment period
EQ-5D-5L 3963 0.011 (0.002) 3976 0.008 (0.001) 0.002 (–0.002 to 0.006) 0.420
mRS mapped to EQ-5D 3993 0.015 (0.002) 3975 0.011 (0.001) 0.004 (0 to 0.009) 0.118
SF-12 (SF-6D) 3963 0.012 (0.001) 3955 0.008 (0.001) 0.004 (0 to 0.007) 0.092
TABLE 23 Health utilities: survivors to hospital discharge
Assessment period Category












Hospital discharge mRS mapped to EQ-5D 126 0.479 (0.031) 89 0.597 (0.029) –0.118 (–0.196 to -0.032) 0.002
0–3 months after
randomisation
EQ-5D-5L 95 0.533 (0.039) 66 0.643 (0.038) –0.11 (–0.211 to 0.004) 0.056
mRS mapped to EQ-5D 109 0.576 (0.032) 76 0.651 (0.033) –0.075 (–0.163 to 0.016) 0.104
SF-12 (SF-6D) 86 0.609 (0.022) 64 0.669 (0.021) –0.06 (–0.116 to 0.003) 0.066
3–6 months post randomisation EQ-5D-5L 81 0.517 (0.046) 51 0.648 (0.051) –0.131 (–0.257 to 0.01) 0.064
mRS mapped to EQ-5D 111 0.538 (0.035) 70 0.62 (0.037) –0.082 (–0.181 to 0.021) 0.116

































(SE) Mean difference (95% CI) Cost-effectiveness









Within-trial base case (adjustedc
multiple imputation), 6 months






































INMB, incremental net monetary benefit; SE, standard error.
a Difference in mean costs and mean QALYs between adrenaline and placebo groups, 95% confidence intervals in brackets.
b Probability that the intervention is cost-effective at willingness-to-pay threshold of £30,000 per QALY gained, based on 1000 Monte Carlo simulations.
c Adjusted analyses were adjusted for patients’ age, sex, interval between emergency call and ambulance arrival at scene, interval between ambulance arrival at scene and
administration of the trial agent, initial cardiac rhythm, cause of cardiac arrest, whether or not the cardiac arrest was witnessed and whether or not a bystander performed CPR.
Note
Mean costs and QALYs are estimated at the mean age of 60 years and for categorical values at the baseline covariate group (sex = female, not witnessed, ambulance arrived in

































































































































































































































































































Incremental net monetary benefits
The associated adjusted mean incremental net monetary benefits (INMBs) of adrenaline at cost-
effectiveness thresholds of £30,000 per QALY were as follows: –£1282 for the within-trial base-case
analysis (adjusted multiple imputation), 6 months post cardiac arrest event; –£1346 for extrapolation
to 12 months post cardiac arrest event; and –£1118 for extrapolation to a lifetime time horizon
(decision-analytic model) (see Table 24). The base-case mean INMB was < £0, suggesting that adopting
the adrenaline protocol would result in a net economic loss of £1258, on average, from an NHS and
PSS perspective [INMB –£1250 (95% CI –£1686 to –£815) at 6 months and –£1118 (95% CI –£2776
to £487) over the lifetime of survivors, assuming a cost-effectiveness threshold of £30,000 per QALY].
The CEAC shows that this results in a probability of cost-effectiveness of < 1% at cost-effectiveness
thresholds of < £200,000 (see Appendix 1, Figure 25); that is, if decision-makers are willing to pay
£30,000 for an additional QALY, the probability that adrenaline is cost-effective remains < 1% over
the 6-month base-case within-trial time horizon and 11% over a lifetime time horizon (see Table 24).
Sensitivity analysis
Several sensitivity analyses were undertaken to assess the impact of uncertainty surrounding key
parameters or methodological features on the cost-effectiveness results. The base-case analyses
were replicated using Stata software and the results were consistent with the primary analyses.
The adjusted and unadjusted complete-case analyses also exhibit the same pattern of results as
the base-case analyses (see Appendix 1, Table 39). The probability that adrenaline is cost-effective
remained relatively static (at about 0%) for the majority of the sensitivity analyses (i.e. societal costs,
QALYs based on the mRS, 12-month time horizon, 12-month time horizon and societal perspective,
and 12-month time horizon and QALYs based on the mRS). All sensitivity analyses showed that the
average INMB value always remains < £0 (see Appendix 1, Table 39).
In sensitivity analyses that explored the impact of the missing not at random assumption on the within-
trial base-case results, imputed utility values and costs were systematically decreased and increased
while holding imputed values for other variables constant. The results are displayed in Appendix 1,
Tables 40 and 41. They suggest that doubling the value of imputed utilities favoured adrenaline (the
ICER decreased to £1,021,684 per QALY), whereas halving them favoured placebo (the ICER increased
to £2,067,739 per QALY gained). Similarly, doubling imputed costs favoured adrenaline and decreased
the ICER to £1,186,037 per QALY, whereas halving them had little effect on the within-trial base-case
cost-effectiveness results (£1,688,008 per QALY). The probability that adrenaline is cost-effective was
zero at cost-per-QALY thresholds of < £100,000 across alternative assessments, in which missing
values for the main economic costs and outcomes were not assumed to be missing at random
(see Appendix 1, Figures 28 and 29).
Subgroup analyses
To explore the heterogeneity in the cost-effectiveness results, 10 variables were considered: cause
of cardiac arrest (medical, non-medical), age (≤ 60 years, > 60 years), sex (female, male), time from
EMS arrival at scene to administration of first dose (≤ 10 minutes, > 10 minutes), time from 999 call
received to EMS arrival at scene (≤ 10 minutes, > 10 minutes), shockable rhythm (yes, no), number
of syringes given out of two (≤ 2, > 2), number of syringes given out of four (≤ 4, > 4), witnessed by
(not witnessed, EMS, bystander), and bystander CPR (no, yes, unknown). All subgroup analyses were
based on the patient-reported EQ-5D and mRS measures and used multiple imputation and covariate
adjustments, as per the primary analyses (see Appendix 1, Table 42). Subgroups for which the probability
of cost-effectiveness was > 10% at £30,000 per QALY gained over the 6 months within-trial time horizon
were cardiac arrest of medical aetiology (probability of cost-effectiveness 15%), EMS witnessed (15%),
aged > 60 years (20%), two or more doses of adrenaline administered (27%) and four or more doses of
adrenaline administered (32%). All other subgroups generated probabilities of cost-effectiveness for
adrenaline of < 10% at a cost-effectiveness threshold of £30,000 per QALY gained.
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Secondary health economic outcomes
Results are presented in Table 25 for the cost-effectiveness of adrenaline expressed as incremental
cost per unit increase in the proportion surviving to 6 months post cardiac arrest and the proportion
surviving with good neurological function (i.e. neurologically intact survivor). The adjusted mean
cost over 6 months was £3654 in the adrenaline arm and £2284 in the placebo arm, generating a
cost-difference of £1370 (95% bootstrapped CI £954 to £1840). The 6-month adjusted survival
probability was 0.0051 in the adrenaline arm and 0.0037 in the placebo arm, generating a difference in
survival probability of 0.0014 (95% CI –0.0003 to 0.003) in favour of adrenaline. The 6-month adjusted
probability of survival with good functional outcome was 0.0026 for adrenaline and 0.0023 for placebo,
generating a difference in probability of 0.0014 (95% CI –0.0003 to 0.003) in favour of adrenaline. The
ICER was £982,880 per percentage point increase in overall survival and £3,772,322 per percentage point
increase in neurological survival.
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TABLE 25 Cost-effectiveness results, secondary health economic outcomes (2017 prices)
Outcome
Adrenaline arm,
mean (SE) Placebo arm, mean (SE) Mean difference (bootstrapped 95%CI) Cost-effectiveness






























































The use of adrenaline during resuscitation for OHCA resulted in a significantly higher rate of survival
to hospital admission (23.6% vs. 8.0% for the adrenaline and placebo arms, respectively; aOR 3.83,
95% CI 3.30 to 4.43) than the use of placebo. Thirty-day survival was also higher (3.2% vs. 2.4% for the
adrenaline and placebo arms, respectively; aOR 1.47, 95% CI 1.09 to 1.97), but the rate of favourable
neurological outcome was not significantly different (2.2% vs. 1.9% for the adrenaline and placebo
arms, respectively; aOR 1.19, 95% CI 0.85 to 1.68). The pattern of improved survival but no significant
improvement in neurological outcomes continued through to 6 months. By 12 months, survival in the
adrenaline arm was 1.5%, compared with 1% in the placebo arm (aOR 1.40, 95% CI 1.00 to 1.96). A
Bayesian analysis found that the probability that the risk difference for survival was > 1%, favouring
the adrenaline arm, was 37%, and the probability that favourable neurological outcome was improved
by > 1% was 1.9%. An adjusted subgroup analysis did not identify a significant interaction for any of
the subgroups studied.
More survivors in the adrenaline group than in the placebo group had severe neurological impairment
at hospital discharge. The number with severe neurological impairment decreased through to 6 months,
although evaluation was limited by greater loss to follow-up. Examining health-related quality of life up
to 6 months after randomisation, and cognitive function, anxiety/depression or post-traumatic stress
to 3 months, showed significant functional impairment in cardiac arrest survivors, compared with the
normal population. One-third to half of patients reported needing help from someone for everyday
activities. For the majority, this was a new situation after their cardiac arrest. Fewer than half reported
having made a full mental recovery after their cardiac arrest. Although underpowered, the pattern of
impairment suggested greater disability in the adrenaline group.
The ICER for adrenaline was estimated at £1,693,003 per QALY gained over the first 6 months after
the cardiac arrest event and £81,070 per QALY gained over a lifetime time horizon. The associated
adjusted mean INMBs of adrenaline at a cost-effectiveness threshold of £30,000 per QALY gained was
–£1282 at 6 months and –£1118 over a lifetime of survivors, suggesting that adopting the adrenaline
protocol would result in a net economic loss. The CEAC shows that these INMBs result in a probability
of cost-effectiveness of < 1% for cost-effectiveness thresholds of < £200,000 for an additional QALY
over a time horizon of up to 1 year after the cardiac arrest. Over the lifetime of survivors, the probability
of cost-effectiveness approaches 50% at a £100,000 per QALY cost-effectiveness threshold.
Interpretation of results
Clinical outcomes
The use of adrenaline, in comparison with placebo, resulted in almost four times the number of
patients being admitted to hospital after OHCA. This finding is broadly consistent with the findings of
the PACA trial,56 which documented an OR of 3.4 (95% CI 2.0 to 5.6) for ROSC in favour of adrenaline
over placebo for OHCA.
Many more patients in the adrenaline group than in the placebo group were admitted to hospital but
did not survive to discharge: 2016 (50.2%) and 1209 (30.2%) patients in the adrenaline and placebo
arms, respectively, were admitted, and 128 (3.2%) and 91 (2.3%) patients in the adrenaline and
placebo arms, respectively, survived to discharge. Thus, 1888 patients in the adrenaline arm died
in hospital, compared with 1118 in the placebo arm. We do not have data on the mode of death,
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but the majority of deaths occurred in the ED. These early deaths are more likely to be caused
by circulatory failure or limitation of treatment due to the presence of severe comorbidities and
functional impairment, as withdrawal of life-sustaining therapy resulting from perceived severe
neurological injury should not normally occur until after 72 hours. However, although several studies
have documented the mode of death among post-cardiac arrest patients admitted to an intensive
trauma unit,161–163 this has not been well documented for those dying in the ED.
In the adrenaline group, 414 of the 566 (73.1%) patients admitted to the ICU died there, compared
with 176 of the 270 (65.1%) placebo group patients admitted to the ICU. Thus, 238 additional patients
in the adrenaline group were admitted to an ICU, but died there. Surviving patients spent, on average,
7 days in intensive care and 21 days in hospital. By the time of hospital discharge, 128 (3.2%) patients
were alive in the adrenaline group, compared with 91 (2.3%) in the placebo group, of whom 87 (2.2%)
and 74 (1.9%), respectively, survived with a favourable neurological outcome. Although, at the time of
discharge, 39 survivors in the adrenaline group and 16 in the placebo group had severe neurological
injury, by 6 months, those with severe neurological injury numbered 23 and 9, respectively. It is well
established that the functional status of cardiac arrest survivors can improve over the first few months
and that some with the most severe neurological injury will die.164 Ultimately, long-term follow-up
at 12 months after cardiac arrest is ideal, but is challenging because of the resources required and
the increasing loss to follow-up over time, which results in attrition bias. Data on 30-day survival
were available for 4012 and 3995 patients in the adrenaline and placebo groups, respectively; by
6 months, these numbers had decreased to 4006 and 3991 for the adrenaline and placebo groups,
respectively, representing a loss to follow-up for survival of just six and four patients, respectively.
However, neurological outcome is more difficult to collect after hospital discharge. Data on neurological
outcome at discharge were available for 4007 and 3994 patients in the adrenaline and placebo groups,
respectively, but, by 6 months, these numbers had decreased to 3991 and 3973, respectively, which is
a loss to follow-up for neurological outcome of 16 and 21 patients, respectively. A series of sensitivity
analyses were undertaken to explore the potential impact of these missing data; the results of most of
these were consistent with the main results.
Patients, clinicians and researchers prioritised health-related quality of life as a core outcome for
evaluation following cardiac arrest.165 In PARAMEDIC2, health-related quality of life was impaired
among survivors at 3 and 6 months, compared with the UK general population, suggesting large
differences between the well-being of OHCA survivors and that of the general population. Moreover,
a reduction in both mental and, to a lesser extent, physical well-being was observed at 6 months,
highlighting the importance of detailed assessment over the longer term. Impairment spanned physical
and mental health domains, leading to reduced health utility scores. Compared with other studies,166
the extent of functional impairment is greater, which is likely to be reflective of the PARAMEDIC2
cohort involving only patients refractory to initial attempts at resuscitation. Although there were no
pronounced differences between the adrenaline and placebo groups, the overall level of impairment
highlights an unmet need for this group of patients.
Meta-analyses of the PARAMEDIC2 and PACA56 trials were, as expected, consistent with adrenaline
increasing survival to hospital admission (RR 2.51, 95% CI 1.67 to 3.76; two studies, 8489 participants;
an increase in the rate of ROSC at hospital admission from 83 to 209 per 1000, 95% CI 139 to 313)
and survival to hospital discharge (RR 1.44, 95% CI 1.11 to 1.86; two studies, 8538 participants; an
increase in survival to hospital discharge from 23 to 32 per 1000, 95% CI 25 to 42). Survival rates with
a favourable neurological outcome at discharge were similar (RR 1.21, 95% CI 0.9 to 1.62; two studies,
8535 participants; an increase from 19 to 22 per 1000, 95% CI 17 to 30).55
A meta-analysis of the PARAMEDIC2 trial with the PACA56 trial according to initial cardiac arrest
rhythm found very low survival-to-discharge rates with an initial non-shockable rhythm, but a significant
effect for adrenaline (0.39% for placebo vs. 1.03% for adrenaline; OR 2.57, 95% CI 1.36 to 4.83). For
shockable rhythms, although survival rates were higher (9.43% vs. 11.66% in placebo and adrenaline
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groups, respectively), the incremental effect of adrenaline was less pronounced (OR 1.26, 95% CI
0.93 to 1.71; between-group heterogeneity p = 0.05). A similar pattern was observed for survival to
discharge with a favourable neurological outcome, but the CI for the OR crossed 1 for both shockable
and non-shockable rhythms.167
Two explanations for the much higher rate of ROSC and survival to hospital admission with adrenaline,
and yet no significant improvement in neurological outcome, are as follows: (1) the heart is much more
resilient than the brain when exposed to a period of hypoxia-ischaemia – thus, the heart can be ‘restarted’
but the brain has already been damaged irreversibly; and (2) even though adrenaline increases coronary
and cerebral perfusion pressure,40 it may reduce microcirculatory flow in the brain.29,66
Minimum clinically important difference
An international survey of key respondents from 46 countries identified that the minimal clinically
important difference for survival with a favourable neurological outcome is 3% (when the baseline
rate for the population is 2%).168 Other trials have used minimal clinically important differences of
1.4%,169 2%56,170 or larger (6.3%).171 The Universal Termination of Resuscitation Rule uses a false-positive
threshold of 1%, whereas neuroprognostication algorithms172 in intensive care allow a false-positive rate
for a favourable neurological outcome of up to 5%.91,173 The 6-month difference for survival (0.8%, 95% CI
0.1% to 1.5%) and survival with a favourable neurological outcome (0.5%, 95% CI –0.1% to 1.1%) fall
below the thresholds set for a minimal clinically important difference in previous studies.
Clinical effectiveness in the context of the chain of survival
The chain of survival describes the system of care required to optimise survival after OHCA.9 It
comprises four links: early access (identifying cardiac arrest early and activating the emergency
services), early CPR (to maintain perfusion to the brain and vital organs), early defibrillation (to
restart the heart for patients with an initially shockable rhythm) and early post-resuscitation care.
The primary PARAMEDIC2 trial publication174 reported that 112 patients would need to be treated
with adrenaline to prevent one death after cardiac arrest. This is substantially more than the number
needed to be treated with other interventions delivered earlier in the chain of survival,175,176 for
example early recognition of cardiac arrest, number needed to treat = 11;177 bystander CPR, number
needed to treat = 15;178 and rapid defibrillation, number needed to treat = 5.179
Cost-effectiveness
Economic evaluations in cardiac arrest research are relatively sparse. An economic model for public-
access defibrillation reported an ICER of US$53,797 per QALY gained.159 An economic evaluation of
a mechanical chest compression device found that manual CPR dominated in health economic terms
(mechanical CPR cost more and led to a reduction in QALYs, on average).136 An extracorporeal CPR
strategy in Sydney reported an ICER of €16,890 per QALY gained. A nurse-led post-cardiac arrest
neurorehabilitation programme found a mean health benefit (0.04 additional QALYs) for minimal
additional costs (€89), giving a 76% probability that the intervention would be cost-effective at a
cost-effectiveness threshold of €80,000.180 The NICE methods guideline132 manual notes that, in
general, interventions with an ICER of < £20,000 per QALY gained are considered to be cost-effective.
ICER values of > £30,000 per QALY gained require consideration of the certainty of the ICER and
evidence that the assessment of the change in the health-related quality of life is inadequately captured
and that the intervention adds demonstrable and distinct substantial benefits that may not have been
adequately captured in the measurement of health gain.
In the present study, the ICER for the base-case analysis is 55-fold higher than the accepted cost-
effectiveness threshold of £30,000. There was a low probability of cost-effectiveness (< 1%) up to a
threshold of £200,000 per QALY gained. Subgroup analyses covering cause of cardiac arrest, age, sex,
ambulance response time, time to drug administration, initial rhythm, witness status and bystander CPR
did not identify any specific subgroups for which the ICER substantially improved. Sensitivity analyses
that included societal costs, QALYs based on mRS values, a 12-month time horizon, a 12-month time
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horizon and societal perspective, and a 12-month time horizon and QALYs based on mRS showed that
the average INMB value is always < £0.
Furthermore, our separate decision-analytic model demonstrated that the survival benefits associated
with adrenaline generate additional QALY benefits, and therefore improved cost-effectiveness, over
an extended time horizon. Nevertheless, even over a lifetime time horizon, the mean ICER associated
with adrenaline exceeds cost-effectiveness thresholds widely accepted by decision-makers and health
technology assessment agencies. Alternative extrapolations of cost-effectiveness, beyond the parameters
of the PARAMEDIC2 trial, that focus solely on individuals experiencing OHCA are unlikely to alter
decisions to recommend adrenaline on cost-effectiveness grounds.
It is possible that some benefits of admission to intensive care following cardiac arrest were incompletely
captured through focusing on survival and health-related quality-of-life outcomes. The prevalence of
post-traumatic stress among relatives of patients who die from cardiac arrest is high.181,182 It is possible
that admission to hospital allows the family time to say goodbye and to be present at the time of death.183
Whether or not this has a beneficial effect, and any economic gains therein, remains to be determined.
Approximately 10% of patients who die in ICU following OHCA become solid organ donors.184 This may
yield additional economic and health-related quality-of-life gains to the organ recipient and is worthy of
further evaluation.
Ethics considerations
The design and conduct of this trial required particularly careful ethics consideration, given the life-
threatening and emergency nature of OHCA. The lack of conclusive evidence of benefit, uncertainty
about potential harm from adrenaline, and the presence of clinical equipoise provided the ethics
justification of the need for a placebo-controlled trial. The implementation of the trial generated public
debate on the ethics implications of conducting research in emergency situations without prior consent
from participants or their legal representative. The public information strategy and process for enabling
people to register their wish not to participate that we developed is, so far as we are aware, the first
such initiative in the UK.
The implications of the trial findings for patients, clinicians, policy-makers and commissioners of health
care also require careful ethics consideration. How an individual balances the chance of survival with
the chance of having severe neurological impairment will be shaped by their personal values, but in the
moment of a cardiac arrest, it is not possible to take into account these values when making a treatment
decision. Thus, the decision about whether or not adrenaline is given will be directed by a policy or
guideline applicable to all patients, informed by available evidence. A further consideration for policy-
makers and commissioners of health care is the overall cost and cost-effectiveness of any treatment. The
NHS is a publicly funded health service with limited financial resources and an obligation to distribute
these resources fairly for everyone in response to health-care need. Our health economic analysis suggests
that adrenaline treatment would not meet the current NICE criteria for cost-effectiveness. Developing
a policy recommendation for the use of adrenaline for OHCA requires a complex balancing of current
clinical practice norms, empirical evidence, and values. Understanding the range of population perspectives
regarding this decision will be an important element of developing such a policy.
Interpretation by the International Liaison Committee on Resuscitation
The ILCOR is a collaboration of resuscitation councils from around the world that collaborate to ‘save
more lives globally through resuscitation’,185 through the use of transparent evaluation of scientific
data to promote, disseminate, and implement international consensus guidelines for resuscitation
and first aid. The publication of the PARAMEDIC2 trial prompted the ILCOR to prioritise a review
of vasopressors as treatment for cardiac arrest.186 The ILCOR commissioned a systematic review
and meta-analysis focusing on the use of standard-dose adrenaline (1 mg), compared with placebo,
vasopressin, or adrenaline and vasopressin.187 Similar to our Cochrane review,55 the review found
moderate-quality evidence that adrenaline improves the rate of ROSC, survival to hospital discharge
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and 3-month survival among those experiencing OHCA. Subgroup analyses found that the improvement
in short-term outcomes was more pronounced for non-shockable rhythms. The systematic review authors
noted, in the pooled analysis, no improvement in mid-term (hospital discharge) neurological outcomes, but
interpret it as showing a signal towards improved outcomes for 3-month survival, based on the findings
from the PARAMEDIC2 trial [2.1% (82/3986) in the adrenaline group, compared with 1.6% (63/3979)
in the placebo group; RR 1.30, 95% CI 0.94 to 1.80; absolute risk difference: 5 more per 1000 people,
95% CI 1 fewer to 13 more]. The authors acknowledge the loss to follow-up and very low event rates,
leading to very low confidence in the effect estimate.
The ILCOR Advanced Life Support Task Force assessed the findings from the systematic review using
the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Evidence to
Decision Framework.188 The Task Force comprised 19 health-care professionals from around the world.
No patient or public representatives participated in the Evidence to Decision Famework or in the
development of treatment recommendations. The assessors considered the problem of OHCA as high
priority. After considering the effect of adrenaline on ROSC, survival and neurological outcomes, the
assessors judged the desirable effects of using adrenaline as moderate and judged the undesirable
effects as small. The overall certainty of evidence was assessed to be moderate, noting that certainty
varies according to outcome (high for ROSC, low for neurological outcomes). The ILCOR assessed that
there was possibly important uncertainty or variability in how much people value the main outcomes,
noting that the Core Outcome Set for Cardiac Arrest investigators reported that patients valued
survival with favourable neurological outcome most highly.165 The ILCOR’s overall judgement of the
balance between desirable and undesirable effects probably favours using adrenaline. They reported
that the intervention was probably acceptable to key stakeholders and considered it feasible to
implement, noting that, although there was no research identified about patient acceptability,
adrenaline use is currently the standard of care in many settings.
The writing group concluded by recommending that adrenaline should be administered as soon as
possible during CPR (strong recommendation for non-shockable rhythms, weak recommendation for
shockable rhythms).186
Internal validity and methodological limitations
The internal validity of the trial is strengthened by the randomised, blinded, placebo-controlled design.
Selection bias was minimised by the computer-generated randomisation sequence using the stratification
method with concealed assignment, using ambulance service as a strata, with an allocation ratio of 1 : 1.
This resulted in almost identical baseline characteristics of the key variables associated with outcome
(age, sex, initial rhythm, cause of cardiac arrest, witnessed status, bystander CPR, ambulance response
time and time to administration of the study intervention). Performance bias was reduced through the
use of treatment packs that were identical in appearance. Laboratory testing of the trial IMP showed no
changes in appearance throughout the duration of the trial. Trial participants were unconscious at the
time of enrolment. No requests for unblinding were received during the treatment phase of the trial.
Although not formally tested for, it is possible that some of the effects of adrenaline (e.g. rhythm
transitions,189,190 higher rate of ROSC, greater cardiovascular instability after ROSC67,70,190) may have led
to paramedics forming a view on the composition of the trial drug. As the acute effects of adrenaline
are short lived, it is less likely to have influenced those treating the patient in hospital. Detection bias
was minimised by the use of outcome assessors who were not involved in the initial treatment of the
participant. Many outcomes (e.g. ROSC, survival status) are objective and would not be influenced by
knowledge of treatment allocation. No unblinding of participants or legal representatives occurred
before outcome assessments were complete. The trial had very high rates of follow-up for survival up
to 12 months after enrolment in the trial. By contrast, beyond hospital discharge, loss to follow-up for
neurological outcomes and health-related quality of life increased significantly. Consistent with previous
studies,102,136,191 those with worse neurological outcomes were more likely to be LTFU. The trial was
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registered on the International Standard Randomised Controlled Trial Number (ISRCTN) registry and
outcomes were defined prior to the enrolment of the first patient. The trial protocol was finalised and
approved prior to commencement of randomisation. This report contains all the trial outcomes, thus
eliminating selective reporting as a source of bias.
External validity and generalisability
External validity is a question of whether or not the results of a study can be applied to patients other
than those enrolled in the study.192 External validity is a matter of judgement and depends on the
characteristics of the participants included in the trial, the trial setting, the treatment regimens tested
and the outcomes assessed.193
The PARAMEDIC2 trial was a pragmatic trial design, intended to show the real-world effectiveness
of the intervention, and maximising the generalisability of findings.194 Patient eligibility for inclusion
was broad, with no exclusion based on age (other than < 16 years), sex, comorbidity (other than
pregnancy), cause of arrest (other than anaphylaxis/asthma), location of arrest, witnessed status of
arrest or initial cardiac arrest rhythm. The patients included in the trial were ‘representative’ of all OHCA
patients attended by the respective ambulance services and where ALS is initiated. Similarly, all standard
ALS interventions were provided to the trial participants, including chest compression, defibrillation and
advanced airway management, as required, with the exception that standard adrenaline was substituted
with trial drug drawn from a single trial treatment pack. The primary outcome of ‘survival to 30 days post
cardiac arrest’ was an objective measurement, directly relevant to participants.
Ambulance system configuration is similar throughout the NHS and is based on a single-tier response
system led by paramedics. Community first responders support emergency response systems. Physician
involvement in initial phases of out-of-hospital resuscitation is relatively rare. NHS paramedics operate
according to national clinical guidelines for cardiac arrest produced by the JRCALC.87 These guidelines
and those used in hospital for post-resuscitation care are based on the NICE-accredited Resuscitation
Council (UK) guidelines,86 which are consistent with the European Resuscitation Council guidelines.88
Although resuscitation guidelines around the world are broadly similar and based on recommendations
from the ILCOR, emergency system response configurations vary. In many parts of the USA, the
paramedic-based system is supplemented by basic life support response units, meaning that there
are often more emergency care workers at the scene of a cardiac arrest than in the UK. In urbanised
areas, emergency response times are quicker, although there is wide variation.
Analysis of the national OHCA registry103 and PARAMEDIC trial102,136 databases for patients treated
for OCHA revealed similar patient characteristics and outcomes to those reported in PARAMEDIC2.39
An evaluation of adrenaline use in the London Ambulance Service prior to the trial (2012–13) showed
similar findings.195 Outside the UK, compared with the Norwegian i.v. versus no i.v. trial,57 patients
enrolled in PARAMEDIC2 were, on average, 4 years older (69 vs. 65 years) and were less likely to have a
bystander-witnessed cardiac arrest (50% vs. 65%) or to have an initial shockable rhythm (19% vs. 33%).
Compared with the PACA trial,56 patients enrolled in the PARAMEDIC2 trial were also, on average,
4 years older and were as likely to have a bystander-witnessed arrest, but were less likely to have an
initially shockable rhythm (45% in the PACA trial56). Observational data from the US Resuscitation
Outcome Consortium for 13,053 patients from 264 EMS agencies across 11 geographically distinct
sites, who sustained an OHCA and were treated with adrenaline between 2005–7, similarly showed a
younger cohort of patients (mean age 65 years); the rate of bystander-witnessed cardiac arrest was
lower (39%) than that seen in the PARAMEDIC2 trial, but the proportion of patients with an initially
shockable rhythm was higher (23%).38 A similar pattern is seen in data from Seattle for cardiac arrests
(from 2006 to 2012).196
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Some studies suggest that the timing of drug administration is critical to its effectiveness.60,197–199
Adrenaline is recommended in European guidelines after the third attempt at defibrillation for
shockable rhythms and after initiating ALS (CPR and airway management) for non-shockable rhythms.
With OHCA, drug administration is usually delayed while paramedics travel to the scene of collapse,
initiate CPR and defibrillation (when indicated) and obtain vascular access. In an evaluation of repeated
doses of adrenaline conducted by the London Ambulance Service, the average time to the first dose of
adrenaline was 21–26 minutes.195 The time from collapse to drug treatment in the PARAMEDIC2 trial
was, on average, 21 minutes. This is longer than the interval during in-hospital cardiac arrest (average
3 minutes)197,200 and in the majority of animal cardiac arrest models (average 9.5 minutes).201 The timing is,
however, similar to a systematic review of time to drug administration across 17 studies (19.4 minutes,
95% CI 12.8 to 25.9 minutes),202 and in more recent studies (range 13–24 minutes).199,203–205 A subgroup
analysis of time to drug administration and paramedic-witnessed cardiac arrest (in which case, adrenaline
is likely to be given earlier) did not find evidence of an interaction. The practicalities of delivering early
drug administration and its influence on outcomes remains to be determined.
Post-resuscitation care across acute NHS hospitals is informed by the NICE-accredited Resuscitation
Council (UK) guidelines.206 These guidelines follow the ILCOR and European Resuscitation Council/
European Society of Intensive Care Medicine recommendations.91 Key components of these guidelines
are the use of targeted temperature management, maintenance of physiological targets (arterial blood
oxygen saturations of 94–98%, normocarbia, normoglycaemia, systolic blood pressure of > 100 mmHg),
targeted temperature management, early percutaneous coronary intervention and delaying multimodal
neuroprognostication to at least 72 hours after cardiac arrest. Although not formally protocolised or
evaluated in the PARAMEDIC2 trial, an observational study across 286 NHS ICUs (29,621 OHCAs)
suggested up to 60% use of targeted temperature management and a median time to treatment
withdrawal of 5 days.184 Evaluation of the Myocardial Ischaemia National Audit Project database
through to 2016 showed percutaneous coronary intervention use in ST elevation myocardial infarction
to be in the region of 75%, and 15% for non-ST elevation myocardial infarction.207 Future data with
the Intensive Care National Audit Project and HES may provide more granular insights into the
post-resuscitation care of patients enrolled in the PARAMEDIC2 trial.
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Implications for health care
Cardiac arrest remains a common and important condition. The PARAMEDIC2 trial found that
adrenaline is effective at restarting the heart, leading to a 3.6-fold higher proportion of patients being
admitted to hospital than if adrenaline was not given. The effect on survival to 30 days was more
modest: 1.5-fold higher, corresponding to a 0.8% absolute increase in survival, giving a number needed
to treat to save one life of 112. Survival with a favourable neurological outcome did not significantly
differ between the adrenaline and placebo groups from hospital discharge. This pattern of better
survival but no significant improvement in neurological outcomes continued through to the 6-month
follow-up. Health-related quality of life was significantly impaired among survivors of OHCA and did
not differ by treatment arm. The ICER for adrenaline was estimated at £1,675,976 per QALY gained.
Based on current standards, this indicates that adrenaline is not a cost-effective intervention for the
treatment of cardiac arrest. Consultation with the wider patient and public community will be
important when considering the implications of the PARAMEDIC2 trial for clinical practice.
Recommendations for research
Unanswered questions about the use of vasopressors in OHCA remain. These include questions about
timing, dosage, rate of administration, route of administration and concomitant therapies. Given the
uncertainty about the effect of adrenaline on neurological outcomes, further research is required to
better understand patients’ preferences in relation to survival and neurological outcome after OHCA.
Further research should explore how patients and the public interpret the findings from the trial, the
priorities of patients and the public, and the implications for practice of the findings.
The NHS guidelines support the use of the intraosseous route for drug administration if initial attempts
at i.v. access fail. In the PARAMEDIC2 trial, one-third of patients received delayed drug administration
through the intraosseous route. It is possible that an intraosseous-first strategy may have enabled drug
treatments to be delivered earlier. However, recent observational studies63,208 raise doubt about the
effectiveness of the intraosseous route for drug administration. Such studies are nevertheless limited
by resuscitation time bias and other unmeasured confounders. The inclusion of a placebo arm in the
PARAMEDIC2 trial should allow a less biased comparison of the i.v. and intraosseous route, which may
guide the need for further research on the role of i.v. and intraosseous drug administration.
The evidence produced by the PARAMEDIC2 trial demonstrates that adrenaline is highly effective at
restarting the heart and sustaining survival to hospital admission. Despite active treatments in intensive
care, two-thirds of these patients will die prior to hospital discharge. The majority of these patients
(65%) die from the devastating consequences of post-cardiac arrest brain injury. Of those who survive
the initial cardiac arrest, the majority experience some neurocognitive functional impairment, ranging
from mild cognitive problems to survival in a persistent vegetative state. There is very limited evidence
about effective neuroprotective strategies beyond targeted temperature management. A key priority for
future research is to identify effective treatment strategies to mitigate the effects of post-resuscitation
brain injury. For those who survive but are left with significant functional impairment, further research in
defining the optimal post-resuscitation rehabilitation care pathway would be beneficial.
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Finally, the ethics and clinical implications of vasopressor use in OHCA and its effects on organ
donation also need to be explored:
l What value do patients and the public place on survival, survival with a favourable neurological
outcome and survival with an unfavourable neurological outcome?
l How do the communities served by NHS ambulance services interpret the findings from the
PARAMEDIC2 trial and what are their views on the implications for practice?
l In the context of cardiac arrest, where do patients and their relatives prefer to die (home
or hospital)?
l Does the effect of adrenaline differ according to the time of administration?
l Does the effect of adrenaline differ according to the dose delivered or the strategy for delivery
(bolus vs. infusion)?
l Does the route of administration (i.v. or intraosseous) influence outcomes?
l What post-resuscitation interventions can improve survival with a favourable neurological outcome?
l What effect does the use of adrenaline have on the rate of organ donation?
CONCLUSIONS
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TABLE 26 Hospital resource use: HES data
Assessment period Category
Adrenaline arm (N= 1833)a Placebo arm (N= 1094)a Adrenaline vs. placebo
nb
Participants with
complete data (n) Mean (SE) nb
Participants with





Inpatient stay – initial admission
Inpatient ward (days) 670 670 6.63 (0.54) 317 317 7.84 (0.9) –1.2 (–3.5 to 0.91) 0.264
ICU (days) 506 505 5.75 (0.43) 234 233 6.29 (0.69) –0.54 (–2.13 to 1.07) 0.518
Inpatient stay, re-admissions
Inpatient ward (days) 56 56 18.55 (3.74) 37 36 16.69 (4.8) 1.86 (–9.84 to 13.71) 0.746




1700 1700 1.05 (0.01) 1040 1040 1.04 (0.01) 0.01 (–0.02 to 0.03) 0.95
Day case (visits) 15 15 5.93 (4.95) 16 16 1.06 (0.06) 4.87 (–0.12 to 15.8) 0.402
Outpatient
attendance (visits)
281 281 5.12 (0.43) 144 144 6.07 (0.66) –0.95 (–2.58 to 0.68) 0.224
6–12 months after
randomisationc
Inpatient stay – re-admissions
Inpatient ward (days) 26 23 5.87 (1.24) 16 11 9.36 (4.84) –3.49 (–14.42 to 4.32) 0.494




30 26 2.27 (0.28) 19 13 1.54 (0.28) 0.73 (–0.08 to 1.45) 0.084
Day case (visits) 10 10 9.1 (7.99) 5 4 1 (0) 8.1 (0.11 to 26.05) 0.062
Outpatient
attendance (visits)
91 71 7.45 (1.48) 62 40 4.3 (0.64) 3.15 (0.31 to 6.74) 0.028
a N refers to number of trial participants with at least one record from the following HES data sets: admitted care, accident and emergency, critical care and outpatient care.
b n refers to number of trial participants with HES records for each category of hospital resource use variable.
c The 12-month costs for patients with < 12 months of complete HES data (adrenaline group, n= 31; placebo group, n = 26) were treated as missing observations.
Notes
This table contains NHS Digital data. Copyright © 2019, the Health and Social Care Information Centre. Re-used with the permission of the Health and Social Care Information
































TABLE 27 Hospitalisation costs: HES data
Assessment period Category













(95% CI) (£) p-value
0–6 months after
randomisation
Inpatient stay – initial admission
Admitted patient care 670 670 4655 (227) 317 316 5536 (410) –881 (–1854 to 9) 0.06
Critical care 506 505 10,162 (608) 234 233 11,338 (1203) –1175 (–3900 to 1494) 0.406
Inpatient stay, re-admissions
Admitted patient care 56 56 9906 (1168) 37 36 10,353 (1984) –447 (–4856 to 3848) 0.904
Critical care 15 15 13,450 (4493) 7 7 19,395 (4947) –5945 (–17,765 to 6726) 0.368
Other hospitalisation episodes
ED 1700 1700 233 (2) 1040 1040 234 (3) –1 (–8 to 6) 0.684
Day case 15 15 2405 (1841) 16 16 925 (288) 1480 (–814 to 5634) 0.652
Outpatient care 281 280 605 (45) 144 144 741 (77) –136 (–311 to 33) 0.14




Admitted patient care 736 692 4840 (266) 361 319 5855 (587) –1015 (–2351 to 130) 0.11
Critical care 525 492 9802 (602) 242 220 11,164 (1297) –1362 (–4413 to 1248) 0.35
Other hospitalisation episodes
ED 1706 1683 237 (3) 1041 1020 236 (3) 2 (–6 to 10) 0.762
Day case 22 19 4062 (2891) 21 18 807 (258) 3255 (–194 to 9952) 0.124
Outpatient care 284 253 790 (94) 145 119 757 (83) 34 (–198 to 291) 0.76
Total costs 1833 1801 4913 (303) 1094 1066 4350 (468) 563 (–660 to 1644) 0.314
a N refers to number of trial participants with at least one record from the following HES data sets: admitted care, accident and emergency, critical care and outpatient care.
b n refers to number of trial participants with HES records for each category of hospital resource use variable.
c The 12-month costs for patients with < 12 months of complete HES data (adrenaline group, n= 31; placebo group, n = 26) were treated as missing observations.
Notes
This table contains NHS Digital data. Copyright © 2019, the Health and Social Care Information Centre. Re-used with the permission of the Health and Social Care Information


































































































































































































































































































TABLE 28 Resources use for NHS and PSS by trial arm: CRF data, all patients
Assessment
period Category
Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean (SE)
Participants with
complete data (n) Mean (SE)
Mean difference




Time 1 (arrival at scene to
departure) (minutes)
4013 60.279 (0.779) 3999 58.745 (0.548) 1.534 (–0.2 to 3.392) 0.1
Time 2a (departure from scene to
arrival at hospital or mortuary)
(minutes)
4011 70.457 (0.234) 3992 70.04 (0.298) 0.418 (–0.332 to 1.151) 0.244
Intervention dose
Number of syringes given 4008 4.923 (0.04) 3990 5.075 (0.037) –0.152 (–0.266 to 0.052) 0.004
Inpatient stay – initial admission
(days)
ED 4006 0.51 (0.009) 3996 0.309 (0.008) 0.201 (0.179 to 0.224) < 0.001
General ward 4013 0.792 (0.098) 3998 0.496 (0.072) 0.296 (0.078 to 0.536) 0.008
ICU 4013 0.91 (0.059) 3999 0.472 (0.047) 0.438 (0.298 to 0.592) < 0.001
Inpatient stay – repeat admissions (days)
ED 3974 0.005 (0.001) 3970 0.003 (0.001) 0.001 (–0.002 to 0.004) 0.652
General ward 3973 0.048 (0.017) 3970 0.024 (0.011) 0.024 (–0.013 to 0.066) 0.214
ICU
Outpatient attendance (visits)
Cardiology 3972 0.02 (0.004) 3968 0.016 (0.003) 0.005 (–0.005 to 0.014) 0.392
Cardiac rehabilitation 3974 0.036 (0.009) 3969 0.033 (0.011) 0.003 (–0.025 to 0.029) 0.85
Nursing/residential home 3974 0.062 (0.03) 3970 0.035 (0.02) 0.027 (–0.039 to 0.107) 0.422


































Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean (SE)
Participants with
complete data (n) Mean (SE)
Mean difference
(bootstrapped 95% CI) p-value
Primary health-care contact (number of contacts)
District nurse 3976 0.025 (0.008) 3970 0.017 (0.006) 0.007 (–0.012 to 0.026) 0.466
GP, surgery visit 3976 0.034 (0.005) 3970 0.029 (0.005) 0.005 (–0.011 to 0.019) 0.558
GP, home visit 3976 0.003 (0.001) 3970 0.003 (0.001) 0 (–0.004 to 0.003) 0.834
GP, telephone consultation 3976 0.002 (0.001) 3969 0.002 (0.001) 0 (–0.002 to 0.002) 0.668
Practice nurse 3976 0.001 (0.001) 3969 0 (0) 0.001 (0 to 0.002) 0.916
Physiotherapy 3976 0.037 (0.035) 3969 0 (0) 0.037 (0 to 0.111) 0.144
Occupational therapy 3976 0.001 (0.001) 3969 0.001 (0.001) 0 (–0.001 to 0.001) 0.442
Social worker 3976 0.003 (0.001) 3970 0.002 (0.001) 0.001 (–0.003 to 0.004) 0.854
Speech therapy 3976 0.009 (0.006) 3970 0.012 (0.008) –0.003 (–0.024 to 0.016) 0.772
Psychiatrist 3976 0.001 (0.001) 3970 0.001 (0.001) 0 (–0.002 to 0.002) 0.646
Psychology 3976 0.005 (0.004) 3970 0.006 (0.004) –0.001 (–0.012 to 0.011) 0.786
Counsellor 3976 0.001 (0.001) 3970 0.001 (0.001) 0.001 (–0.001 to 0.002) 0.982
Home care worker 3976 0.107 (0.06) 3970 0.051 (0.038) 0.056 (–0.07 to 0.22) 0.4
Lunch or social club 3976 0.003 (0.003) 3970 0.007 (0.004) –0.003 (–0.013 to 0.006) 0.498
Self-help groups 3976 0.046 (0.033) 3970 0.005 (0.003) 0.041 (–0.007 to 0.112) 0.274
Meals and laundry 3976 0.046 (0.036) 3970 0.026 (0.016) 0.02 (–0.045 to 0.11) 0.716
Other community care 3976 0 (0) 3969 0.002 (0.002) –0.002 (–0.006 to 0.001) 0.184
Medications
Medication, number of items 3975 2.119 (0.016) 3970 2.088 (0.012) 0.031 (–0.009 to 0.07) 0.132
Aids and adaptations (per item/pair when appropriate)
Defibrillator 3974 0 (0) 3969 0 (0) 0 (–0.001 to 0) < 0.001
Heart monitor 3974 0.001 (0.001) 3969 0 (0) 0 (–0.001 to 0.001) 0.62



































































































































































































































































































TABLE 28 Resources use for NHS and PSS by trial arm: CRF data, all patients (continued )
Assessment
period Category
Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean (SE)
Participants with
complete data (n) Mean (SE)
Mean difference
(bootstrapped 95% CI) p-value
Hoist 3974 0.001 (0.001) 3969 0 (0) 0.001 (0 to 0.001) 0.954
Wheelchair 3974 0.001 (0.001) 3969 0 (0) 0.001 (0 to 0.002) 0.258
Walking aid 3974 0.003 (0.001) 3969 0.003 (0.001) 0 (–0.003 to 0.002) 0.558
Hand aid 3974 0 (0) 3969 0.001 (0.001) –0.001 (–0.002 to 0) 0.022
Stair rail 3974 0 (0) 3969 0 (0) 0 (0 to 0) < 0.001




ED 3965 0.005 (0.002) 3953 0.004 (0.001) 0.002 (–0.002 to 0.006) 0.62
General ward 4004 0.114 (0.059) 3988 0.078 (0.043) 0.036 (–0.094 to 0.195) 0.638
ICU 4006 0.008 (0.008) 3989 0 (0) 0.008 (0 to 0.025) 0.276
Outpatient attendance (visits)
Cardiology 3964 0.017 (0.003) 3951 0.011 (0.003) 0.006 (–0.002 to 0.013) 0.172
Cardiac rehabilitation 3964 0.036 (0.011) 3953 0.034 (0.012) 0.002 (–0.029 to 0.033) 0.97
Nursing/residential home 3964 0.102 (0.047) 3952 0.028 (0.024) 0.074 (–0.019 to 0.182) 0.124
Other outpatient attendance 3963 0.005 (0.002) 3953 0.005 (0.002) –0.001 (–0.006 to 0.005) 0.784
Primary health-care contact (number of contacts)
District nurse 3965 0.059 (0.038) 3954 0.004 (0.001) 0.055 (0.003 to 0.141) 0.004
GP, surgery visit 3965 0.035 (0.007) 3954 0.022 (0.005) 0.013 (–0.003 to 0.029) 0.134
GP, home visit 3965 0.005 (0.002) 3954 0.002 (0.001) 0.004 (–0.001 to 0.008) 0.154
GP, telephone consultation 3964 0.001 (0.001) 3953 0.002 (0.001) –0.001 (–0.003 to 0.002) 0.384
Practice nurse 3964 0 (0) 3953 0 (0) 0 (0 to 0.001) 0.42
Physiotherapy 3964 0.001 (0.001) 3953 0 (0) 0.001 (0 to 0.003) 0.772


































Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean (SE)
Participants with
complete data (n) Mean (SE)
Mean difference
(bootstrapped 95% CI) p-value
Social worker 3965 0.005 (0.002) 3954 0.002 (0.001) 0.003 (–0.001 to 0.008) 0.276
Speech therapy 3965 0.003 (0.002) 3954 0 (0) 0.002 (0 to 0.006) 0.238
Psychiatrist 3965 0.001 (0.001) 3954 0 (0) 0 (–0.001 to 0.001) 0.606
Psychology 3965 0.002 (0.001) 3954 0.002 (0.001) 0 (–0.002 to 0.003) 0.84
Counsellor 3965 0.003 (0.003) 3954 0.001 (0.001) 0.002 (–0.002 to 0.008) 0.786
Home care worker 3965 0.069 (0.05) 3954 0.002 (0.002) 0.067 (–0.003 to 0.181) 0.218
Lunch or social club 3965 0.001 (0.001) 3954 0 (0) 0.001 (0 to 0.004) 0.762
Self-help groups 3965 0.027 (0.024) 3954 0.004 (0.003) 0.023 (–0.006 to 0.084) 0.344
Meals and laundry 3965 0.047 (0.033) 3954 0.001 (0.001) 0.046 (–0.001 to 0.116) 0.174
Other community care 3964 0.007 (0.006) 3953 0 (0) 0.007 (0 to 0.024) 0.146
Medications
Medication, number of items 3961 2.063 (0.012) 3952 2.03 (0.007) 0.033 (0.008 to 0.058) 0.006
Aids and adaptations (per item/pair when appropriate)
Defibrillator 3964 0 (0) 3954 0 (0) 0 (0 to 0) < 0.001
Heart monitor 3964 0 (0) 3954 0 (0) 0 (0 to 0) < 0.001
PEG pump 3964 0 (0) 3954 0 (0) 0 (0 to 0) < 0.001
Hoist 3964 0.001 (0.001) 3954 0 (0) 0.001 (0 to 0.002) 0.358
Wheelchair 3964 0.002 (0.001) 3954 0.001 (0.001) 0.001 (–0.001 to 0.002) 0.68
Walking aid 3964 0.001 (0.001) 3954 0.001 (0.001) 0.001 (–0.001 to 0.002) 0.954
Hand aid 3964 0 (0) 3954 0 (0) 0 (–0.001 to 0) < 0.001
Stair rail 3964 0 (0) 3954 0 (0) 0 (–0.001 to 0) < 0.001
Other aids and adaptations 3964 0.005 (0.002) 3954 0.001 (0.001) 0.004 (0.001 to 0.007) 0.03
PEG, percutaneous endoscopic gastrostomy.
a We added 60 minutes (step-down or restock time) to account for time that ambulance crew use to restock before they are available for the next assignment. This is based on


































































































































































































































































































TABLE 29 Resource use for non-NHS and PSS by trial arm: CRF data, all patients
Assessment period Category
Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean (SE)
Participants with
complete data (n) Mean (SE)
Mean difference
(bootstrapped 95% CI) p-value





3975 2.001 (0.001) 3970 2 (0) 0.001 (0 to 0.001) 0.952
Additional costs (number of occurrences)
Child care 3976 0.013 (0.002) 3970 0.008 (0.001) 0.005 (0.001 to 0.01) 0.048
House work 3976 0.014 (0.002) 3970 0.01 (0.002) 0.004 (–0.001 to 0.009) 0.144
Travel costs 3977 0.024 (0.004) 3970 0.015 (0.003) 0.01 (0 to 0.019) 0.052
Other additional
costs
3977 0.037 (0.005) 3970 0.024 (0.004) 0.014 (0 to 0.027) 0.062
3–6 months after randomisation Medications (item)
Medication,
number of items
3962 2 (0) 3953 2 (0) 0 (0 to 0.001) 0.456
Additional costs (number of occurrences)
Child care 3964 0.008 (0.001) 3955 0.004 (0.001) 0.004 (0.001 to 0.007) 0.044
House work 3964 0.009 (0.002) 3955 0.005 (0.001) 0.004 (0 to 0.008) 0.086
Travel costs 3964 0.015 (0.003) 3955 0.008 (0.002) 0.007 (0.001 to 0.014) 0.036
Other additional
costs
































TABLE 30 Resource use for NHS and PSS by trial arm: CRF data, survivors to hospital discharge
Assessment
period Category
Adrenaline arm (N= 128) Placebo arm (N= 91) Adrenaline vs. placebo
Participants with
complete data (n) Mean (SE)
Participants with
complete data (n) Mean (SE)
Mean difference




Time 1 (arrival at scene to
departure)
128 44.388 (1.529) 91 40.24 (1.607) 4.148 (–0.245 to 8.459) 0.064
Time 2a (departure from scene to
arrival at hospital or mortuary)
128 74.017 (0.95) 91 73.859 (1.387) 0.158 (–3.18 to 3.237) 0.84
Intervention dose
Number of syringes given 128 2.094 (0.144) 91 2.385 (0.224) –0.291 (–0.825 to 0.223) 0.264
Inpatient stay – initial admission (days)
ED 124 0.992 (0.014) 90 1.089 (0.058) –0.097 (–0.227 to 0.003) 0.042
General ward 127 22.118 (2.297) 90 19.233 (2.266) 2.885 (–3.624 to 8.857) 0.368
ICU 127 10.283 (1.101) 91 8.143 (1.123) 2.141 (–0.911 to 5.027) 0.182
Inpatient stay – repeat admissions (days)
ED 93 0.194 (0.05) 66 0.197 (0.058) –0.003 (–0.16 to 0.15) 0.99
General ward 92 2.065 (0.692) 66 1.455 (0.656) 0.611 (–1.258 to 2.511) 0.546
ICU
Outpatient attendance (visits)
Cardiology 91 0.879 (0.132) 64 0.969 (0.169) –0.09 (–0.526 to 0.331) 0.666
Cardiac rehabilitation 93 1.527 (0.349) 65 2.015 (0.627) –0.489 (–2.08 to 0.731) 0.502
Nursing/residential home 93 2.634 (1.273) 66 2.106 (1.213) 0.528 (–2.754 to 3.844) 0.73



































































































































































































































































































TABLE 30 Resource use for NHS and PSS by trial arm: CRF data, survivors to hospital discharge (continued )
Assessment
period Category
Adrenaline arm (N= 128) Placebo arm (N= 91) Adrenaline vs. placebo
Participants with
complete data (n) Mean (SE)
Participants with
complete data (n) Mean (SE)
Mean difference
(bootstrapped 95% CI) p-value
Primary health-care contact (number of contacts)
District nurse 95 1.032 (0.299) 66 1.045 (0.352) –0.014 (–0.926 to 0.884) 0.992
GP, surgery visit 95 1.411 (0.182) 66 1.727 (0.241) –0.317 (–0.943 to 0.287) 0.31
GP, home visit 95 0.116 (0.036) 66 0.167 (0.088) –0.051 (–0.263 to 0.108) 0.644
GP, telephone consultation 95 0.084 (0.033) 65 0.123 (0.051) –0.039 (–0.165 to 0.077) 0.544
Practice nurse 95 0.021 (0.022) 65 0 (0) 0.021 (0 to 0.078) 0.76
Physiotherapy 95 1.568 (1.596) 65 0 (0) 1.568 (0.01 to 5.117) 0.042
Occupational therapy 95 0.021 (0.015) 65 0.031 (0.031) –0.01 (–0.085 to 0.049) 0.852
Social worker 95 0.126 (0.043) 66 0.136 (0.078) –0.01 (–0.192 to 0.149) 0.986
Speech therapy 95 0.389 (0.221) 66 0.742 (0.463) –0.353 (–1.485 to 0.518) 0.548
Psychiatrist 95 0.053 (0.028) 66 0.076 (0.047) –0.023 (–0.136 to 0.08) 0.724
Psychology 95 0.221 (0.159) 66 0.364 (0.236) –0.143 (–0.709 to 0.368) 0.628
Counsellor 95 0.042 (0.025) 66 0.03 (0.032) 0.012 (–0.073 to 0.087) 0.738
Home care worker 95 4.495 (2.346) 66 3.076 (2.291) 1.419 (–5.2 to 7.616) 0.676
Lunch or social club 95 0.137 (0.114) 66 0.394 (0.271) –0.257 (–0.884 to 0.261) 0.408
Self-help groups 95 1.916 (1.321) 66 0.273 (0.201) 1.643 (–0.426 to 4.5) 0.27
Meals and laundry 95 1.926 (1.609) 66 1.576 (0.938) 0.351 (–2.92 to 4.276) 0.916
Other community care 95 0.011 (0.011) 65 0.123 (0.129) –0.113 (–0.414 to 0.029) 0.474
Medications


































Adrenaline arm (N= 128) Placebo arm (N= 91) Adrenaline vs. placebo
Participants with
complete data (n) Mean (SE)
Participants with
complete data (n) Mean (SE)
Mean difference
(bootstrapped 95% CI) p-value
Aids and adaptations (per item/pair when appropriate)
Defibrillator 93 0 (0) 65 0.015 (0.015) –0.015 (–0.05 to 0) < 0.001
Heart monitor 93 0.022 (0.015) 65 0.015 (0.015) 0.006 (–0.037 to 0.047) 0.794
PEG pump 93 0.011 (0.01) 65 0 (0) 0.011 (0 to 0.034) 0.758
Hoist 93 0.022 (0.015) 65 0 (0) 0.022 (0 to 0.052) 0.306
Wheelchair 93 0.043 (0.022) 65 0 (0) 0.043 (0 to 0.09) 0.052
Walking aid 93 0.118 (0.033) 65 0.185 (0.057) –0.066 (–0.208 to 0.057) 0.296
Hand aid 93 0.011 (0.011) 65 0.062 (0.03) –0.051 (–0.118 to 0.005) 0.066
Stair rail 93 0 (0) 65 0 (0) 0 (0 to 0) < 0.001




ED, visits 84 0.25 (0.072) 49 0.306 (0.097) –0.056 (–0.298 to 0.154) 0.616
General ward 122 3.746 (1.826) 83 3.741 (2.092) 0.005 (–5.431 to 5.353) 0.98
ICU 124 0.274 (0.263) 84 0 (0) 0.274 (0 to 0.992) 0.094
Outpatient attendance (visits)
Cardiology 83 0.807 (0.106) 47 0.936 (0.219) –0.129 (–0.617 to 0.295) 0.596
Cardiac rehabilitation 83 1.711 (0.485) 49 2.755 (0.925) –1.044 (–3.262 to 0.755) 0.298
Nursing/residential home 83 4.867 (2.177) 48 2.271 (1.905) 2.597 (–3.022 to 8.345) 0.344



































































































































































































































































































TABLE 30 Resource use for NHS and PSS by trial arm: CRF data, survivors to hospital discharge (continued )
Assessment
period Category
Adrenaline arm (N= 128) Placebo arm (N= 91) Adrenaline vs. placebo
Participants with
complete data (n) Mean (SE)
Participants with
complete data (n) Mean (SE)
Mean difference
(bootstrapped 95% CI) p-value
Primary health-care contact (number of contacts)
District nurse 84 2.774 (1.745) 50 0.28 (0.091) 2.494 (0.013 to 6.315) 0.046
GP, surgery visit 84 1.631 (0.252) 50 1.72 (0.293) –0.089 (–0.934 to 0.643) 0.826
GP, home visit 84 0.25 (0.095) 50 0.12 (0.052) 0.13 (–0.072 to 0.342) 0.254
GP, telephone consultation 83 0.06 (0.03) 49 0.143 (0.079) –0.083 (–0.264 to 0.059) 0.348
Practice nurse 83 0.012 (0.012) 49 0 (0) 0.012 (0 to 0.039) 0.714
Physiotherapy 83 0.048 (0.049) 49 0 (0) 0.048 (0 to 0.16) 0.71
Occupational therapy 83 0 (0) 49 0.061 (0.058) –0.061 (–0.18 to 0) < 0.001
Social worker 84 0.214 (0.096) 50 0.14 (0.064) 0.074 (–0.143 to 0.298) 0.512
Speech therapy 84 0.119 (0.075) 50 0.02 (0.02) 0.099 (–0.022 to 0.272) 0.136
Psychiatrist 84 0.024 (0.017) 50 0.02 (0.019) 0.004 (–0.048 to 0.053) 0.902
Psychology 84 0.083 (0.049) 50 0.12 (0.074) –0.037 (–0.212 to 0.128) 0.7
Counsellor 84 0.119 (0.118) 50 0.06 (0.046) 0.059 (–0.13 to 0.345) 0.794
Home care worker 84 3.262 (2.398) 50 0.16 (0.127) 3.102 (–0.208 to 8.501) 0.196
Lunch or social club 84 0.048 (0.047) 50 0 (0) 0.048 (0 to 0.158) 0.708
Self-help groups 84 1.274 (1.111) 50 0.32 (0.286) 0.954 (–0.704 to 3.612) 0.454
Meals and laundry 84 2.214 (1.531) 50 0.1 (0.064) 2.114 (–0.1 to 5.762) 0.168
Other community care 83 0.337 (0.299) 49 0 (0) 0.337 (0 to 1.043) 0.084
Medications


































Adrenaline arm (N= 128) Placebo arm (N= 91) Adrenaline vs. placebo
Participants with
complete data (n) Mean (SE)
Participants with
complete data (n) Mean (SE)
Mean difference
(bootstrapped 95% CI) p-value
Aids and adaptations (per item/pair when appropriate)
Defibrillator 83 0 (0) 50 0 (0) 0 (0 to 0) < 0.001
Heart monitor 83 0 (0) 50 0 (0) 0 (0 to 0) < 0.001
PEG pump 83 0 (0) 50 0 (0) 0 (0 to 0) < 0.001
Hoist 83 0.06 (0.025) 50 0.02 (0.02) 0.04 (–0.021 to 0.105) 0.228
Wheelchair 83 0.072 (0.029) 50 0.06 (0.034) 0.012 (–0.079 to 0.093) 0.842
Walking aid 83 0.06 (0.032) 50 0.06 (0.034) 0 (–0.097 to 0.092) 0.974
Hand aid 83 0 (0) 50 0.02 (0.02) –0.02 (–0.071 to 0) < 0.001
Stair rail 83 0 (0) 50 0.02 (0.02) –0.02 (–0.066 to 0) < 0.001
Other aids and adaptations 83 0.241 (0.072) 50 0.1 (0.057) 0.141 (–0.028 to 0.323) 0.112
PEG, percutaneous endoscopic gastrostomy.
a We added 60 minutes (step-down or restock time) to account for time that ambulance crew use to restock before they are available for the next assignment. This is based on


































































































































































































































































































TABLE 31 Resources use for non-NHS and PSS by trial arm: CRF data, survivors to hospital discharge
Assessment period Category
Adrenaline arm (N= 128) Placebo arm (N= 128) Adrenaline vs. placebo
Participants with
complete data (n) Mean (SE)
Participants with
complete data (n) Mean (SE)
Mean difference
(bootstrapped 95% CI) p-value





94 2.021 (0.015) 66 2 (0) 0.021 (0 to 0.054) 0.274
Additional costs (number of occurrences)
Child care 95 0.558 (0.051) 66 0.5 (0.062) 0.058 (–0.102 to 0.208) 0.512
House work 95 0.579 (0.054) 66 0.576 (0.082) 0.003 (–0.195 to 0.178) 0.994
Travel costs 96 1.01 (0.099) 66 0.894 (0.128) 0.116 (–0.22 to 0.422) 0.514
Other additional
costs
96 1.552 (0.15) 66 1.424 (0.202) 0.128 (–0.381 to 0.585) 0.596
3–6 months after randomisation Medications
Medication,
number of items
81 2.012 (0.013) 49 2 (0) 0.012 (0 to 0.042) 0.726
Additional costs (number of occurrences)
Child care 83 0.361 (0.053) 51 0.294 (0.069) 0.067 (–0.117 to 0.242) 0.472
House work 83 0.41 (0.062) 51 0.353 (0.082) 0.057 (–0.157 to 0.272) 0.64
Travel costs 83 0.735 (0.103) 51 0.627 (0.123) 0.107 (–0.224 to 0.433) 0.582
Other additional
costs
































TABLE 32 Unit costs for NHS, non-NHS and PSS
Type of resource
Unit cost
(£) Unit Source Notes
Emergency response
Emergency ambulance 8.00 Minute PSSRU 2008,160 p. 82 £6.80 (2008) prices
inflated to £8.00
(2017 prices)






Primary source of unit cost of hospital services (raw resource use data derived from HES), mean (SD), range
Inpatients (initial): £6022.47
(£20,869.58), £352–683,381

































Attendance National Schedule of
Reference Costs,
2016–17135
Secondary source of unit costs for hospital services (raw resource use data derived from trial CRFs)
Inpatient care






ICU bed-day 2114.13 Bed-day National Schedule of
Reference Costs,
2016–17135
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TABLE 32 Unit costs for NHS, non-NHS and PSS (continued )
Type of resource
Unit cost
(£) Unit Source Notes







































Nursing/residential home 162.00 Attendance PSSRU 2017140 Local authority own-
provision residential
care for older people
(£162/day, p. 35140)
Home carers twice a day 27.00 Attendance PSSRU 2017140 p. 178.140 Face to face:
£26 per hour on a
weekday (£27 per hour
on weekend day, £27
per hour on night-time
weekday); assumed 1 hour
of care provided each day
at £27 per hour
Other outpatient services:
mean £155.78 (SD £244.19),
range £1–2114
Community health and social care services
Counsellor 53.00 Contact PSSRU 2017140 Community-based
professional (band 7)
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TABLE 32 Unit costs for NHS, non-NHS and PSS (continued )
Type of resource
Unit cost
(£) Unit Source Notes
District nurse 41.04 Contact PSSRU 2013209 The mean average cost for
a face-to-face contact in
district nursing services
for 2012/2013 was £39,
inflated to 2017 prices
GP, home visit 38.00 Contact PSSRU 2017140 Per patient contact lasting
9.22 minutes including
CO2 emissions (page 162)
GP, surgery visit 37.00 Contact PSSRU 2017140 Per surgery consultation
lasting 9.22 minutes
(page 162)




Home care worker 13.50 Contact PSSRU 2017140 Page 178. Face to face:
£26 per hour weekday
(£27 per day-time
weekend, £27 per night-
time weekday, £27 per
night-time weekend).
Assumed 30 minutes
contact at £27 per hour
Meals and laundry 6.94 One meal PSSRU 2014210 The average cost per meal
on wheels was £6.60 for the
local authority in 2012/13
(PSSRUUnit Costs 2014,
page 127). Inflated to 2017
prices using the Hospital &
Community Health Services
(HCHS) Pay and Prices index









Practice nurse 10.85 Contact PSSRU 2017140 Practice nurse hourly
costs including
qualifications £42 (page
160); duration of contact
15.5 minutes (PSSRU
2013, page 188)
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TABLE 32 Unit costs for NHS, non-NHS and PSS (continued )
Type of resource
Unit cost
(£) Unit Source Notes
Lunch or social club 6.94 One meal PSSRU 2014210 The average cost per meal
on wheels was £6.60 for
the local authority in
2012/13 (PSSRU 2014,
page 127). Inflated to
2017 prices using the
Hospital & Community
Health Services (HCHS)
Pay and Prices index
Social worker 43.07 Contact PSSRU 2017140 Social worker (adult
services) with qualifications
cost £59 per hour, page
174; assumed 73% of time
is spent on client-related
activities (PSSRU 2017,
page 174) including direct
contact (includes travel)




Other primary care services: mean £58.98 (SD £19.43), range £21–98
Additional costsa over 6 months




Additional costs over 6 months




PSSRU, Personal Social Services Research Unit.
a Additional non-health and social care costs reported by patients and or their proxies. These include child-care costs,
purchase of equipment and over-the-counter medication by patients themselves, laundry, hospital parking charges
and lost income.
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TABLE 33 NHS and PSS costs (2017 prices) by trial arm, all patients, based on resource use collected through trial CRF data
Assessment
period Category
Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean cost (SE) (£)
Participants with
complete data (n) Mean cost (SE) (£)
Mean difference in costs




Time 1 (arrival at scene
to departure)
4012 1152.27 (17.13) 3999 1099.38 (10.71) 52.89 (14.73 to 91.44) 0.002
Time 2a (arrival at
scene to departure)
4011 563.66 (1.87) 3992 560.32 (2.38) 3.34 (–2.66 to 9.21) 0.244
Total emergency
response costs
4010 1716.03 (17.05) 3992 1659.61 (10.41) 56.41 (18.54 to 94.42) < 0.001
Intervention costs
Syringes given 4008 33.82 (0.27) 3990 0 (0) 33.82 (33.27 to 34.32) < 0.001
Inpatient costs
ED 7980 99.26 (1.6) 7966 60.43 (1.52) 38.83 (34.66 to 43.08) < 0.001
General ward 7986 129.07 (15.65) 7968 79.88 (11.44) 49.19 (13.4 to 87.45) 0.006
ICU 4013 1924.47 (124.11) 3999 997.59 (99.04) 926.88 (629.78 to 1250.56) < 0.001
Total inpatient costs 3964 2093.96 (128.43) 3967 1082.18 (88.63) 1011.78 (729.39 to 1325.13) < 0.001
Outpatient costs
Cardiology 3972 2.76 (0.5) 3968 2.14 (0.45) 0.62 (–0.64 to 1.91) 0.326
Cardiac rehabilitation 3974 2.85 (0.68) 3969 2.63 (0.88) 0.22 (–2.03 to 2.31) 0.83
Nursing/residential
home
3974 9.99 (4.91) 3970 5.67 (3.24) 4.32 (–6.28 to 17.34) 0.412
Other outpatient costs 3972 3.12 (1.14) 3964 2.63 (1.16) 0.49 (–2.59 to 3.6) 0.674



































































































































































































































































































TABLE 33 NHS and PSS costs (2017 prices) by trial arm, all patients, based on resource use collected through trial CRF data (continued )
Assessment
period Category
Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean cost (SE) (£)
Participants with
complete data (n) Mean cost (SE) (£)
Mean difference in costs
(95% CI) (£) p-value
Primary health-care costs
GP, surgery visit 3976 1.25 (0.2) 3970 1.06 (0.2) 0.18 (–0.39 to 0.7) 0.53
GP, home visit 3976 0.11 (0.03) 3970 0.11 (0.05) 0 (–0.13 to 0.11) 0.98
GP, telephone
consultation
3976 0.06 (0.02) 3969 0.06 (0.02) 0 (–0.07 to 0.06) 0.936
District nurse 3976 1.13 (0.33) 3970 0.71 (0.25) 0.41 (–0.39 to 1.24) 0.326
Practice nurse 3976 0.01 (0.01) 3969 0 (0) 0.01 (0 to 0.02) 0.644
Physiotherapy 3976 1.8 (1.7) 3969 0 (0) 1.8 (0.01 to 5.34) 0.034
Occupational therapy 3976 0.03 (0.02) 3969 0.03 (0.03) 0 (–0.08 to 0.07) 0.898
Social worker 3976 0.13 (0.05) 3970 0.1 (0.06) 0.03 (–0.13 to 0.17) 0.69
Speech therapy 3976 0.9 (0.56) 3970 1.19 (0.76) –0.29 (–2.28 to 1.55) 0.8
Psychiatrist 3976 0.11 (0.06) 3970 0.11 (0.07) 0 (–0.17 to 0.15) 0.898
Psychology 3976 0.89 (0.69) 3970 1.02 (0.71) –0.13 (–2.03 to 1.87) 0.848
Home care worker 3976 1.45 (0.82) 3970 0.69 (0.51) 0.76 (–0.95 to 2.97) 0.4
Lunch or social club 3976 0.02 (0.02) 3970 0.05 (0.03) –0.02 (–0.09 to 0.04) 0.448
Self-help groups 3976 0 (0) 3970 0 (0) 0 (0 to 0) < 0.001
Meals and laundry 3976 0.32 (0.25) 3970 0.18 (0.11) 0.14 (–0.31 to 0.76) 0.72
Counsellor 3976 0.05 (0.03) 3970 0.03 (0.03) 0.03 (–0.05 to 0.12) 0.606
Other community
care costs
3976 2.45 (2.31) 3969 0.09 (0.07) 2.35 (–0.13 to 7.2) 0.414
Total community
care costs


































Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean cost (SE) (£)
Participants with
complete data (n) Mean cost (SE) (£)
Mean difference in costs
(95% CI) (£) p-value
Medication costs
Medication 3975 6.8 (1.7) 3970 4.98 (1.68) 1.82 (–2.96 to 6.61) 0.45
Aids and adaptations costs
Defibrillator 3974 0 (0) 3968 0 (0) 0 (0 to 0) < 0.001
Heart monitor 3974 0 (0) 3969 0 (0) 0 (0 to 0) < 0.001
PEG pump 3973 0 (0) 3969 0 (0) 0 (0 to 0) < 0.001
Hoist 3974 2.11 (1.46) 3969 0 (0) 2.11 (0 to 5.27) 0.262
Wheelchair 3974 0.2 (0.1) 3969 0 (0) 0.2 (0.05 to 0.43) 0.038
Walking aid 3974 0.1 (0.04) 3969 0.09 (0.04) 0.01 (–0.09 to 0.12) 0.882
Hand aid 3974 0 (0) 3969 0 (0) 0 (0 to 0) < 0.001
Stair rail 3974 0 (0) 3969 0 (0) 0 (0 to 0) < 0.001
Other aids and
adaptations costs
3968 0.49 (0.29) 3965 1.68 (1.29) –1.19 (–4.25 to 0.69) 0.476
Total aids and
adaptations costs
3967 1.78 (1.29) 3964 1.75 (1.29) 0.02 (–3.8 to 3.88) 0.972
0–3 months: total NHS
and PSS costs



































































































































































































































































































TABLE 33 NHS and PSS costs (2017 prices) by trial arm, all patients, based on resource use collected through trial CRF data (continued )
Assessment
period Category
Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean cost (SE) (£)
Participants with
complete data (n) Mean cost (SE) (£)
Mean difference in costs




ED 3965 2.06 (0.65) 3953 1.48 (0.51) 0.59 (–0.83 to 2.23) 0.454
General ward 4003 44.09 (15.06) 3987 36.02 (14.8) 8.07 (–36.25 to 50.39) 0.662
ICU 4005 65.98 (51.66) 3989 15.37 (15.4) 50.61 (–29.07 to 182.2) 0.234
Total inpatient costs 3961 83.1 (50.84) 3949 37.36 (19.5) 45.73 (–37.8 to 172.54) 0.388
Outpatient costs
Cardiology 3964 2.32 (0.41) 3951 1.53 (0.4) 0.79 (–0.32 to 1.82) 0.136
Cardiac rehabilitation 3964 2.86 (0.86) 3953 2.72 (0.95) 0.13 (–2.29 to 2.66) 0.948
Nursing/residential
home
3964 16.51 (7.68) 3952 4.47 (3.81) 12.04 (–3.12 to 29.51) 0.118
Other outpatient costs 3963 0.6 (0.23) 3953 0.65 (0.31) –0.05 (–0.85 to 0.67) 0.938
Total outpatient costs 3960 18.59 (6.93) 3949 9.25 (4.02) 9.34 (–4.73 to 25.67) 0.218
Primary health-care costs
GP, surgery visit 3965 1.29 (0.25) 3954 0.8 (0.18) 0.48 (–0.1 to 1.08) 0.116
GP, home visit 3965 0.21 (0.08) 3954 0.06 (0.03) 0.15 (–0.01 to 0.34) 0.082
GP, telephone
consultation
3964 0.04 (0.02) 3953 0.05 (0.03) –0.01 (–0.09 to 0.04) 0.646
District nurse 3965 2.41 (1.57) 3954 0.15 (0.05) 2.27 (0.13 to 5.8) 0.002
Practice nurse 3964 0 (0) 3953 0 (0) 0 (0 to 0.01) 0.494
Physiotherapy 3964 0.05 (0.05) 3953 0 (0) 0.05 (0 to 0.15) 0.772
Occupational therapy 3964 0 (0) 3953 0.05 (0.05) –0.05 (–0.15 to 0) < 0.001


































Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean cost (SE) (£)
Participants with
complete data (n) Mean cost (SE) (£)
Mean difference in costs
(95% CI) (£) p-value
Speech therapy 3965 0.24 (0.16) 3954 0.02 (0.02) 0.22 (0 to 0.58) 0.09
Psychiatrist 3965 0.13 (0.09) 3954 0.02 (0.02) 0.11 (–0.04 to 0.3) 0.29
Psychology 3965 0.3 (0.18) 3954 0.26 (0.16) 0.04 (–0.4 to 0.55) 0.95
Home care worker 3965 0.93 (0.68) 3954 0.03 (0.02) 0.91 (–0.03 to 2.45) 0.206
Lunch or social club 3965 0.01 (0.01) 3954 0 (0) 0.01 (0 to 0.03) 0.762
Self-help groups 3965 0 (0) 3954 0 (0) 0 (0 to 0) < 0.001
Meals and laundry 3965 0.33 (0.23) 3954 0.01 (0.01) 0.32 (–0.01 to 0.81) 0.182
Counsellor 3965 0.13 (0.14) 3954 0.04 (0.03) 0.09 (–0.09 to 0.41) 0.762
Other community
care costs
3964 0.28 (0.2) 3953 0 (0) 0.28 (0.03 to 0.78) 0.004
Total community
care costs
3964 6.54 (2.03) 3953 1.55 (0.33) 4.99 (1.36 to 9.26) < 0.001
Medications
Medication 3961 3.68 (1.2) 3952 1.03 (0.26) 2.65 (0.71 to 5.61) 0.002
Aids and adaptations costs
Defibrillator 3964 0 (0) 3954 0 (0) 0 (0 to 0) < 0.001
Heart monitor 3964 0 (0) 3954 0 (0) 0 (0 to 0) < 0.001
PEG pump 3964 0 (0) 3954 0 (0) 0 (0 to 0) < 0.001
Hoist 3964 5.28 (2.4) 3954 1.06 (1.04) 4.22 (–0.11 to 9.53) 0.106
Wheelchair 3964 0.3 (0.12) 3954 0.15 (0.08) 0.15 (–0.1 to 0.45) 0.348
Walking aid 3964 0.02 (0.02) 3954 0.02 (0.02) 0 (–0.05 to 0.05) 0.752
Hand aid 3964 0 (0) 3954 0 (0) 0 (0 to 0) < 0.001



































































































































































































































































































TABLE 33 NHS and PSS costs (2017 prices) by trial arm, all patients, based on resource use collected through trial CRF data (continued )
Assessment
period Category
Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean cost (SE) (£)
Participants with
complete data (n) Mean cost (SE) (£)
Mean difference in costs
(95% CI) (£) p-value
Other aids and
adaptations costs
3959 0.24 (0.2) 3954 0.01 (0.01) 0.22 (0 to 0.66) 0.15
Total aids and
adaptations costs
3959 4.78 (2.18) 3954 1.24 (1.09) 3.54 (–1 to 8.89) 0.12
Total costs
3–6 months: total NHS
and PSS costs
3948 93.75 (50.8) 3940 47.62 (20.86) 46.13 (–38.68 to 169.18) 0.382
0–6 months: total NHS
and PSS costs
3919 3641.84 (149.13) 3914 2548.36 (84) 1093.49 (800.43 to 1442) < 0.001
PEG, percutaneous endoscopic gastrostomy.
a We added 60 minutes (step-down or restock time) to account for time that ambulance crew use to restock before they are available for the next assignment. This is based on
































TABLE 34 Non-NHS and PSS costs by trial arm, all patients, CRF data
Assessment
period Category
Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean cost (SE) (£)
Participants with
complete data (n) Mean cost (SE) (£)
Mean difference in costs




Medication 3975 0.04 (0.03) 3970 0 (0) 0.04 (0 to 0.09) 0.26
Additional costs
Child care 3976 0 (0) 3970 0 (0) 0 (0 to 0) < 0.001
Housework 3976 0.1 (0.09) 3970 0.24 (0.16) –0.15 (–0.55 to 0.18) 0.364
Travel costs 3977 1.66 (0.74) 3970 1.38 (0.63) 0.28 (–1.44 to 2.29) 0.73
Other additional
costs
3977 37.61 (10.35) 3970 18.3 (6.25) 19.31 (–4.21 to 42.52) 0.116
Total additional
costs





3973 37.34 (10.32) 3970 19.93 (6.45) 17.4 (–6.71 to 40.77) 0.156
0–3 months: total
societal costs



































































































































































































































































































TABLE 34 Non-NHS and PSS costs by trial arm, all patients, CRF data (continued )
Assessment
period Category
Adrenaline arm (N= 4015) Placebo arm (N= 3999) Adrenaline vs. placebo
Participants with
complete data (n) Mean cost (SE) (£)
Participants with
complete data (n) Mean cost (SE) (£)
Mean difference in costs




Medication 3962 0 (0) 3953 0 (0) 0 (0 to 0) < 0.001
Additional costs
Child care 3964 0 (0) 3955 0.08 (0.08) –0.08 (–0.23 to 0) < 0.001
Housework 3964 0.47 (0.32) 3955 0.07 (0.04) 0.39 (–0.06 to 1.1) 0.19
Travel costs 3964 1.99 (1.02) 3955 0.4 (0.15) 1.59 (0 to 3.98) 0.052
Other additional
costs
3964 16.06 (7.56) 3955 4.47 (2.19) 11.59 (–0.73 to 30.2) 0.076
Total additional
costs





3962 18.51 (8.13) 3953 4.95 (2.25) 13.56 (0.49 to 33.62) 0.038
3–6 months: total
societal costs




3956 50.84 (14.62) 3952 15.07 (5.59) 35.77 (8.1 to 68.61) 0.01
0–6 months: total
societal costs
































TABLE 35 NHS and PSS costs (2017 prices) by trial arm, survivors to hospital discharge, CRF data
Assessment
period Category
Adrenaline arm (n= 128) Placebo arm (n= 91) Adrenaline vs. placebo
Participants
with complete
data (n) Mean cost (SE) (£)
Participants
with complete
data (n) Mean cost (SE) (£)
Mean difference in costs




Time 1 (arrival at
scene to departure)
127 942.98 (43.08) 91 865 (50.55) 77.98 (–49.91 to 214.72) 0.23
Time 2a (arrival at
scene to departure)
128 592.13 (7.6) 91 590.87 (11.09) 1.26 (–25.44 to 25.9) 0.84
Total emergency
response costs
127 1535.32 (45.62) 91 1455.87 (53.8) 79.45 (–51.87 to 222.5) 0.242
Intervention costs
Intervention costs 128 14.38 (0.99) 91 0 (0) 14.38 (12.44 to 16.33) < 0.001
Inpatient costs
ED 217 251.49 (9.81) 156 254.88 (11.24) –3.39 (–35.3 to 24.12) 0.8
General ward 219 4188.33 (433.9) 156 3581.97 (426.11) 606.36 (–597.29 to 1729.24) 0.322
ICU 127 21,740.58 (2328.42) 91 17,215.06 (2373.78) 4525.52 (–1925.88 to 10,628.52) 0.182
Total inpatient costs 88 29,425.72 (3032.74) 65 24,356.65 (3055.72) 5069.07 (–3985.61 to 13,777.15) 0.244
Outpatient costs
Cardiology 91 120.5 (18.14) 64 132.79 (23.19) –12.29 (–72.07 to 45.37) 0.67
Cardiac rehabilitation 93 121.69 (27.84) 65 160.63 (49.99) –38.93 (–165.76 to 58.3) 0.506
Nursing/residential
home
93 426.77 (206.19) 66 341.18 (196.55) 85.59 (–446.07 to 622.75) 0.73
Other outpatient costs 91 136.08 (47.11) 60 173.61 (72.69) –37.53 (–218.24 to 115.95) 0.676



































































































































































































































































































TABLE 35 NHS and PSS costs (2017 prices) by trial arm, survivors to hospital discharge, CRF data (continued )
Assessment
period Category
Adrenaline arm (n= 128) Placebo arm (n= 91) Adrenaline vs. placebo
Participants
with complete
data (n) Mean cost (SE) (£)
Participants
with complete
data (n) Mean cost (SE) (£)
Mean difference in costs
(bootstrapped 95% CI) (£) p-value
Primary health-care costs
GP, surgery visit 95 52.19 (6.72) 66 63.91 (8.93) –11.72 (–34.89 to 10.61) 0.312
GP, home visit 95 4.4 (1.38) 66 6.33 (3.34) –1.93 (–9.99 to 4.11) 0.644
GP, telephone
consultation
95 2.4 (0.93) 65 3.51 (1.44) –1.11 (–4.69 to 2.19) 0.548
District nurse 95 47.09 (12.98) 66 42.91 (14.46) 4.18 (–34.82 to 41.28) 0.826
Practice nurse 95 0.23 (0.24) 65 0 (0) 0.23 (0 to 0.85) 0.76
Physiotherapy 95 75.28 (76.62) 65 0 (0) 75.28 (0.47 to 245.62) 0.042
Occupational therapy 95 1.37 (0.98) 65 2 (2) –0.63 (–5.52 to 3.17) 0.858
Social worker 95 5.44 (1.84) 66 5.87 (3.38) –0.43 (–8.28 to 6.41) 0.98
Speech therapy 95 37.59 (21.36) 66 71.66 (44.72) –34.07 (–143.35 to 50.01) 0.548
Psychiatrist 95 4.45 (2.39) 66 6.41 (3.96) –1.96 (–11.47 to 6.74) 0.728
Psychology 95 37.28 (26.86) 66 61.33 (39.74) –24.05 (–119.63 to 62.08) 0.632
Home care worker 95 60.68 (31.67) 66 41.52 (30.93) 19.16 (–70.19 to 102.83) 0.676
Lunch or social club 95 0.95 (0.79) 66 2.84 (1.88) –1.89 (–6.25 to 1.71) 0.376
Self-help groupsb 95 – 66 – – < 0.001
Meals and laundry 95 13.37 (11.17) 66 10.94 (6.51) 2.43 (–20.26 to 29.67) 0.918
Counsellor 95 2.23 (1.35) 66 1.61 (1.68) 0.63 (–3.86 to 4.63) 0.73
Other community
care costs
95 102.41 (103.78) 65 5.71 (4.21) 96.71 (–9.68 to 329.22) 0.542
Total community
care costs


































Adrenaline arm (n= 128) Placebo arm (n= 91) Adrenaline vs. placebo
Participants
with complete
data (n) Mean cost (SE) (£)
Participants
with complete
data (n) Mean cost (SE) (£)
Mean difference in costs
(bootstrapped 95% CI) (£) p-value
Medications
Medication 94 287.66 (64.88) 66 299.49 (93.53) –11.83 (–250.68 to 183.9) 0.97
Aids and adaptations costs
Hoist 93 90.01 (61.56) 65 0 (0) 90.01 (0 to 215.81) 0.306
Wheelchair 93 8.39 (4.31) 65 0 (0) 8.39 (0 to 17.53) 0.052
Walking aid 93 4.36 (1.59) 65 5.41 (2.22) –1.05 (–6.56 to 4.07) 0.726
Hand aid 93 0.02 (0.02) 65 0.13 (0.07) –0.11 (–0.25 to 0.01) 0.052
Other aids and
adaptations costs
87 22.24 (13.52) 61 109.1 (82.98) –86.87 (–271.51 to 24.64) 0.336
Total aids and
adaptations costs
86 81.91 (63.42) 60 115.82 (84.33) –33.91 (–263.39 to 159.46) 0.736
Total costs
0–3 months: total NHS
and PSS costs




ED 84 97.45 (27.96) 49 119.33 (37.73) –21.88 (–116.02 to 60.14) 0.616
General ward 121 1458.47 (450.89) 82 1,687.77 (697.84) –229.3 (–1938.34 to 1295.45) 0.76
ICU 123 2148.51 (1649.51) 84 0 (0) 2148.51 (17.47 to 5940.07) 0.032



































































































































































































































































































TABLE 35 NHS and PSS costs (2017 prices) by trial arm, survivors to hospital discharge, CRF data (continued )
Assessment
period Category
Adrenaline arm (n= 128) Placebo arm (n= 91) Adrenaline vs. placebo
Participants
with complete
data (n) Mean cost (SE) (£)
Participants
with complete
data (n) Mean cost (SE) (£)
Mean difference in costs
(bootstrapped 95% CI) (£) p-value
Outpatient costs
Cardiology 83 110.65 (14.53) 47 128.32 (30.04) –17.67 (–84.6 to 40.45) 0.596
Cardiac rehabilitation 83 136.35 (38.67) 49 219.58 (73.76) –83.23 (–260.01 to 60.19) 0.298
Nursing/residential
home
83 788.53 (352.6) 48 367.88 (308.67) 420.66 (–489.54 to 1352) 0.344
Other outpatient costs 82 29.24 (10.35) 49 52.8 (25.37) –23.56 (–86.71 to 19.04) 0.384
Total outpatient costs 79 932.02 (328.67) 45 812.04 (331.92) 119.97 (–835.56 to 1002.03) 0.736
Primary health-care costs
GP, surgery visit 84 60.79 (9.33) 50 63.64 (10.85) –2.85 (–34.14 to 24.32) 0.864
GP, home visit 84 9.95 (3.62) 50 4.56 (1.99) 5.39 (–2.17 to 13.33) 0.19
GP, telephone
consultation
83 1.72 (0.86) 49 4.07 (2.25) –2.35 (–7.51 to 1.67) 0.348
District nurse 84 113.84 (71.63) 50 11.49 (3.73) 102.35 (0.54 to 259.15) 0.046
Practice nurse 83 0.13 (0.13) 49 0 (0) 0.13 (0 to 0.42) 0.714
Physiotherapy 83 2.31 (2.34) 49 0 (0) 2.31 (0 to 7.68) 0.71
Occupational therapy 83 0 (0) 49 3.98 (3.77) –3.98 (–11.7 to 0) < 0.001
Social worker 84 9.23 (4.12) 50 6.03 (2.77) 3.2 (–6.16 to 12.84) 0.51
Speech therapy 84 11.49 (7.22) 50 1.93 (1.93) 9.56 (–2.09 to 26.22) 0.134
Psychiatrist 84 6.04 (4.24) 50 1.69 (1.63) 4.35 (–2.54 to 14.61) 0.316
Psychology 84 14.05 (8.31) 50 20.24 (12.44) –6.18 (–35.83 to 21.53) 0.702
Home care worker 84 44.04 (32.37) 50 2.16 (1.71) 41.88 (–2.81 to 114.76) 0.196
Lunch or social club 84 0.33 (0.33) 50 0 (0) 0.33 (0 to 1.1) 0.708


































Adrenaline arm (n= 128) Placebo arm (n= 91) Adrenaline vs. placebo
Participants
with complete
data (n) Mean cost (SE) (£)
Participants
with complete
data (n) Mean cost (SE) (£)
Mean difference in costs
(bootstrapped 95% CI) (£) p-value
Meals and laundry 84 15.37 (10.63) 50 0.69 (0.45) 14.67 (–0.69 to 39.99) 0.168
Counsellor 84 6.31 (6.26) 50 3.18 (2.42) 3.13 (–6.87 to 18.28) 0.794
Other community care
costs
83 13.16 (9.54) 49 0 (0) 13.16 (1.47 to 36.46) 0.004
Total community care
costs
83 312.26 (86.32) 49 125.27 (19.78) 187 (29.94 to 378.04) 0.02
Medications
Medication 80 182.04 (54.94) 48 84.86 (18.07) 97.18 (2.6 to 225.3) 0.044
Aids and adaptations costs
Hoist 83 252.14 (105.74) 50 83.71 (83.57) 168.43 (–89.17 to 438.34) 0.222
Wheelchair 83 14.1 (5.57) 50 11.7 (6.71) 2.4 (–15.49 to 18.19) 0.836
Walking aid 83 0.97 (0.82) 50 1.45 (1.3) –0.48 (–3.77 to 2.37) 0.768
Hand aid 83 0 (0) 50 0.03 (0.03) –0.03 (–0.12 to 0) < 0.001
Other aids and
adaptations costs
78 12.07 (10.15) 50 1.07 (0.62) 11 (–0.77 to 34.02) 0.192
Total aids and
adaptations costs
78 242.69 (104.76) 50 97.99 (87.6) 144.7 (–117.87 to 409.13) 0.296
Total costs
3–6 months: total NHS
and PSS costs
67 5524.18 (2914.88) 36 3508.31 (1334.03) 2015.87 (–3297.29 to 8742.91) 0.598
0–6 months: total NHS
and PSS costs
54 33,385.85 (7293.82) 29 29,144.43 (4609.34) 4241.42 (–9982.79 to 22,538.49) 0.698
a We added 60 minutes (step-down or restock time) to account for the time that ambulance crew use to restock before they are available for the next assignment. This is based on
asking ambulance crew during one of the meetings to discuss the trial results.
b The unit cost of running a self-help group activity for OHCA was not available, hence when calculating costs in the economic analysis, we assumed that the cost of self-help group


































































































































































































































































































TABLE 36 Non-NHS and PSS costs by trial arm, survivors to hospital discharge, CRF data
Assessment period Category
Adrenaline arm (n= 128) Placebo arm (n= 91) Adrenaline vs. placebo
Participants
with complete
data (n) Mean cost (SE) (£)
Participants
with complete
data (n) Mean cost (SE) (£)
Mean difference in costs






94 1.64 (1.13) 66 0.14 (0.07) 1.5 (–0.14 to 4.01) 0.216
Additional costs
Child care 95 0 (0) 66 0 (0) 0 (0 to 0) < 0.001
Housework 95 4 (3.55) 66 14.7 (9.18) –10.7 (–33.51 to 4.85) 0.24
Travel costs 96 68.8 (28.7) 66 83.18 (35.48) –14.38 (–106.34 to 73.34) 0.762
Other additional costs 96 1558.05 (405.25) 66 1100.98 (366.5) 457.06 (–640.29 to 1562.61) 0.404
Total additional costs 95 1640.32 (411.74) 66 1198.86 (372.51) 441.46 (–667.47 to 1553.23) 0.416
0–3 months: total
non-NHS and PSS costs







81 0.07 (0.03) 49 0.12 (0.11) –0.04 (–0.32 to 0.12) 0.818
Additional costs
Child care 83 0 (0) 51 5.88 (5.69) –5.88 (–18.37 to 0) < 0.001
Housework 83 22.29 (14.06) 51 5.67 (3.15) 16.62 (–5.81 to 47.85) 0.298
Travel costs 83 95.07 (45.79) 51 31.11 (11.3) 63.96 (–13.94 to 165.39) 0.128
Other additional costs 83 766.96 (343.22) 51 346.71 (163.69) 420.26 (–219.52 to 1305.15) 0.27
Total additional costs 83 884.33 (363.5) 51 389.36 (167.28) 494.96 (–182.1 to 1441.7) 0.192
3–6 months: total
non-NHS and PSS costs
































TABLE 37 Distribution of EQ-5D-5L responses: survivors to hospital discharge
EQ-5D domain













Mobility, n (%) 0.449 0.554
Level 1: no problems 36 (28.1) 31 (34.1) 37 (28.9) 21 (23.1)
Level 2: slight problems 24 (18.8) 13 (14.3) 11 (8.6) 10 (11)
Level 3: moderate problems 13 (10.2) 13 (14.3) 11 (8.6) 15 (16.5)
Level 4: severe problems 7 (5.5) 5 (5.5) 5 (3.9) 1 (1.1)
Level 5: unable to walk 8 (6.2) 2 (2.2) 10 (7.8) 2 (2.2)
Missing 40 (31.2) 27 (29.7) 54 (42.2) 42 (46.2)
Self-care, n (%) 0.020 0.420
Level 1: no problems 55 (43) 52 (57.1) 48 (37.5) 36 (39.6)
Level 2: slight problems 13 (10.2) 2 (2.2) 9 (7) 7 (7.7)
Level 3: moderate problems 10 (7.8) 5 (5.5) 5 (3.9) 3 (3.3)
Level 4: severe problems 1 (0.8) 1 (1.1) 2 (1.6) 0 (0)
Level 5: unable to wash or
dress
9 (7) 4 (4.4) 10 (7.8) 3 (3.3)
Missing 40 (31.2) 27 (29.7) 54 (42.2) 42 (46.2)
Usual activities, n (%) 0.161 0.547
Level 1: no problems 25 (19.5) 26 (28.6) 25 (19.5) 20 (22)
Level 2: slight problems 25 (19.5) 16 (17.6) 17 (13.3) 11 (12.1)
Level 3: moderate problems 15 (11.7) 13 (14.3) 16 (12.5) 11 (12.1)
Level 4: severe problems 6 (4.7) 1 (1.1) 2 (1.6) 2 (2.2)
Level 5: unable to perform
usual activities
17 (13.3) 8 (8.8) 14 (10.9) 5 (5.5)
Missing 40 (31.2) 27 (29.7) 54 (42.2) 42 (46.2)
Pain/discomfort, n (%) 0.814 0.299
Level 1: no pain or discomfort 37 (28.9) 29 (31.9) 28 (21.9) 24 (26.4)
Level 2: slight pain or
discomfort
25 (19.5) 19 (20.9) 25 (19.5) 13 (14.3)
Level 3: moderate pain or
discomfort
18 (14.1) 8 (8.8) 14 (10.9) 8 (8.8)
Level 4: severe pain or
discomfort
4 (3.1) 5 (5.5) 5 (3.9) 3 (3.3)
Level 5: extreme pain or
discomfort
4 (3.1) 3 (3.3) 2 (1.6) 1 (1.1)
Missing 40 (31.2) 27 (29.7) 54 (42.2) 42 (46.2)
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TABLE 37 Distribution of EQ-5D-5L responses: survivors to hospital discharge (continued )
EQ-5D domain













Anxiety/depression, n (%) 1 0.757
Level 1: not anxious or
depressed
40 (31.2) 29 (31.9) 28 (21.9) 21 (23.1)
Level 2: slightly anxious or
depressed
22 (17.2) 17 (18.7) 25 (19.5) 16 (17.6)
Level 3: moderately anxious or
depressed
15 (11.7) 13 (14.3) 12 (9.4) 8 (8.8)
Level 4: severely anxious or
depressed
8 (6.2) 4 (4.4) 4 (3.1) 0 (0)
Level 5: extremely anxious or
depressed
3 (2.3) 1 (1.1) 4 (3.1) 4 (4.4)
Missing 40 (31.2) 27 (29.7) 55 (43) 42 (46.2)
a Based on the chi-squared test of differences between proportions.
TABLE 38 Distribution of SF-12 responses: survivors to hospital discharge
SF-12 domain













General health, n (%) 0.590 0.693
Excellent 5 (3.9) 6 (6.6) 4 (3.1) 1 (1.1)
Very good 10 (7.8) 16 (17.6) 8 (6.2) 13 (14.3)
Good 32 (25) 24 (26.4) 29 (22.7) 15 (16.5)
Fair 22 (17.2) 10 (11) 22 (17.2) 12 (13.2)
Poor 17 (13.3) 7 (7.7) 14 (10.9) 7 (7.7)
Missing 42 (32.8) 28 (30.8) 51 (39.8) 43 (47.3)
Moderate activities, n (%) 0.321 1
Yes, limited a lot 31 (24.2) 17 (18.7) 21 (16.4) 14 (15.4)
Yes, limited a little 26 (20.3) 18 (19.8) 25 (19.5) 18 (19.8)
No, not limited at all 29 (22.7) 28 (30.8) 30 (23.4) 17 (18.7)
Missing 42 (32.8) 28 (30.8) 52 (40.6) 42 (46.2)
Climbing stairs, n (%) 0.171 0.970
Yes, limited a lot 38 (29.7) 20 (22) 26 (20.3) 16 (17.6)
Yes, limited a little 19 (14.8) 16 (17.6) 26 (20.3) 19 (20.9)
No, not limited at all 29 (22.7) 27 (29.7) 23 (18) 14 (15.4)
Missing 42 (32.8) 28 (30.8) 53 (41.4) 42 (46.2)
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TABLE 38 Distribution of SF-12 responses: survivors to hospital discharge (continued )
SF-12 domain













Accomplished less physically, n (%) 0.519 1
All of the time 19 (14.8) 11 (12.1) 17 (13.3) 11 (12.1)
Most of the time 11 (8.6) 10 (11) 8 (6.2) 6 (6.6)
Some of the time 18 (14.1) 14 (15.4) 20 (15.6) 16 (17.6)
A little of the time 16 (12.5) 8 (8.8) 12 (9.4) 5 (5.5)
None of the time 19 (14.8) 21 (23.1) 19 (14.8) 11 (12.1)
Missing 45 (35.2) 27 (29.7) 52 (40.6) 42 (46.2)
Limited physically, n (%) 0.193 0.786
All of the time 23 (18) 11 (12.1) 18 (14.1) 14 (15.4)
Most of the time 9 (7) 7 (7.7) 8 (6.2) 7 (7.7)
Some of the time 16 (12.5) 17 (18.7) 18 (14.1) 13 (14.3)
A little of the time 19 (14.8) 8 (8.8) 13 (10.2) 4 (4.4)
None of the time 16 (12.5) 21 (23.1) 16 (12.5) 11 (12.1)
Missing 45 (35.2) 27 (29.7) 55 (43) 42 (46.2)
Did less work,b n (%) 0.691 1
All of the time 5 (3.9) 6 (6.6) 13 (10.2) 9 (9.9)
Most of the time 8 (6.2) 3 (3.3) 7 (5.5) 2 (2.2)
Some of the time 12 (9.4) 12 (13.2) 15 (11.7) 12 (13.2)
A little of the time 20 (15.6) 9 (9.9) 13 (10.2) 5 (5.5)
None of the time 33 (25.8) 32 (35.2) 29 (22.7) 21 (23.1)
Missing 50 (39.1) 29 (31.9) 51 (39.8) 42 (46.2)
Accomplished less emotionally, n (%) 0.495 0.885
All of the time 3 (2.3) 5 (5.5) 14 (10.9) 8 (8.8)
Most of the time 4 (3.1) 2 (2.2) 7 (5.5) 2 (2.2)
Some of the time 8 (6.2) 10 (11) 10 (7.8) 10 (11)
A little of the time 16 (12.5) 7 (7.7) 11 (8.6) 6 (6.6)
None of the time 46 (35.9) 38 (41.8) 30 (23.4) 22 (24.2)
Missing 51 (39.8) 29 (31.9) 56 (43.8) 43 (47.3)
Pain, n (%) 0.603 1
Not at all 39 (30.5) 26 (28.6) 32 (25) 21 (23.1)
A little bit 20 (15.6) 17 (18.7) 17 (13.3) 10 (11)
Moderately 10 (7.8) 12 (13.2) 8 (6.2) 8 (8.8)
Quite a bit 8 (6.2) 7 (7.7) 11 (8.6) 7 (7.7)
Extremely 6 (4.7) 1 (1.1) 9 (7) 3 (3.3)
Missing 45 (35.2) 28 (30.8) 51 (39.8) 42 (46.2)
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TABLE 38 Distribution of SF-12 responses: survivors to hospital discharge (continued )
SF-12 domain













Calm, n (%) 0.385 1
All of the time 11 (8.6) 13 (14.3) 9 (7) 5 (5.5)
Most of the time 40 (31.2) 34 (37.4) 30 (23.4) 20 (22)
Some of the time 16 (12.5) 11 (12.1) 22 (17.2) 14 (15.4)
A little of the time 11 (8.6) 3 (3.3) 11 (8.6) 7 (7.7)
None of the time 2 (1.6) 2 (2.2) 5 (3.9) 3 (3.3)
Missing 48 (37.5) 28 (30.8) 51 (39.8) 42 (46.2)
Energy, n (%) 0.178 0.886
All of the time 5 (3.9) 9 (9.9) 3 (2.3) 3 (3.3)
Most of the time 20 (15.6) 20 (22) 19 (14.8) 13 (14.3)
Some of the time 21 (16.4) 18 (19.8) 19 (14.8) 17 (18.7)
A little of the time 20 (15.6) 5 (5.5) 19 (14.8) 6 (6.6)
None of the time 15 (11.7) 11 (12.1) 17 (13.3) 10 (11)
Missing 47 (36.7) 28 (30.8) 51 (39.8) 42 (46.2)
Feeling downhearted, n (%) 1 0.859
All of the time 5 (3.9) 3 (3.3) 5 (3.9) 2 (2.2)
Most of the time 6 (4.7) 3 (3.3) 12 (9.4) 8 (8.8)
Some of the time 24 (18.8) 17 (18.7) 19 (14.8) 12 (13.2)
A little of the time 22 (17.2) 19 (20.9) 24 (18.8) 11 (12.1)
None of the time 24 (18.8) 21 (23.1) 17 (13.3) 16 (17.6)
Missing 47 (36.7) 28 (30.8) 51 (39.8) 42 (46.2)
Social activities, n (%) 1 0.953
All of the time 10 (7.8) 8 (8.8) 11 (8.6) 6 (6.6)
Most of the time 10 (7.8) 4 (4.4) 6 (4.7) 6 (6.6)
Some of the time 19 (14.8) 13 (14.3) 18 (14.1) 10 (11)
A little of the time 7 (5.5) 10 (11) 9 (7) 7 (7.7)
None of the time 35 (27.3) 28 (30.8) 33 (25.8) 20 (22)
Missing 47 (36.7) 28 (30.8) 51 (39.8) 42 (46.2)
a Based on the chi-squared test of differences between proportions.
b Carried out work or other activities less carefully than usual because of emotional problems.
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TABLE 39 Cost-effectiveness results: sensitivity analyses (2017 prices)
Analysis model





































































































QALYs based on EQ-5D/mRS,













































































































































































































































































































TABLE 39 Cost-effectiveness results: sensitivity analyses (2017 prices) (continued )
Analysis model






























QALYs based on EQ-5D/mRS


























Excluded estimated cost of
transporting deceased patients
to nearest hospital mortuary if
patient died at scene of cardiac
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patients to nearest mortuary












































TABLE 40 Sensitivity analyses exploring the impact of missing-not-at-random assumption on the within-trial base-case cost-effectiveness results (imputed utility values were
systematically increased/decreased from 0% to 100% of imputed value within the imputation model)
Missing-not-at-
random assumption












QALY (95% CI) (£)
Increased imputed utility by
100% 3601 (529) 0.0022 (0.0036) 2320 (534) 0.0009 (0.0036) 1281 (821 to 1741) 0.0013 (–0.0018 to 0.0043) 1,021,684 –1243 (–1681 to –805)
75% 3594 (534) 0.0021 (0.0033) 2307 (538) 0.0009 (0.0034) 1287 (823 to 1750) 0.0012 (–0.0017 to 0.0041) 1,072,646 –1251 (–1693 to –808)
50% 3606 (530) 0.0022 (0.0031) 2322 (534) 0.001 (0.0031) 1284 (823 to 1744) 0.0011 (–0.0015 to 0.0038) 1,120,679 –1249 (–1689 to –810)
25% 3595 (540) 0.0024 (0.0029) 2302 (545) 0.0012 (0.0029) 1294 (824 to 1763) 0.0011 (–0.0014 to 0.0036) 1,158,930 –1260 (–1709 to –811)
0.0% 3582 (532) 0.0024 (0.0025) 2292 (537) 0.0016 (0.0025) 1291 (828 to 1754) 0.0008 (–0.0014 to 0.003) 1,670,014 –1268 (–1712 to –823)
Decreased imputed utility by
25% 3594 (522) 0.0027 (0.0023) 2298 (527) 0.002 (0.0023) 1296 (842 to 1750) 0.0006 (–0.0013 to 0.0026) 2,036,654 –1277 (–1717 to –837)
50% 3580 (538) 0.0026 (0.0023) 2262 (543) 0.002 (0.0023) 1318 (850 to 1786) 0.0006 (–0.0014 to 0.0026) 2,114,049 –1299 (–1753 to –845)
75% 3574 (539) 0.0027 (0.0023) 2269 (543) 0.002 (0.0023) 1305 (837 to 1773) 0.0006 (–0.0014 to 0.0026) 2,067,739 –1286 (–1740 to –832)


































































































































































































































































































TABLE 41 Sensitivity analyses exploring the impact of missing-not-at-random assumption on the within-trial base-case cost-effectiveness results (imputed costs were systematically
increased/decreased from 0% to 100% of imputed value within the imputation model)
Missing-not-at-random
assumption













Increased imputed costs by
100% 3175 (874) 0.0024 (0.0028) 2285 (881) 0.0017 (0.0028) 890 (131 to 1650) 0.0008 (–0.0017 to 0.0032) 1,186,037 0.008
75% 3196 (802) 0.0024 (0.0027) 2238 (808) 0.0017 (0.0027) 958 (261 to 1655) 0.0007 (–0.0016 to 0.0031) 1,301,145 0.003
50% 3300 (703) 0.0025 (0.0026) 2331 (709) 0.0017 (0.0026) 969 (358 to 1580) 0.0008 (–0.0015 to 0.0031) 1,246,202 0
25% 3384 (621) 0.0024 (0.0026) 2335 (626) 0.0017 (0.0026) 1049 (509 to 1589) 0.0008 (–0.0015 to 0.003) 1,363,580 0
0.0% 3582 (532) 0.0024 (0.0025) 2292 (537) 0.0016 (0.0025) 1291 (828 to 1754) 0.0008 (–0.0014 to 0.003) 1,670,014 0
Decreased imputed costs by
25% 3634 (516) 0.0024 (0.0025) 2299 (520) 0.0017 (0.0025) 1335 (887 to 1783) 0.0008 (–0.0014 to 0.0029) 1,746,277 0
50% 3650 (507) 0.0024 (0.0025) 2334 (512) 0.0017 (0.0025) 1315 (874 to 1756) 0.0008 (–0.0014 to 0.0029) 1,687,983 0
75% 3663 (511) 0.0024 (0.0025) 2359 (515) 0.0016 (0.0025) 1304 (860 to 1747) 0.0008 (–0.0014 to 0.0029) 1,688,008 0
































TABLE 42 Cost-effectiveness results: subgroup analyses (2017 prices)
Subgroup
















Cause of cardiac arrest




































































EMS time from arrival at scene to administration of first dose (minutes)
























































































































































































































































































































TABLE 42 Cost-effectiveness results: subgroup analyses (2017 prices) (continued )
Subgroup
















Time from 999 call received to EMS arrival at scene (minutes)













































Number of syringes given (out of two)






















Number of syringes given (out of four)


























































































































































































































































































































































































































































































































FIGURE 25 Health-related quality of life at baseline, at hospital discharge and at 3 and 6 months after randomisation.
(a) EQ-5D/mRS (whole trial); (b) mRS (whole trial); (c) EQ-5D/mRS (survivors); and (d) mRS (survivors). (continued )
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FIGURE 25 Health-related quality of life at baseline, at hospital discharge and at 3 and 6 months after randomisation.





















































FIGURE 26 Adjusted multiple imputation (base case). (a) Cost-effectiveness plane; and (b) CEAC.
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FIGURE 27 The 12-month time horizon (QALYs based on EQ-5D-5L and mRS data, NHS/PSS costs). (a) Cost-effectiveness



















































FIGURE 28 The lifetime time horizon (QALYs based on mRS data, NHS/PSS costs). (a) Cost-effectiveness plane; and
(b) CEAC.
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Increased imputed utility by 100%
Increased imputed utility by 75%
Increased imputed utility by 50%
Increased imputed utility by 25%
Increased imputed utility by 0.0%
Decreased imputed utility by 25%
Decreased imputed utility by 50%
Decreased imputed utility by 75%
Decreased imputed utility by 100%
FIGURE 29 The CEAC from sensitivity analyses assessing the impact of missing-not-at-random assumptions on imputed
utilities (QALYs based on mRS data, NHS/PSS costs over 6 months).
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Increased imputed costs by 100%
Increased imputed costs by 75%
Increased imputed costs by 50%
Increased imputed costs by 25%
Increased imputed costs by 0.0%
Decreased imputed costs by 25%
Decreased imputed costs by 50%
Decreased imputed costs by 75%
Decreased imputed costs by 100%
FIGURE 30 The CEAC from sensitivity analyses assessing the impact of missing-not-at-random assumptions on imputed
costs (QALYs based on mRS data, NHS/PSS costs over 6 months).
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